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CHAPTER I 
 
INTRODUCTION 
 
1. Mechanisms of NF-κB signaling  
1.1 General introduction to NF-κB family  
Nuclear factor-kappa B (NF-κB) was discovered more than 20 years ago as a nuclear factor that 
binds a site in the immunoglobulin κ enhancer and regulates expression of the κB light chain in B 
cells 
3
. There are five NF-κB/REL genes that encode seven proteins—p65 (RelA), c-Rel, RelB, NF-
κB1 (p50/p105), NF-κB2 (p52/p100) (reviewed in 4, 2) (Fig. 1.1 adapted from2 ). All members of the 
family share an N-terminal Rel homology domain (RHD) responsible for DNA binding, homo- and 
hetero-dimerization and interactions with IκB proteins2. The transcription activation domain (TAD) 
necessary for the positive regulation of gene expression is present in 3 family members: p65, c-Rel, 
and RelB. Two of the proteins, NF-κB1 (p105) and NF-κB2 (p100), contain multiple copies of the 
so-called ankyrin repeat at their C-termini with inhibitory function. Processing of these proteins 
leads to the production of the p50 and p52 subunits. 
NF-κB is active and binds DNA as a dimer. Classic NF-κB (the dimer of p50 and RelA) has been 
most intensively studied, although many other homo- and heterodimers have been described with 
some distinct characteristics attributed to. NF-κB dimers bind to κB sites within the 
promoters/enhancers of target genes and regulate transcription through the recruitment of co-
activators or co-repressors. Different NF-κB dimers prefer slightly different DNA sequences 
enabling differential and enhanced regulation of target gene expression. Dimers composed of 
p50/p65, p50/c-rel, p65/p65, and p65/c-rel possess transcriptional potential, whereas homodimers of 
p50 or p52 uniformly inhibit transcription when bound to DNA. More studies to determine 
biologically relevant targets for different NF-κB dimers are needed. Additional differences between 
2 
NF-κB dimers include: cell type specificity, differential subcellular localization, differential 
interactions with forms of IκB, and differential activation 5, 6. 
  
Fig. 1.1 The NF-κB/Rel and IκB families of proteins, adapted from2. The NF-κB/Rel family is 
characterized by the presence of the Rel homology domain.    
Figure 1.0.1 The NF-κB/Rel and IκB families of proteins 
3 
1.2 Regulation of NF-κB activation and nuclear translocation 
NF-κB is a ubiquitous eukaryotic transcription factor that resides in the cytoplasm of most cells in 
an inactive form bound to the inhibitor, IκB. Diverse signals such as inflammatory cytokines, UV, 
and LPS, trigger destruction of IκB and release of NF-κB which translocates to the nucleus where it 
regulates transcription of target genes. It is critical to note that NF-κB’s ability to respond to signals 
makes it an inducible factor, and since activation of NF-κB does not require new protein synthesis, 
the signal is transmitted rapidly 
7
. 
Two major NF-κB activating pathways have been characterized, canonical (or classical) and non-
canonical (or alternative) These distinct methods for NF-κB activation target different NF-κB 
homo/heterodimers via distinct kinases and IκB proteins (reviewed in8 and9). The canonical pathway 
activates NF-κB dimers consisting of combinations of  RelA (p65), c-Rel, RelB and p50 while the 
non-canonical pathway is responsible for the activation of p100/RelB complexes (Fig. 1.2 adapted 
from
10
). 
IκB binds to the RHD domain of NF-κB and sequesters it in the cytoplasm. Inhibitory activity of 
IκB requires direct binding to NF-κB dimers and is thought to be mediated through masking of the 
nuclear localization signals also located in the RHD
11
. Signaling through inflammatory cytokines 
such as TNFα and IL-1 activates a high molecular weight protein complex known as the signalsome 
that contains IκB kinases (IKKα/β/γ) responsible for phosphorylation of IκB. The IKK complex also 
has NF-κB regulatory functions (see below). Phosphorylation of IκB marks it for ubiquitination and 
subsequent degradation that is dependent on the 26S proteasome (Fig. 1.2). Degradation of IκB 
results in NF-κB nuclear localization and dependent on post-translational modification of Rel family 
proteins, transcription or transcriptional inhibition of NF-κB responsive genes. The elaborate system 
of sequestration of NF-κB in the cytoplasm allows rapid induction of NF-κB activity within cells 
following appropriate stimulation. 
4 
  
Fig. 1.2 Schema of canonical and non-canonical NF-κB activation. In the 
canonical NF-B activation pathway, stimulus-induced phosphorylation of two N-
terminal serines in the IκBs is mediated by the IKKs. After ubiquitination and 
degradation of IκB by the 26S proteasome complex, the liberated NF-κB 
heterodimer (p50:p65) translocates to the nucleus and regulates transcription of 
target genes dependent on post-translational modification. In the alterative (non-
canonical) pathway, IKK is activated by different members of the TNF-family 
(for example, BAFF and CD40). Along with NIK, IKK induces the 
phosphorylation-dependent processing of p100 and generation of p52:RelB 
heterodimers. p52:RelB translocates to the nucleus and regulates transcription 
target genes. 
 Figure 1.0.2 Schema of canonical and non-canonical NF-κB activation 
5 
1.3 Post-translational modification of RelA 
Like many transcription factors (e.g. E2F1 and p53), post-translational modification alters various 
physiological functions of the NF-κB including DNA binding, interactions with co-activators and co-
repressors, as well as, termination of the NF-κB response 2, 12-14. To date, most studies have focused 
on RelA modification, with reports related to modifications of other NF-κB subunits being extremely 
limited. Even with RelA, the complexity of its nuclear regulation and modification is only beginning 
to be understood. Basal and signal-induced phosphorylations of RelA are most thoroughly-
characterized. Site-specific phosphorylation is often a prerequisite for additional modifications 
(acetylation, ubiquitination, and isomerization of specific amino acid residues
15
) regulating RelA 
activity . As is frequently the case,  studies examining NF-κB post-translational modification present 
different levels of evidence that a specific enzyme is modifying a particular site, and it is recognized 
that modifications likely differ dependent on cell type and the nature of the NF-κB-inducing 
stimulus
16
. 
The RelA subunit of NF-κB is targeted for phosphorylation at many phospho-acceptor sites 
within both the RHD (S205, S276, S281, S311, T254) and TAD (S468, S529, S535, S536, T435, 
T505) (Table.1.1, adapted from 
10
 and 
14
). Phosphorylation of RelA occurs both within the cytoplasm 
and nucleus and many responsible kinases that are activated by a variety of stimuli have been 
identified (reviewed in 
2
). Phosphorylation of individual amino acids has been associated with 
different consequences, both activation and inactivation. Phosphorylation of S536 increases NF-κB 
transcriptional activity while phosphorylation of S529 increases NF-κB DNA binding and 
oligomerization. On the other hand, phosphorylation of T505 inhibits RelA transcription possibly 
through promoting association of RelA with HDAC
17
. A recent study shows that phosphorylation of 
S468 controls RelA COMMD1-dependent ubiquitination and target gene-specific proteasomal 
elimination.  
  
6 
Table 1.1 Summary of RelA PTM sites and functions (adapted from 
10
 and 
14
) 
 
  
Table 1.0.1 Summary of RelA PTM 
sites and functions 
7 
The serine 536 residue of RelA is conserved between human, mouse, chicken, and xenopus. 
Phosphorylation of S536 was first identified by Sakurai et al. through an in vitro kinase assay using 
TNFα stimulated whole cell lysate and immunoprecipitated IKKα or IKKβ18. Further, with inhibition 
of IκBα degradation by a proteasome inhibitor, N-acetylleucyl-leucyl-norleucinal (ALLN), this 
group demonstrated that the activity to phosphorylate Ser-536 could be induced in the cytoplasm
19
. 
Whether phosphorylation at S536 by IKKs is part of the activation mechanism leading to RelA 
nuclear translocation or a mechanism to prime RelA's transactivation potential before nuclear 
localization is unknown. However, phosphorylation of Ser-536 can also result in an IκB-independent 
mechanism of NF-κB activation20,21. Specifically, in some cell types, induction of the p53 tumor 
suppressor results in RSK1 kinase activation
20
, which phosphorylates RelA at S536. Since activation 
of RSK1 is associated with its cytoplasmic to nuclear translocation, it is proposed that, in this 
instance, Ser-536 phosphorylation occurs in the nucleus. This results in RelA nuclear accumulation 
through disruption of the cytoplasmic/nuclear shuttling of NF-κB/IκBα complexes that occurs in 
unstimulated cells
20
. 
The phosphorylation of highly conserved serine 276 and its critical role for RelA transcription 
activity was identified by Zhong et al. and protein kinase A (PKAc) was the first known kinase 
targeting this residue
22
. Ser-276 in RelA is also phosphorylated by the MSK1 kinase, although this is 
a nuclear event
12
. Phosphorylation of S276 promotes RelA interaction with transcriptional co-
activator CBP/p300
22
 altering the balance between transcriptionally repressed RelA bound to 
HDACs vs. transcriptionally activated RelA bound to p300/CBP
23
. The finding that the 
phosphorylation status of Rel proteins, especially of RelA, is the decisive parameter for their 
association with either transcriptional activators HATs (e.g. CBP/p300) or suppressors (e.g. HDACs) 
is important for understanding of NF-κB regulation.  Both S536 and S276 residues of RelA may be 
important for promoting association with HDACs since phosphorylation of both residues is required 
for RelA acetylation at K310
24
.  
8 
It is becoming more and more apparent that RelA phosphorylation at different sites serves as an 
integrator for multiple incoming signals, which likely serve to regulate the kinetics, strength and 
selectivity of RelA transcriptional activity.   
1.4 Down regulation of canonical NF-κB responses 
NF-κB is activated by various stimuli including: TNFα and bacterial/viral signal triggered 
danger-sensing receptors of the innate and adaptive immune systems. Active NF-κB binds to 
consensus target sequences in various promoters and induces the expression of a plethora of genes 
encoding molecules that promote proliferation, survival and differentiation of immune cells, as well 
as driving expression of factors such as proinflammatory cytokines that organize and execute 
immune and inflammatory responses. Thus, prompt activation of NF-κB is critical for host defense 
against various classes of pathogens; however, NF-κB activity can be deleterious resulting in tissue 
damage, uncontrolled immune response, and cancer if they are not appropriately down regulated
25, 26
. 
Many distinct negative regulatory mechanisms have evolved that operate at different molecular 
levels in the NF-κB signaling pathways to maintain homeostasis (review 27).  
1.4.1 Inhibition of canonical NF-κB activity by classical IκB proteins 
Degradation of IκB proteins is a decisive step in canonical NF-κB activation (see section 1.2); 
however, re-establishment of IκB serves as a critical regulator to limit excessive NF-κB activity28.  
Restoration of IκB following its proteasomal destruction is accomplished largely through a negative 
feedback loop, where IκBα genes are directly transcribed by active NF-κB29-31. Newly synthesized 
IκBα enters the nucleus and associates with DNA-bound NF-κB dimers32, resulting in cytoplasmic 
re-localization of NF-κB via the nuclear-export sequence present in IκBα., Acetylation of RelA by 
lysine acetyltransferase CBP (p300) complexes prevents IκBα binding to RelA and extends the 
promoter occupancy of functional RelA complexes 
33
. 
 
9 
1.4.2 Termination of canonical NF-κB responses in the nucleus 
Although IκB-mediated cytoplasmic export of nuclear NF-κB is important for deactivation of 
NF-κB responses, additional negative regulatory mechanism operate in the nucleus. These include 
IκB-independent displacement of active NF-κB from DNA and proteolytic degradation of active NF-
κB dimers. The SUMO E3 ligase PIAS1 can directly interfere with the binding of RelA dimers to 
DNA and regulates expression of distinct NF-κB target genes, particularly at early time points 
following NF-κB activation34. IKKα has additional negative regulatory roles in the termination of 
nuclear canonical NF-κB responses, as it accelerates the turnover of RelA and c-Rel35,36. While 
activated in the cytoplasm by pro-inflammatory signals, IKKα phosphorylates RelA specifically at 
Ser536 and thereby enhances its later proteasomal degradation in the nucleus. 
At least two E3 ubiquitin ligases control degradation of nuclear RelA
37
. One of these, PDLIM2, is 
essential to prevent uncontrolled inflammation in vivo
38
. PDLIM2 has a PDZ (postsynaptic density 
65–discs large–zonula occludens 1) domain in addition to its E3 ligase activity. The PDZ domain of 
PDLIM2 has chaperone function and promotes the transport of RelA to promyelocytic leukemia 
(PML) nuclear bodies. Thus, PDLIM2 not only targets nuclear RelA for proteasomal degradation but 
also re-localizes DNA-bound RelA to areas of transcriptional silencing. The other known E3 ligase 
that terminates the RelA responses in the nucleus is the EC2S complex, which contains SOCS1, 
Cullin-2 and COMMD1
39,40
. Functionally, COMMD1 bridges RelA to SOCS1 and Cullin-2 after 
pro-inflammatory stimulation where the EC2S complex mediates ubiquitin-dependent degradation of 
RelA. The EC2S complex appears to be particularly important for termination of NF-κB responses at 
later stages of cell stimulation
39
. Phosphorylation of p65 at Ser468 controls its COMMD1-dependent 
ubiquitination and target gene-specific proteasomal elimination 
41
. 
1.4.3 Dephosphorylation of RelA and responsible phosphatases 
Phosphorylation of RelA is dynamically regulated with a balance between protein 
serine/threonine kinases, and protein serine/threonine phosphatases. Time course experiments reveal 
10 
that nuclear RelA S536 phosphorylation markedly decreases 10-20 min after TNF-α stimulation. 
Pre-treatment with calyculin A (CalyA), a phosphatase inhibitor for protein phosphatase PP1 and 
PP2A partially inhibited dephosphorylation
18
, suggesting that CalyA-sensitive phosphatases 
dephosphorylate RelA after the nuclear translocation.  Nelson et al. showed that following TNFα 
stimulation, RelA dynamically oscillates between the nucleus and cytoplasm corresponding to rapid 
dephosphorylation at Ser-536, suggesting that dephosphorylation at S536 may be intricately involved 
in regulating the level and duration of NF-κB activity42. Despite these data that dephosphorylation of 
RelA is critical for RelA regulation; identification of involved phosphatases, as well as mechanisms 
regulating involved phosphatases is lacking. To date,  phosphatases implicated as direct or indirect 
regulators of NF-κB include only  serine/threonine type 2C protein phosphatase (PPM) family 
members (Wip1 (PPM1D, PPMδ), PPM1A and PPM1B) and the serine/threonine type 2A protein 
phosphatase (PP2A).  
RelA was found to bind protein phosphatase 2A (PP2A) subunit A (PR65) and was 
dephosphorylated by a purified PP2A core enzyme, a heterodimer formed by the catalytic subunit of 
PP2A (PP2Ac) and PR65, in a concentration-dependent manner
43
. Okadaic acid, an inhibitor of 
PP2A, increased  basal RelA phosphorylation in melanocytes and blocked dephosphorylation of 
RelA after interleukin-1 stimulation
43
. The PP2A family contains many different subunits and has 
been reported to have tumor suppressor-like function or oncogenic functions depending on context 
and the particular activated PP2A trimeric complex (reviewed in 
44,45
and
46
). An emerging view 
suggests that specific PP2A complexes play critical roles in cell transformation by regulating 
particular substrates. 
More recently, a genome-wide search for regulators of NF-κB using RNAi identified Wip1 as a 
negative regulator of NF-κB signaling. Wip1 was found to directly dephosphorylate RelA at S536, a 
residue critical for full activation of transcriptional activity
47
. Overexpression of Wip1 resulted in 
decreased RelA phosphorylation and NF-κB inhibition in a dose-dependent manner. Conversely, 
Wip1 knockdown resulted in increased NF-κB function. TNFα mRNA is increased in WIP1-/- mice 
11 
where enhanced inflammation in many organs is also observed
47
. PPM1D, which encodes Wip1, is a 
transcriptional target of NF-κB, suggesting a potential negative feedback loop48. Inhibition or 
activation of NF-κB decreases or increases Wip1 expression, respectively. ChIP analysis showed 
basal binding of the p65 subunit to the PPM1D promoter region encompassing the κB site, which is 
enhanced after NF-κB activation by TNFα. Wip1 expression is induced by LPS-stimulation of mouse 
splenic B-cells and is required for maximum proliferation. Taken together, these data suggest that 
Wip1 likely regulates RelA activity through a negative feedback loop. 
PPM1A and PPM1B are the other members of PPM family and these PPM family members 
indirectly regulate NF-κB through dephosphorylation and inhibition of IKKβ49. Overexpression of 
PPM1A or PPM1B results in dephosphorylation of IKKβ at Ser177 and Ser181 and termination of 
IKKβ-induced NF-κB activation. PPM1A and PPM1B associate with the phosphorylated form of 
IKKβ, and the interaction between PPM1A/PPM1B and IKKβ is transiently induced by TNFα. 
Functionally, knockdown of PPM1A and PPM1B expression enhances TNFα-induced IKKβ 
phosphorylation, NF-κB nuclear translocation and NF-κB-dependent gene expression (IL-6). 
2. NF-κB signaling in cancer 
NF-κB target genes regulate development, inflammation, immune response, proliferation, 
apoptosis, cellular transformation, angiogenesis and differentiation (reviewed in 
50
). Given its 
involvement in multiple cellular processes, NF-κB activity is tightly and intricately controlled. 
Constitutive NF-κB activity is associated with human diseases including asthma, arthritis, 
Alzheimer’s disease, diabetes and inflammatory bowel disease (reviewed in 51) and aberrant NF-κB 
activity has been shown to directly contribute to tumorigenesis, neovascularization, tumor growth 
and metastases
25
 and reviewed in 
50
.  
NF-κB is amplified, overexpressed, or activated in various tumor types including breast, stomach, 
thyroid and colon cancer and NF-κB activities promotes many aspects of oncogenesis including 
cellular transformation and proliferation while protecting tumor cells from apoptosis (reviewed in 
52
 
12 
and 
53
). NF-κB activation and increased S276 phosphorylation has been described in head and neck 
squamous cell carcinoma (HNSCC) and adjacent dysplastic mucosa
54
 and multiple NF-κB 
responsive genes are overexpressed in these tumors 
55
.  
Experimental data also supports the role of NF-κB in tumorigenesis. Inhibition of NF-κB through 
expression of either IκB super repressor56 or dominant negative IKK57 markedly inhibits foci 
formation while increasing apoptosis. Many anti-apoptosis genes are NF-κB targets including: 
TRAF1, TRAF2, c-IAP1, c-IAP2, xIAP, BCL-XL (reviewed in 
53
 and 
58
). A genetically modified 
mouse model expressing c-Rel driven the mouse mammary tumor virus promoter revealed that c-Rel 
expression associated with development of breast adenocarcinomas in one-third of mice post-partum. 
Increased NF-κB signaling was associated with increased expression of anti-apoptotic and 
proliferation promoting genes in tumors 
59
. Inhibition of NF-κB activity in HNSCC cells was shown 
to inhibit xenograft tumor growth and since these tumors had no know activation of oncogenes, these 
data suggest that NF-κB activation may be important for tumors without known alteration of 
oncogenes 
60
. 
Dysregulation of NF-κB in prostate cancer has been identified as a major driver of distant 
metastasis, which is the primary cause of death in this common male cancer
61-63
. Comparison of 
metastatic prostate cancer and localized disease in multiple expression array profiling studies using 
the integrative microarray analysis of pathways (IMAP) revealed that NF-κB was the third most 
dysregulated pathway from a list of approximately 100 pathways that were significantly dysregulated  
in metastatic prostate cancer
64
. Min et al. substantiated the importance of NF-κB for prostate 
metastases using a murine model showing that an oncogene-tumor suppressor cascade drives 
metastatic prostate cancer by coordinately activating Ras and NF-κB63. One transcriptional target of 
NF-κB, monocyte chemotactic protein-1 (MCP-1), also known as chemokine (C-C motif) ligand 2 
(CCL2), has been implicated in prostate cancer migration, invasion and metastasis altering both 
tumor cells and the microenvironment
65
. MCP-1 is particularly implicated in bony prostate 
metastases as well as in other tumor types including renal cancer, bladder cancer, and breast cancer 
66
. 
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Mechanisms governing MCP-1 expression are not fully described; however the suspected 
importance of this cytokine in tumor progression is affirmed by the recent initiation of clinical trials 
using a neutralizing antibody targeting MCP-1. IL-6, another transcriptional target of NF-κB and a 
cytokine is also implicated in metastases, particularly in cancers of the prostate
67
, colon
68
, and 
breast
69
. Studies reveal that both MCP-1 and IL-6 facilitate the survival of myeloid monocytes within 
the tumor microenvironment, as well as their differentiation to tumor-promoting M2-type 
macrophages
70,71
 that are implicated in promotion of prostate and breast tumor metastasis. Inhibition 
of IL-6 and IL-6 receptor are also therapeutic targets for prevention of inflammation, tumor 
progression and metastasis and their targeting has shown promise in pre-clinical models and phase II 
clinical trials (prostate and ovarian cancer) 
72, 73
. Additional phase II clinical trials using an anti-IL-6 
monoclonal antibody are currently underway or have been recently completed. 
3. Serine/threonine protein phosphatase magnesium/manganese-dependent family (PPM/PP2C) 
3.1 The PPM family 
Ser/Thr protein phosphatases are divided into three super-families based on their unique sequence 
and structure composition, namely phospho-protein phosphatase (PPP), protein phosphatase 
magnesium/manganese-dependent (PPM) and transcription factor II F (TFIIF)-interacting carboxyl 
terminal domain (CTD) phosphatase (FCP)
74
. The PPP family, including PP1, PP2A and PP2B 
(calcineurin), consists of oligomeric holoenzymes, composed of a highly conserved catalytic subunit 
and one or two regulatory subunits essential for subcellular localization and substrate specificity. 
Two of the phosphatases involved in regulation of NF-κB signaling, PPM1A and Wip1/PPM1D, are 
members of the PPM family (formerly PP2C family). PPM family members (solely represented by 
PPM) have two structural domains, a conserved N-terminal catalytic domain and a C-terminal region 
with substantial structural and sequence variance among different isoforms. Unlike their PPP 
counterparts, which function as homo- and hetero-, di- and trimetric complexes, PPMs are functional 
as monomeric enzymes. Therefore, their activity is not regulated by inhibitory proteins or by 
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regulatory subunits. PPM phosphatase requires divalent cations (Mg
2+
 or Mn
2+
) for catalytic activity. 
Because intracellular concentrations of Mg
2+
 and Mn
2+
 do not fluctuate substantially under 
physiological conditions, it is also unlikely that these metal-dependent phosphatases are regulated by 
the availability of bivalent cations. Based on these two observations, it is expected that activities of 
type 2C protein phosphatases are controlled predominantly by: 1) tissue- or cell type-specific 
expression, 2) post-translational modification, 3) subcellular compartmentalization, or 4) protein 
stability or degradation. PPM phosphatases are insensitive to the potent inhibitor of the PP1 and 
PP2A phosphatases, okadaic acid. Sanguinarine was identified as a potent and specific PPM inhibitor 
with selectivity for PPM as compared with PP1, PP2A and PP3B in vitro
75
. 
PPM family members are evolutionarily conserved in prokaryotes and eukaryotes and in 
multicellular organisms ranging from plants to mammals, (reviewed in
76-78
). Following functional 
diversification via gene duplication in metazoa, PPM isoforms have gained specificity for various 
signaling pathways and tissue expression patterns. Recent studies in mammalian cells have revealed 
at least 18 PPM family members, namely PP2Cα/PPM1A, PP2Cβ/PPM1B, PP2Cγ, PP2Cɛ, PP2Cη, 
PP2Cm, T-cell activation-PPM (TA-PPM), integrin-linked kinase-associated serine/threonine 
phosphatase 2C (ILKAP), NERRP-2C, Wild-type p53-induced phosphatase (Wip1)/PPM1D, partner 
of Pix 1 and 2 (POPX1 and POPX2, respectively), PH domain and leucine-rich repeat protein 
phosphatase 1 and 2 (PHLPP1 and PHLPP2, respectively), pyruvate dehydrogenase phosphatase 
isoenzyme 1 and 2 (PDP1 and PDP2, respectively), PPM1H and PPM1J. These proteins are largely 
implicated in the regulation of stress signaling cascades, phosphatidylinositol 3-kinase (PI3-K)/Akt 
signaling, pre-mRNA splicing, protein ubiquitination and degradation and cell metabolism, as well 
as cell death/survival signaling 
74
.  
 
3.2 PPM1A/PP2Cα 
PPM1A is the best characterized member of the type 2C family of protein phosphatases. It was 
first identified in 1992, using a rat liver library and a human teratocarcinoma library
79
. A few years 
15 
later, the structure of human PPM1A 
80
revealed a novel protein fold that consists of two domains; an 
N-terminal catalytic domain, that is composed of a central β-sandwich surrounded by α-helices and 
that is common to all PPMs, and a 90-residue C-terminal domain, that merely contains α-helices and 
that is characteristic for mammalian PPMs. This latter domain is remote from the catalytic site, 
suggesting that it has a role in defining substrate specificity. PPM1A is expressed in virtually all 
tissues with both cytoplasmic and nuclear and localization 
81
.  
As an enzyme with broad substrate specificity, PPM1A participates in the regulation of several 
important signaling pathways including TGFβ/Smad82, MAPK (JNK/p38), AMPK, p53/MDM2, 
Wnt/Axin, Cdk2 and Cdk6 (reviewed in 
1
) and the nerve growth factor activated Akt/ERK pathway
83
.  
MAPK: The modular mitogen-activated protein kinase (MAPK) cascades contain a core of three 
protein kinases (MAPK kinase kinase (MAPKKK), MAPK kinase (MAPKK) and MAPK that are 
evolutionarily conserved from yeast to mammals. In mammals, MAPK cascades regulate various 
cellular activities, including gene expression, proliferation, survival/apoptosis, differentiation and 
embryogenesis. These functions mediated by MAPK signaling that transduces signals from G-
protein-coupled receptors (GPCR), tyrosine receptor kinases and oxidative stress sensors in response 
to diverse intracellular and extracellular cues. The activation of MAPKs is mediated through a 
phosphorylation relay mechanism from MAPKKK, MAPKK to MAPK. Activity of MAPKKK and 
MAPKK can be inhibited through phosphorylation suggesting that protein dephosphorylation by 
phosphatases can modulate MAPK pathways both positively and negatively
74
. In mammalian cells, 
three distinct MAPK cascades are found. The prototypic MAP kinases ERK1 and ERK2 are 
activated by mitogenic signaling through the MAPKKKs A-RAF, B-RAF, and C-RAF, and the 
MAPKKs MEK1 and MEK2 
84
. The two other MAPKs, JNK and p38, are activated by stress such as 
UV radiation, heat shock, osmotic shock, or wound stress 
85
. 
Upon such environmental stresses, PPM1A inhibits activation of both the JNK and the p38 
pathway. Down regulation of JNK signaling has been attributed to PPM1A inhibition of MAPKKs as 
both MKK4 and MKK7, two major upstream regulators of JNK, are dephosphorylated by PPM1A 
16 
under physiological as well as under stress conditions. Regulation of p38 activity, by PPM1A was 
also attributed to dephosphorylation and inhibition of p38 specific MAPKKs, f MKK3b and MKK6b. 
In addition, PPM1A and p38 co-immunoprecipitate in a single complex, indicating that they also 
interact directly. Interestingly, p38 and PPM1A could only be co-immunoprecipitated when 
following stress, suggesting that PPM1A may only complex with p38 when the latter is present in its 
phosphorylated (i.e., stress-activated) form. 
Recently, PPM1A has been shown to directly dephosphorylate the extracellular receptor-activated 
kinase (Erk). Using biochemistry techniques, Li et al. found that PPM1A negatively regulated ERK 
by directly dephosphorylating its Thr202 position after EGF stimulation. Additional kinetic studies 
revealed key residues involved in phospho-ERK recognition by PPM1A. Importantly, PPM1A 
preferred the phospho-ERK peptide sequence over a panel of other phosphopeptides through the 
interactions of basic residues in the active site of PPM1A with the pThr-Glu-pTyr motif of ERK. 
Whereas Lys165 and Arg33 were required for efficient catalysis or phospho-substrate binding of 
PPM1A, Gln185 and Arg186 determined of PPM1A substrate specificity. The interaction between 
Arg186 of PPM1A and Glu203 and pTyr204 of phospho-ERK was identified as a hot-spot for 
phospho-ERK-PPM1A interaction
86
.   
p53/MDM2: PPM1A increases the transcriptional activity of p53, in a p53 dose-dependent 
manner 
87
. Using cells that stably express the human papilloma virus E6 protein, inhibition of colony 
formation by PPM1A was mediated (at least in part) by p53. These findings indicated, for the first 
time, that PPM1A is an important physiological regulator of p53 signaling. While a phosphatase 
deficient mutant of PPM1A did not alter MDM2, PPM1A down regulates MDM2 expression and 
activity to inhibit of p53. The mechanism of PPM1A increasing the proteasomal degradation of 
MDM2 has yet to be elucidated. It is not clear if MDM2 is directly dephosphorylated by PPM1A or 
if MDM2 is regulated indirectly by PPM1A.  
IKKβ/NF-κB: Recently, PPM1A has been identified as an indirect regulator of NF-κB by 
dephosphorylating and inactivating IKKβ49. PPM1A and PPM1B were first identified as IKKβ 
17 
phosphatases through a functional genomic approach by screening a library of serine/threonine 
phosphatases and identifying those whose overexpression inhibits IKKβ-mediated NF-κB activation 
with dephosphorylation of IKKβ at the conserved residues Ser177 and Ser181 within the kinase 
activation loop. In vitro phosphatase assays confirmed that bacterially synthesized GST-PPM1A and 
GST-PPM1B dephosphorylated immunoprecipitated IKKβ while the phosphatase-dead mutants did 
not. Functionally PPM1A was shown to inhibit NF-κB transcription though inhibition of IKKβ. 
Expression of IL-6, a pleiotropic cytokine as well as target of NF-κB was inhibited by PPM1A 
following TNFα stimulation 49 or the hepatitis B virus X protein (HBx) perturbation88. 
Regulation of these pathways has been attributed to PPM1A phosphatase activity toward key 
components of the pathway in some cases (Smad2/3, MKK6, MKK4, p38 and Axin), but has not 
been fully characterized in others (Akt/ERK, p53/MDM2 and Cdk2 and Cdk6). In addition, PPM1A 
has been implicated in regulation of proliferation
1
, cell invasion and migration
89
, but PPM1A targets 
regulating these activities have not been identified.  
Little is known about the regulation of PPM1A expression and/or activity. Recently, protein N-
myristoylation, the irreversible covalent linkage of 14-carbon saturated fatty acid, myristic acid, to 
the N-terminal glycines was reported to be essential for PPM1A and PPM1B to dephosphorylate a 
physiological substrate, a subunit of AMPK (AMPKa) 
90
. An additional study revealed that hepatitis 
B virus X protein binds to endogenous PPM1A and that recombinant HBx dose-dependently reduced 
phosphatase activity of recombinant PPM1A in vitro
88
.  
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3.3 PPM1B 
 As was the case for PPM1A, PPM1B was first identified using a rat liver library and a human 
teratocarcinoma library 
79
. Investigation of the transcripts of the PPM1B gene revealed that there are 
at least five different isoforms. As these isoforms differed only in their C-terminal domains, it has 
been suggested that the C-terminus is responsible for substrate specificity
91
. Several studies provided 
evidence showing that PPM1B is an important negative regulator of cellular signaling with similar 
physiological functions as PPM1A. PPM1B participates in the regulation of MAPK (p38/JNK), 
IKKβ/NF-κB, TAK1, p53/MDM2 and BAD (reviewed in1). In regulation of pathways PPM1B shares 
with PPM1A, it is not clear if the two phosphatases have redundant roles or have different substrate 
specificities that may make their function complementary. 
 
3.4 Wip1/PPM1D 
The Wip1/PPM1D (wild- type p53-induced phosphatase 1) gene was originally identified by 
screening for p53 activated genes in WMN Burkitt lymphoma cells
92
. Tumor cell lines with wild-
type p53 consistently showed that IR increases Wip1 mRNA while p53-deficient cell lines showed 
little or no induction of Wip1 expression. Like other 2C family members, Wip1 is insensitive to 
Okadaic acid-mediated inhibition. Cellular fractionation and indirect immunofluorescence indicated 
that the 61kDa Wip1 protein localizes to the nucleus
92
. In independent studies, Tong and colleagues
93
 
identified human Wip1 as a ubiquitously expressed protein up regulated in response to different 
types of stress, e.g., UV radiation or ethanol incubation. Overexpression of Wip1 in HEK293 cells 
blocks cell cycle progression, induces cell cycle arrest in early S phase, inhibits DNA synthesis, and 
induces cell death. Because of these findings, and because of the fact that it was a p53-induced gene, 
Wip1 was initially assumed to be a protein with growth inhibitory functions. Later experiments, 
however, convincingly demonstrated that it possesses growth-promoting, rather than growth 
suppressing properties, and that it contributes substantially to the development of several different 
types of malignancy. As outlined below, over the past few years, a significant amount of evidence 
19 
suggests that Wip1 functions as an oncogene, and that it exerts its effects through a variety of 
downstream mechanisms, e.g. inhibiting p38, p53, and ATM, interfering with cell cycle checkpoints 
(Chk1 and Chk2), and negatively affecting base-excision repair. 
MAPK: The first report describing Wip1 as a regulator of cell growth and cellular stress 
signaling was provided by Imai and colleagues
94
. Besides being activated by IR- or UV-induced 
stress, they observed up regulation of Wip1 expression in response to oxidative (H2O2) and 
ribotoxic stress (anisomycin). In addition, Wip1 dephosphorylates and inactivates the MAPK, p38 
and attenuates the stress-induced p38- mediated phosphorylation of p53 on Serine 38 and Serine 46, 
resulting in a reduced transcriptional activity of p53 and in an inhibition of p53-mediated apoptosis
94
. 
Taking into account that p53 induces the expression of Wip1, that Wip1 dephosphorylates and 
inactivates p38, and that this reduced activity of p38 results in a reduced transcriptional activity of 
p53, these three proteins seem to promote and negative feedback loop that is of substantial 
importance for regulating both cell growth and cellular stress signaling.  
ERK activation by HER2/neu is also Wip1 dependent and crossing of MMTV-neu mice with 
Wip1 KO mice revealed that  in the absence of Wip1, ERK activation by HER2/neu in cells 
responsive to hormone signaling was significantly reduced 
95
. However, to date, it remains unclear if 
Wip1 functions as a direct ERK phosphatase. 
p53: In addition to inactivating p53 through a p38-dependent mechanism, Wip1 also directly 
dephosphorylates p53
96
. In an in vitro phosphatase assay, purified Wip1 robustly dephosphorylates 
p53 Serine 15 phospho-peptide as well as full-length Serine 15-phosphorylated p53 in a magnesium-
dependent and okadaic acid-independent fashion. Phosphorylation of p53 on Serine 15 is mediated 
by the kinases ATM and ATR in response to IR and UV irradiation, and it has been shown to be 
important for the apoptotic activity of p53
97
, as well as for p53 stability, as pS15 inhibits the 
interaction of p53 with MDM2
98
. Analyses of effects of IR and UV irradiation on protein levels and 
phosphorylation of p53 in mouse embryonic fibroblasts (MEFs) provided additional evidence for 
involvement of Wip1 in regulating p53 signaling
96
. Transfection of the cells with wild-type Wip1 
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attenuated Serine 15 phosphorylation, and reduced the overall level of p53 (by promoting its 
interaction with MDM2). Transfection with phosphatase-dead mutant Wip1, or co-expression of 
Wip1 siRNA did not inhibit p53 activity
96
. Taken together, these observations convincingly 
demonstrate that Wip1 plays an important role in regulating the activity and the stability of p53. 
MDM2: In addition to promoting MDM2 interaction with p53 by dephosphorylating p53 at S15, 
Wip1 also directly stabilizes Mdm2
99
. Wip1 interacts with and dephosphorylates Mdm2 at serine 395, 
a site phosphorylated by the ATM kinase. Dephosphorylated Mdm2 has increased stability and 
affinity for p53, facilitating p53 ubiquitination and degradation. 
ATM: Wip1 dephosphorylates the ataxia-telangietasia muted kinase (ATM) at Ser1981, a site 
critical for ATM monomerization and activation; moreover Wip1 is critical for resetting ATM 
phosphorylation as cells repair damaged DNA
100
. Wip1 physically interacts with ATM even in 
unstressed cells, which seems to point towards a mechanism by which Wip1 assists in setting a 
threshold for the initial activation of ATM. The tumor suppressor protein ATM is known to be a 
master regulator of cell cycle checkpoints after DNA damage, specifically after IR-induced DNA 
double-strand breaks. ATM (co-)controls the activities of several different signaling pathways 
involved in cell cycle regulation and in the cellular stress response (e.g. p53), and its net effects 
include cell cycle arrest, activation of DNA repair and induction of apoptosis
101
. Taking the 
abovementioned observations into account, it seems reasonable to assume that by dephosphorylating 
and inactivating ATM, Wip1 functions as a positive regulator of cell growth and as an inhibitor of 
cellular stress signaling. 
Chk1: Co-immunoprecipitation analyses, revealed that Wip1 also interacts with checkpoint 
kinase 1 (Chk1), yet another important regulator of cell cycle progression and cellular stress 
signaling
96
. Wip1 directly dephosphorylates Chk1 on Serine 345 and Serine 317, and as a result, 
overexpression of Wip1 significantly reduced the kinase activity of Chk1 following UV-induced 
stress. Several breast cancer cell lines that endogenously express high amounts of Wip1 exhibited an 
attenuated UV-induced Chk1 Ser-345 phosphorylation as compared to cells expressing low amounts 
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of the phosphatase, confirming that Wip1 plays a physiological role in regulating Chk1 signaling. 
Again Wip1 abrogates both the intra-S and the G2/M checkpoint after IR and UV radiation in U2OS 
cells. These findings suggest that one of the primary functions of Wip1 is to reverse the p53- and the 
Chk1-induced cell cycle arrest, and to return the cells to a homeostatic state following the 
completion of DNA repair 
96
. 
Chk2: Not long after Wip1 was identified as a Chk phosphatase, two groups showed that Wip1 
also dephosphorylates Checkpoint kinase 2 (Chk2)
102, 103
. Chk2 and Wip1 physically interact in a 
yeast two-hybrid screen and co-immunoprecipitated. After IR-induced Chk2 phosphorylation, Wip1 
dephosphorylates two Serines (S19 and S33/35) and two Threonine (T68 and T432) residues in Chk2. 
siRNA-mediated knockdown of Wip1 resulted in an abnormally sustained Threonine 68 
phosphorylation of Chk2 with increased susceptibility of several cell types to IR. As a result, 
overexpression of Wip1 suppressed the contribution of Chk2 to the IR-mediated induction of the 
G2/M checkpoint. Based on these studies, Wip1 can be considered not only a regulator of Chk1, but 
also an important physiological inhibitor of Chk2 signaling in response to DNA damage. 
RelA/NF-κB: Wip1 was recently identified as a negative regulator of NF-κB signaling pathway47 
in both a p38-dependent and independent manner. Wip1 inhibits expression of NF-κB target genes 
IL-6, IRF-1 and ICAM expression through p38 while Wip’s effect on expression of TNFα, IκBα and 
MCP-1 is p38-independent. In a dose dependent manner, overexpression of WIP1 decreases NF‑κB 
activation, whereas WIP1 knockdown increases NF‑κB function. In vitro phosphatase assays using 
full-length RelA or S536 phospho-peptide as substrates confirmed that WIP1 is a direct phosphatase 
targeting Ser536 of RelA. Phosphorylation of Ser536 is required for recruitment of the 
transcriptional co-activator p300 and is essential for the transactivation function of RelA.Wip1 
regulates binding of NF‑κB to p300 with downstream effects on chromatin remodeling. Consistent 
with the function of Wip1 to inhibit NF-κB activity, mice lacking WIP1 have phenotypic 
characteristics of enhanced inflammation providing the first genetic evidence that a phosphatase 
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directly regulates NF‑κB signaling in vivo. Wip1 activity to inhibit NF-κB including NF-κB 
oncogenic activities, suggest that in addition to the accepted role of Wip1 as an oncogene, it may 
also have tumor suppressor activities.  Although untested, the balance between Wip1’s oncogenic 
and tumor suppressive activities may depend on tissue, cellular or molecular context.  
 
Collectively, the findings outlined above demonstrate that PPM phosphatases (Wip1, PPM1A, 
and PPM1B) are widely regulate proteins critical for cell growth and cellular stress signaling. Table 
1.2 (adapted from
1
) summarizes the pathways and the proteins impacted by PPM-mediated 
dephosphorylation. The number of proteins with known activity as tumor suppressors or oncogenes 
regulated by PPM family members is remarkable. PPM1A and PPM1B share many targets, 
suggesting either a collaborative or redundant regulation of these signaling pathways. A smaller 
number of targets are shared between Wip1 and the other 2 PPM family members (PPM1A and 
PPM1B) possibly attributable to the high amino acid sequence homology of PPM1A and PPM1B, 
compared to Wip1. There are several cases where PPM1A and Wip1 target distinct proteins within 
the same pathway with the same effect to increase or decrease activity (e.g. p38, NF-κB). The major 
difference between PPM1A and Wip1 relates to their opposite roles in p53 regulation. Wip1 
activates MDM2 and directly inhibits p53, whereas PPM1A destabilizes and inhibits MDM2 (Fig. 
1.3, adapted from
1
). Given the direct and indirect targets of Wip1 (p53, ATM, Chk1, Chk2, MDM2, 
ARF, and p16), Wip1 has been implicated as an oncogene. Expression data from human cancers also 
revealed that the Wip1 gene is amplified in many tumor types including pancreas, lung, liver, 
bladder and breast cancers
104-106
.  It is not clear whether if PPM1A and Wip1 compete for substrates 
in these pathways or if they are selectively regulated by different upstream signals. Also the 
biological functions within the different pathways regulated by each of the PPM phosphatases 
suggest both oncogenic and tumor suppressor capacities. Regulation of PPM phosphatase activities 
toward specific targets with the ability to increase preference for one set of targets over others is 
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likely critical for determining cellular consequences. Given activities that have opposing tumor 
outcomes, it is likely that the biological consequences associated with PPM phosphatase activity 
reflect an orchestra of all regulated pathways.    
 
 
 
     
PPM 
phosphatase 
Signaling 
pathway 
Target protein(s) in this 
pathway 
Effect on 
cell growth 
Effect on 
stress 
signaling 
PPM1A AMPK AMPK — ↓ 
 
JNK MKK4,MKK7 — ↓ 
 
p38 p38, MKK3b, MKK6b — ↓ 
 
CDK Cdk2, Cdk6 ↓ — 
 
p53 MDM2 ↓ ↑ 
 
TGFβ Smad2/3 ↓ — 
 
NF-κB IKKα, IKKβ ↓ ↓ 
PPM1B JNK mkk4,MKK7, TAK1 — ↓ 
 
p38 MKK3b, MKK6b — ↓ 
 
NF-κB IKKα, IKKβ ↓ ↓ 
 
CDK Cdk2, Cdk6 ↓ — 
 
p53 MDM2 ↓ ↑ 
 
Bcl-xL BAD ↓ — 
Wip1/PPM1D p38 p38 — ↓ 
 
p53 p53, p38, ATM, MDM2 ↑ ↓ 
 
ATM ATM ↑ ↓ 
 
Chk Chk1, Chk2 ↑ — 
 
ARF p38 ↑ — 
 
INK4A p38 ↑ — 
  NF-κB RelA ↓ ↓ 
      
  
Table. 1.2 Overview of PPM phosphatases interaction with proteins regulating cell growth 
and cellular stress signaling (adapted from 
1
). ↓Indicates that the (over-)expression of the 
respective phosphatase results in an inactivation of the indicated pathway, ↑ indicates an 
activation of the pathway. 
 
 
Table 1.0.2 Overview of PPM phosphatases interaction with proteins 
regulating cell growth and cellular stress signaling. 
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Fig. 1.3 PPM phosphatases regulate p53 signaling (adapted from
1). ┴ 
indicates inhibition of the respective protein, ↑ indicates activation. 
Figure 1.0.3 PPM 
phosphatases regulate p53 
signaling 
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4. LZAP 
4.1 General introduction to LZAP 
LZAP (also called CDK5rap3 or C53) was first described as a binding partner of the 35kDa 
CDK5 activator binding protein p35Nck5a in 2000
107
. Activity of CDK5rap3 related to p35Nck5a 
has not been further characterized and is unlikely to represent its major activity since expression of 
CDK5 and p35Nck5a is restricted to neurons while LZAP is ubiquitously but variably expressed in 
all tissues tested
82, 107
. Consistent with alternative roles for CDK5rap3, we have identified this protein 
as a novel binding partner for the tumor suppressor ARF (alternative reading frame) through an 
unbiased yeast two-hybrid screen approach in 2006. Based on these data, we renamed this protein 
LZAP for LXXLL/leucine zipper-containing ARF-binding protein. LZAP is a highly conserved 
protein in vertebrates, invertebrates and plants, but not in yeast and bacteria. Within the cell LZAP 
localizes to cytoplasmic and nuclear compartments. Database searches and publications have failed 
to identify homologs and amino acid or nucleotide alignment of suggest that LZAP shares no 
significant amino acid homology with any known protein and also lacks conserved functional 
domains, except for putative leucine zipper (amino acid 357-385) and LXXLL motifs. Human LZAP 
has two LXXLL motifs and one conserved LXXLL-like LXXFL motif. These motifs are of unknown 
significance for LZAP activity, but are important for nuclear hormone receptor co-regulator binding 
to steroid receptors and transcriptional co-activators
108, 109
. We previously demonstrated that loss of 
LZAP promotes tumor growth in vivo and that LZAP is lost in ~30% of human HNSCC
110
. We have 
targeted LZAP in mice and our preliminary findings suggest that homozygous knockout of LZAP is 
embryonic lethal in early stage of development with inability to identify LZAP-/- embryo as early as 
embryonic day 4.5 (unpublished data). Interestingly, heterozygous mice with targeted LZAP are 
susceptible to lung tumor formation (unpublished data). We further explored developmental roles of 
the LZAP gene during zebrafish morphogenesis
111
. LZAP is maternally deposited in the zebrafish 
embryo. Expression is initially ubiquitous during gastrulation, and later becomes more prominent in 
the pharyngeal arches, digestive tract, and brain. Morpholino-mediated depletion of LZAP delays 
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cell divisions and induces apoptosis during blastomere formation, resulting in fewer and larger cells 
before epiboly. Cell cycle analyses suggested that LZAP loss in early embryonic cells precipitates a 
G2/M arrest. Furthermore, the LZAP-deficient embryos failed to initiate epiboly--the earliest 
morphogenetic movement in animal development--which has few described requirements, but has 
been shown to depend on cell adhesion and migration of epithelial sheets. These functions provide 
further insight into LZAP activity and suggest that LZAP is required during early development and 
inhibits tumor formation. Molecular mechanisms of LZAP activities continue to emerge. We and 
others have described LZAP functions to regulate activities of ARF, p53, p38 MAPK, NF-κB, Wip1, 
Chk1 and Chk2. 
 
4.2 Mechanisms of LZAP activity 
RelA and NF-κB pathway: Our lab reported that LZAP directly binds to RelA and that amino 
acids 195-313 of RelA are required for the interaction
110
. LZAP inhibits RelA phosphorylation at 
S536 and decreases RelA transcriptional activity toward selective gene targets, as well as increases 
RelA association with HDAC1, HDAC2 and HDAC3. Conversely, loss of LZAP increases both 
basal and cytokine-induced RelA transcriptional activity. Based on ChIP analyses, LZAP is present 
on chromatin at select NF-κB-responsive promoters. These data suggest that LZAP is a potent NF-
κB inhibitor and that endogenous LZAP inhibits both basal and activated NF-κB, possibly by 
converting NF-κB to a transcriptional repressor through interaction with HDACs. Functionally, 
decreased expression of LZAP increases expression of MMP-9 and increases cellular invasion, both 
of which are dependent on NF-κB. Overexpression of LZAP sensitizes cells to TNFα-induced cell 
death similar to effects of the NF-κB inhibitor IκB likely through inhibition of NF-κB mediated anti-
apoptotic signaling. Knockdown LZAP in xenograft tumor cells promotes tumor growth and 
angiogenesis. In primary HNSCC tumors LZAP protein levels inversely correlated with expression 
of the NF-κB regulated genes IL-8 and IκBα. Collectively, these data suggest that LZAP is a putative 
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tumor suppressor and that LZAP regulation of NF-κB activity requires LZAP association with RelA 
and modification of RelA phosphorylation. 
ARF and p53 pathway: Our lab found that LZAP binds ARF in a yeast two-hybrid screen 
designed to identify ARF-interacting proteins potentially involved in regulation of ARF activity. 
LZAP binds ARF, co-localizes with ARF, and forms a ternary complex with ARF, HDM2 and p53 
in mammalian cells. Expression of LZAP in the presence of ARF further enhances p53-mediated 
expression of the cyclin-dependent kinase inhibitor p21/Cip1 and enhances the ARF-mediated G1 
cell cycle arrest. Upon direct binding to ARF, LZAP reverses ARF inhibition of HDM2’s p53 
ubiquitination activity, but despite its ability to restore HDM2-mediated p53 ubiquitination, LZAP 
expression does not decrease p53 stability in the presence of ARF. In fact, when expressed with 
HDM2 and ARF, LZAP stabilizes p53 protein by inhibiting p53 nuclear export and further 
augmentations p53 transcriptional activity. Ectopic expression of LZAP in mammalian cells induces 
a p53-dependent G1 cell cycle arrest. Remarkably, a similar pattern of p53 activation and a p53-
dependent G1 cell-cycle arrest were observed in ARF null cells. Because LZAP does not inhibit 
proliferation in cells lacking p53 activity, LZAP mediated cell cycle arrest is dependent on p53
112
. 
These findings suggest that LZAP regulates p53 through ARF-dependent and -independent 
mechanism(s), the later could be attributable to activity of novel LZAP-binding partners. 
Chk1/2: To date, there is a single publication describing LZAP activity towards the checkpoint 
kinases Chk1 and Chk2 (hereafter called Chk1/2)
113
. Passage through the G2/M checkpoint depends 
on activation of the CDK1/cyclin B complex and is tightly regulated by Chk1/2 through CDC25. 
Recent evidence indicates that in response to DNA damage, p38 MAPK also triggers the G2/M 
checkpoint through regulation of CDC25
114
. Endogenous and exogenous stresses, such as replication 
fork collapse or IR, result in DNA damage and activation of the apical serine/threonine protein 
kinases belonging to the PI3K family, including ATM, ATR and DNA-PK. Activated PI3Ks in turn 
phosphorylate and activate the downstream checkpoint kinases Chk1/2. Although both Chk1 and 
Chk2 can phosphorylate and inhibit CDC25, Chk1 seems to be the primary kinase responsible for the 
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G2/M checkpoint
115
. Chk1/2-mediated phosphorylation of CDC25C at S216 is required for its 
recruitment of 14-3-3. Binding of 14-3-3 to CDC25C, either directly or through cytoplasmic 
sequestration, inhibits CDC25C binding to the CDK1/cyclin B complexes
114
. Jiang et al. reported 
that during DNA damage response, LZAP inhibits Chk1/2 phosphorylation and activation. By 
counteracting Chk1, LZAP activates CDC25C resulting in downstream CDK1 activation
113
 (Fig. 1.4). 
It is well known that Chk1/2 are phosphorylated and activated after DNA damage by ATM and ATR. 
Expression of LZAP is associated with decreased phosphorylation and inhibition of Chk1/2, but this 
effect is not mediated through decreasing the activities of their upstream kinases. Since checkpoint 
kinases are inhibited by LZAP, their activity toward CDC25C is similarly inhibited, resulting in 
activation of CDK1 and inappropriate or early progression into mitosis
113
. Jiang et al. have shown 
that knockdown of LZAP inhibits CDK1 and delays mitotic entry
113
. These results are consistent 
with an earlier report by the same group that LZAP increases sensitivity to genotoxins related to 
inappropriate progression through the G2/M checkpoint
116
. These data show that LZAP binds and 
inhibits Chk1 resulting in dysregulation of cell cycle progression; however, Chk1 and Chk2 kinases 
phosphorylate and regulate targets in addition to CDK1, including p53. Mechanisms explaining how 
LZAP alters Chk1/2 phosphorylation and activity remain unclear. 
  
Fig. 1.4 LZAP Inhibits Checkpoint Kinases.  LZAP inhibits Chk1 and Chk2 causing 
activation of CDC25C and CDK1. Simplified, LZAP is an activator of CDK1 through 
inhibition of checkpoint kinases. Arrows indicate activation and T shapes indicate 
inhibition. 
Figure 1.0.4 LZAP 
Inhibits Checkpoint 
Kinases 
29 
p38: To better understand LZAP biological activities and to gain mechanistic insight, additional 
LZAP binding partners have been sought. Through a Scan Site Search (http://scansite.mit.edu/) using 
LZAP sequence, we found that LZAP contains sites predicted to bind to the common MAPK 
docking domain (D domain). LZAP binding to p38α MAPK was confirmed by in vivo binding assays 
and immunofluorescent staining of expressed proteins shows nuclear co-localization of p38α with 
LZAP
117
. LZAP expression is associated with a dose dependent decrease in p38 phosphorylation and 
activity, both at basal level and following cytokine stimulation while siRNA-mediated loss of LZAP 
increases p38 phosphorylation and activity after cytokine treatment indicating that LZAP regulates 
p38 phosphorylation at both basal and stimulated levels. LZAP’s activity to inhibit p38 
phosphorylation does not depend on upstream p38 activating MAPK kinases, MKK3 or MKK6. 
 
4.3 Regulation of LZAP 
To date, little is understood regarding regulation of LZAP in normal or tumor tissues. We and 
others have shown that LZAP is ubiquitously expressed in all human, rat and mouse tissues tested, 
including pancreas, brain, liver, heart, intestine, spleen, thymus, muscle and lung (
118, 119
 and 
unpublished data). Expression of LZAP is markedly decreased or undetectable in 30% of HNSCC, 
but mechanisms of LZAP loss are currently unknown
110
. LZAP can be phosphorylated in in vitro 
kinase assay by Cdk5
107
; however, it is not clear if LZAP is phosphorylated in vivo or what sites of 
LZAP are phospho-acceptor sites. LZAP homodimerization has been suggested by one publication 
that used LC/MALDI mass spectrometry of bands separated by polyacrylamide gel electrophoresis 
after Flag-LZAP immunoprecipitation
119
.   
Recently, a novel protein, KIAA0776 (also RCAD/NLBP/UFL1) was reported as a novel LZAP 
binding partner by four independent groups. KIAA0776 was first reported by Kwon et al. using 
tandem affinity purification of LZAP followed by mass spectrometry
120
. Binding domain mapping 
determined that amino acids 301-400 in LZAP and 121-250 in KIAA0776 is required for the 
interaction the two proteins. Loss of KIAA0776 by siRNA knockdown decreases LZAP stability 
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which could be mediated by binding between LZAP and KIAA0776, since co-expression of LZAP 
with a KIAA0776 deletion mutant lacking binding activity to LZAP did not influence ubiquitination 
levels of LZAP and vice versa. On the other hand, expression of wild-type KIAA0776 decreases 
LZAP ubiquitination
120
. Wu et al. reported the identification of two LZAP binding partners, 
KIAA0776 /RCAD and C20orf116 /DDRGK1
119
. LZAP forms a large protein complex with these 
two proteins as demonstrated by size exclusion chromatography.Loss of KIAA0776 decreases LZAP 
and C20orf116 protein half-life. LZAP and C20orf116 are fairly stable in control cells and are not 
very robustly subjected to  proteasome-mediated degradation; however, after siRNA knockdown of 
KIAA0776, they observed significant elevation of LZAP and C20orf116 proteins even by 2 hours 
after MG132 treatment. This is different from the result of the Kwon group where they showed that 
in control cells, the LZAP level is increased after treatment with MG132. Both of the groups showed 
that KIAA0776 inhibits cell invasion and negatively regulates the NF-κB signaling pathway thought 
to be through interaction with LZAP. Wu et al. also determined C20orf116, the second LZAP 
binding protein localizes to the endoplasmic reticulum (ER) and is anchored there by its amino (N)-
terminal signal peptide. A third group
121
 using Bergmann glia cells further showed that 
KIAA0776/Maxer is also a novel ER-associated protein and KIAA0776 anchors LZAP to the ER 
and inhibits LZAP  function in the nucleus, e.g. Cyclin D1 transcription repression though NF-κB. 
KIAA0776 shRNA knockdown shifted LZAP from the cytoplasm to nucleus. This is the first report 
demonstrating regulation of LZAP subcellular localization. Loss of KIAA0776 eventually induces 
cell accumulation at G1 phase and suppresses proliferation of C6 glioma cells which are rescued by 
simultaneous knockdown of LZAP
121
. These data are consistent with our finding that LZAP 
regulates cell cycle arrest in G1 phase
112
. The fourth paper by Lemaire et al, 2011
118
  identified 
another LZAP binding protein, UFM1 (ubiquitin fold modifier 1) which belongs to ubiquitin-like 
proteins family, a novel protein-conjugating system displaying a similar tertiary structure to 
ubiquitin
122
. Similar to ubiquitin, UFM1 also requires a three enzyme system to complete 
conjugation to targeted proteins. UFM1 is activated via the E1 enzyme, UBA5, and then conjugated 
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by the E2 enzyme, UFC1. UFL1 has very recently been identified as the E3 conjugating enzyme
123
. 
Interestingly, UFL1 is KIAA0776, one of the LZAP binding proteins; moreover, C20orf116/UFBP1, 
the other LZAP binding protein, is a substrate of UFM1
123
. In vitro pull down assays confirmed 
binding between LZAP and UFM1 and again LZAP and KIAA0776
118
. Co-immunoprecipitation data 
suggests UFM1, LZAP, KIAA0776 and C20orf116 do not directly interact with each other but rather 
are part of the complex. It is unclear whether LZAP is a substrate of UFM1 or the interaction 
between KIAA0776 and LZAP is dependent on KIAA0776 E3 ligase activity. Also there are no 
reports identifying lysine residue(s) in LZAP targeted for ubiquitination. Due to the consistent results 
that KIAA0776 decreases LZAP ubiquitination, it is possible that there is competition between 
KIAA0776 and E3 ubiquitin ligases for the same lysine residue(s) in LZAP. In addition to 
ubiquitination-mediated proteasome degradation, Jiang et al. mentioned as unpublished data in their 
recent paper that LZAP is cleaved by caspase-3 at three sites (D268, D282 and D311)
113
. 
 
5. Summary and Dissertation Goals 
NF-κB, a family of transcription factors, mediates effector function of almost all innate and 
adaptive immune responses and regulates cell proliferation, differentiation and apoptosis. Activated 
NF-κB also functions as an oncogene in tumorigenesis, progression and metastasis. Because of the 
role of NF-κB in important biological processes, NF-κB activity is intricately controlled at multiple 
levels with post-translational modification, in particular phosphorylation, serving a critical role. 
RelA is the most well studied transactivation-domain containing family member of NF-κB.  Our 
interest in RelA phosphorylation was peeked when we found that LZAP tumor suppressor activity 
was in part mediated by inhibition of RelA phosphorylation at serine 536
110
. Since LZAP has no 
known enzymatic activity and LZAP has no activity to inhibit RelA specific kinases (IKKα/β/ε, 
TBK1 and RSK, data not shown), the role of LZAP as a regulator of phosphatases was explored. 
Though dozens  kinases have been identified that modify specific serine or threonine residues in 
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RelA, less is known about RelA specific phosphatases. Given the number of RelA kinases, it is 
reasonable to expect that more than two phosphatases (PP2A and Wip1) target RelA for 
dephosphorylation as a mechanism to restore basal steady state RelA activity. I hypothesized that 
PPM1A, the PPM family member may function as a RelA phosphatase and that the tumor suppressor 
activity of PPM1A is at least partially dependent on its negative regulation of NF-κB. We noticed an 
overlap of LZAP regulated proteins and substrates of PPM1A, PPM1B and Wip1 (e.g. RelA, p53, 
Chk1/2 and p38) and developed preliminary data suggesting that PPM family members bound to 
LZAP. Based on these findings, I further hypothesized that LZAP regulated protein phosphorylation 
and activity through facilitating interaction of PPM phosphatases and target proteins. In this 
dissertation, RelA and p38 were chosen from the pool of LZAP targets and used as models to study 
the mechanism(s) of LZAP-mediated dephosphorylation and activity. Since a growing body of 
literature demonstrates pleiotropic roles of LZAP, including that of a putative tumor suppressor, it is 
important to understand the regulation of LZAP. Given that LZAP binds to phosphatases, I further 
hypothesized that post-translational phosphorylation and ubiquitination may regulate LZAP activity 
and protein stability. The primary objective of my work is to test these hypotheses and more 
importantly, contribute to the understanding of NF-κB and LZAP activities and regulation.   
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CHAPTER II 
 
PPM1A IS A RELA PHOSPHATASE WITH TUMOR SUPPRESSOR-LIKE ACTIVITY 
 
Part of the work presented in this chapter is published under the identical title in Oncogene, 2013. 
 
Abstract 
NF-κB signaling contributes to human disease processes, notably inflammatory diseases and 
cancer. NF-κB plays a role in tumorigenesis and tumor growth, as well as promotion of metastases. 
Mechanisms responsible for abnormal NF-κB activation are not fully elucidated; however, RelA 
phosphorylation, particularly at residues S536 and S276, is critical for RelA function. Kinases that 
phosphorylate RelA promote oncogenic behaviors suggesting that phosphatases targeting RelA 
could have tumor inhibiting activities; however, few RelA phosphatases have been identified. Here, 
we identified tumor inhibitory and RelA phosphatase activities of the PPM phosphatase family 
member, PPM1A. We show that PPM1A directly dephosphorylated RelA at residues S536 and 
S276 and selectively inhibited NF-κB transcriptional activity resulting in decreased expression of 
MCP-1/CCL2 and IL-6, cytokines implicated in cancer metastasis. PPM1A depletion enhanced NF-
κB-dependent cell invasion while PPM1A expression inhibited invasion. Analyses of human 
expression data revealed that metastatic prostate cancer deposits had lower PPM1A expression 
compared to primary tumors without distant metastases. A hematogenous metastasis mouse model 
revealed that PPM1A expression inhibited bony metastases of prostate cancer cells after vascular 
injection. In another xenograft model, PPM1A depletion facilitated tumor growth and cellular 
proliferation while inhibiting apoptosis. In summary, our findings suggest that PPM1A is a RelA 
phosphatase with NF-κB regulatory activity, and that PPM1A has tumor suppressor-like activity. 
Our analyses also suggest that PPM1A inhibits prostate cancer metastases and since neither gene 
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deletions nor inactivating mutations of PPM1A have been described, increasing PPM1A activity in 
tumors represents a potential therapeutic strategy to inhibit NF-κB signaling or bony metastases in 
human cancer. 
 
Introduction  
NF-κB, comprised of a family of pluripotent transcription factors, plays a fundamental role in 
inflammatory and immune responses and aberrant NF-κB activity can directly contribute to 
tumorigenesis, neovascularization, tumor growth and metastases
25, 50
. NF-κB activation has been 
described in many tumors including: HNSCC
54, 110 
and breast cancer
124, 125
. Dysregulation of NF-κB 
in prostate cancer has been identified as a major driver of distant metastasis, which is the primary 
cause of death in this common male cancer
61-63
. One transcriptional target of NF-κB, monocyte 
chemotactic protein-1 (MCP-1), also known as chemokine (C-C motif) ligand 2 (CCL2), has been 
implicated in prostate cancer migration, invasion and metastasis through effects on both tumor cells 
and the microenvironment
65
. MCP-1 seems to be particularly implicated in bony metastases for 
prostate cancer and in other tumor types including renal cancer, bladder cancer and breast cancer 
66
. 
Although mechanisms governing MCP-1 expression are not fully described, the suspected 
importance of this cytokine in tumor progression is affirmed by the recent initiation of clinical trials 
using neutralizing antibody targeting MCP-1.  
Because of the role of NF-κB in varied biological processes, NF-κB activity is intricately 
controlled at multiple levels. Inhibition of NF-κB through binding to IκBα with prevention of 
nuclear translocation has been well characterized; however, full activation of nuclear NF-κB 
transcriptional activity requires phosphorylation of RelA
126
. Phosphor-acceptor sites of RelA have 
been characterized
126, 15
 particularly implicating serine 536 and serine 276 as critical for NF-κB 
activation
19,23
. Although not as extensively studied, dephosphorylation of RelA is needed to prevent 
harmful effects of prolonged RelA signaling
42
. To date, only two phosphatases, PP2A and 
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Wip1/PPM1D, have been shown to directly dephosphorylate RelA, both having activity toward 
S536
43, 47
. Deficiency of PP2A contributes to the constitutive activation of RelA in melanoma cells
43
 
and mice lacking Wip1 have an inflammatory phenotype
47
 suggesting that loss of RelA-targeting 
phosphatases can impact pathological processes including cancer. 
PPM1A belongs to the protein phosphatase magnesium/manganese-dependent family (PPM) 
family together with Wip1 and PPM1B. PPM1A has been implicated in regulation of several 
signaling pathways including TGFβ/Smad 82, MAPK (JNK/p38), Cdk2 and Cdk61 and the nerve 
growth factor activated Akt/ERK pathway
83
. Regulation of these pathways has been attributed to 
PPM1A phosphatase activity toward key pathway components in some cases (e.g. Smad2/3 and 
p38), but has not been fully characterized in others (e.g. Akt/ERK, Cdk2 and Cdk6). In addition, 
PPM1A has been implicated in regulation of proliferation
1
, cell invasion and migration
89
, but targets 
of PPM1A activity that regulate these activities have not been identified. Recently, PPM1A has 
been described as an indirect regulator of NF-κB through dephosphorylation and inactivation of 
IKKβ49. Here we show that PPM1A directly dephosphorylated RelA at Ser-536 and Ser-276 with 
resultant inhibition of NF-κB transactivation and decreased expression of target genes, notably 
including MCP-1/CCL2. We report that PPM1A expression was down-regulated in human 
metastatic prostate cancer, and that restoration of PPM1A decreased seeding and bony growth of 
prostate cancer cells in an animal vascular injection model. In addition, loss of PPM1A increased 
NF-κB dependent invasion and accelerated xenograft tumor growth. These data suggest that 
PPM1A has tumor suppressor-like qualities that are, at least partially, dependent on regulation of 
RelA. 
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Materials and Methods 
Expression Plasmid and small hairpin RNA expression Constructs 
Myc-PPM1A, Myc-PPM1A (R174G) mutant, GST-PPM1A and GST-PPM1A (R174G) were 
gifts from Dr. Sun
49
. His-Wip1 was a gift from Dr. Donehower
99
. PPM1A was PCR amplified and 
subcloned into the pHIT-dell2-puro retroviral expression vector. Other constructs were described 
previously 
110
. A pSuper-retro vector (provided by Dr. Reuven Agami) was used to generate shRNA 
plasmids for PPM1A with the following target sequence 5'-AAGTACCTGGAATGCAGAGTA-3' 
(ref.
49
). Lentiviral vector pGIPZ and plasmid coding for PPM1A-targeting shRNA (Clone ID 
V2LHS_35113) were from Open Biosystems, Waltham, MA. PPM1A-1 (catalog# SI02659258, 
Hs_PPM1A_5) and PPM1A-2 (catalog # SI02659265, Hs_PPM1A_6) siRNA were purchased from 
QIAGEN, Germantown, MD. Control siRNA (nontargeting#1) was from Dharmacon, Waltham, MA. 
Cell lines, cell culture, transfection and virus infection 
IKKalpha-/-, IKKbeta-/- (IKK1-/-, IKK2-/-) double null MEFs were a gift from Dr. Verma (the 
Salk Institute for Biological Studies, Laboratory of Genetics, San Diego, CA). PC3 and LNCaP cell 
lines were provided by Dr. Renjie Jin (Vanderbilt University, Nashville, TN). Cell lines were 
maintained according to ATCC protocol. TransIT-2020 (Mirus, Madison, WI) was used for MEFs 
transfection. SiRNA was transfected at 20nM using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, 
CA). All transfection reagents were used according to the manufacturers’ instructions. Cells 
expressing PPM1A or shRNA targeting PPM1A were infected with indicated virus-containing 
medium with 4mg/ml polybrene (Sigma-Aldrich, St. Louis, MO). For transient expression, cells 
were used after 24 h of infection. Stable cell lines were selected for 10 days in puromycin (1ug/ml).  
Antibodies and reagents 
Rabbit anti-RelA (C20), anti-phospho-S276 RelA (sc101749), anti-GAPDH, anti-IκBα (C21), 
anti-IKKα/β (sc7607) and HRP-conjugated secondary donkey anti-mouse and anti-rabbit antibodies 
were from Santa Cruz Biotechnology, Santa Cruz, CA. Mouse and rabbit anti-PPM1A were from 
Abcam, Cambridge, MA (p6c7) and GeneTex, Irvine, CA (GTX109744), respectively. Rabbit anti-
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phospho-S468 RelA (Ab31473) was from Abcam. Mouse anti-Flag M2, anti-Flag M2 affinity gel 
and 3XFlag peptide were from Sigma-Aldrich. Anti-phospho-S536 RelA (Cell Signaling, Boston, 
MA). TNFα and IL-1β were from PeproTech, Rocky Hill, NJ. 
Immunoprecipitation and immunoblotting 
Cells were lysed in 0.5% (v/v) Nonidet P-40 lysis buffer supplemented with protease inhibitor 
cocktail (Roche, Indianapolis, IN) and phosphatase inhibitor III (Sigma-Aldrich). Total cell lysate 
was incubated with anti-Flag M2 affinity gel (Sigma-Aldrich) and immunoprecipitation was 
performed according to manufacturer’s instruction.  Immunoblotting was performed as previously 
described 
117
.  
In vitro phosphatase reaction and malachite green phosphatase assay  
The experiment was performed as described
49
 with modified phosphatase 2C buffer (50mM Tris-
HCl pH7.5, 0.1mM EGTA, 0.02% 2-mercaptoethanol ±25mM MgCl2). Flag-RelA protein was used 
as substrate after elution with using 3×Flag peptide (Sigma-Aldrich). Phospho-peptide analysis was 
performed as described 
47
 with modified PPM buffer and malachite green assay kit (#POMG-25H, 
BioAssay Systems, Hayward, CA). Phospho-peptides synthesized by LifeTein: RelAS536 
(GDEDFSpSIADMD), RelAS276 (QLRRPpSDRELS)
47
. His-Wip1 was purified using Ni-beads as 
described
99
.  
Luciferase reporter gene assay 
Dual-Luciferase Reporter Assay (Promega, Madison, WI) was performed as previously 
described
110
. 
cDNA synthesis and real-time PCR 
mRNA was extracted using RNeasy mini (QIAGEN). cDNA synthesis was performed using 
iScript cDNA synthesis kit (BIO-RAD, Hercules, CA). Real-time PCR was performed using iQ 
SYBR green supermix (BIO-RAD). RT-PCR Array (PAHS-025A, SABiosciences) was used 
according to manufacturer’s instructions. MCP-1 primer sequences: forward 
5’ctgctcatagcagccacctt3’, reverse 5’gcactgagatcttcctattggtg3’. GAPDH was used as control. 
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Chromatin Immunoprecipitation (ChIP) Assays 
ChIP assays were performed using Magna ChIP A/G (#17-10085, EMD Millipore, Billerica, MA) 
following manufacturer’s instructions. 3×106 HeLa cells were used for each assay. Anti-RelA 
antibody (SC-109 X) and normal rabbit IgG (Santa Cruz) were used for immunoprecipitation. 
Purified DNA was analyzed by real time PCR. Primers ((NM_002982.3 (-) 03Kb) for the κB binding 
site on MCP-1 promoter were from SA Bioscience/Qiagen.  
In vitro cell invasion assay 
Transwell invasion assay was performed as described 
110
. 2×10
4 
HeLa cells, 5×10
4 
PC3-LUC cells 
or 1×10
5 
LNCaP cells were seeded into the upper chamber and analyzed after 21 h, 42 h and 46 h 
respectively. Membranes mounted to slides were scanned at 1.25×, 10× and 20× using the Ariol SL-
50 platform at Vanderbilt Epithelial Biology Center or under microscope with 200 × magnifications. 
Cell fractionation 
Cell fractionation was performed as described
127
 with modified hypotonic buffer (10mM HEPES 
pH 7.1, 50mM NaCl, 0.3M sucrose, 0.1mM EDTA, 0.5% TritonX100, 1mM DTT) and washing 
buffer (10mM HEPES pH 7.1, 0.1mM EDTA, 1mM DTT).  
DNA binding assay 
Assay was performed as described 
110
 using TransAM NF-κB p65 assay kit ( cat# 40096, Active 
Motif, Carlsbad, CA ). 
Obtaining conditioned medium (CM) and ELISA Assay 
Conditioned media were obtained from PC3 cell cultures as described
128
. Cell number from each 
well was counted to normalize data for differences. MCP-1 concentration was measured by MCP-1 
ELISA kit (R&D system, Minneapolis, MN) following manufacturer’s protocol.   
The Gene Expression Omnibus (GEO) analysis 
Normalized PPM1A expression data were downloaded from GEO 
(http://www.ncbi.nlm.nih.gov/projects/geo/) with citations for individual studies. Gene expression 
were analyzed and plotted with average ± SD in Prism 5.0 (GraphPad, La Jolla, CA). 
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In vivo tumor metastasis assay and BLI ex vivo analysis 
1×10
5
 PC3-LUC cells
 
infected with control or PPM1A-expressing retrovirus suspended in 0.1 ml 
of PBS were inoculated into the left cardiac ventricle of male nude mice. Metastases were monitored 
by bioluminescent imaging weekly (Xenogen IVIS 200 imaging system, Alameda, CA). Mice with 
bioluminescent signal in the chest cavity 1 h post-injection were excluded from the study since this 
indicated leakage of tumor cells during injection 
129
. Four weeks after injection mice were 
radiographed (Faxitron X-ray system, Tucson, Arizona), and long bones and spines were decalcified 
and paraffin embedded. Sections were stained with hematoxylin and eosin. 
In vivo xenograft tumor growth assay 
Animal protocols were approved by the Vanderbilt University Institutional Animal Care and Use 
Committee. Female nude mice (Harlan, Indianapolis, IN) were inoculated subcutaneously at 4 spots 
at age 6 to 10 weeks using 1×10
6
 HeLa cells infected with control retrovirus or retrovirus driving 
expression of PPM1A-specific shRNA. Tumor length (L) and width (W) was recorded weekly using 
calipers until the largest tumors approached 20 mm in length. Tumor volume was calculated using 
the formula: volume = ½ ×L×W
2
. Each mouse received 100ul (10mg/ml) BrdU i.p. injection 2 hrs 
before sacrifice. Excised tumors were weighed, and portions frozen or fixed in 4% paraformaldehyde 
before embedding in paraffin. PPM1A expression was determined in tumors by immunoblotting (10 
of 17 control tumors and 12 of 18 PPM1A knockdown tumors were large enough and with sufficient 
growth record) and tumor growth analyses stratified based on PPM1A expression (maintenance of 
knockdown). Hematoxylin and eosin staining and immunostaining of BrdU and cleaved Caspase3 
were performed by the Vanderbilt Immunohistochemistry Core Laboratory. At least five high-
powered fields were counted for each tumor. 
Statistical analysis 
Statistical analyses were performed using R version 2.14.1 for Windows, and data plotted and 
analyzed using student t-test, fisher exact test, Wilcoxon rank sum test or Kruskal-Wallis chi-square 
test. To take into account the correlation among repeated measurements from the same tumor, linear 
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mixed-effect models were fit to the tumor volume over time. *, **, *** represents p values less than 
0.05, 0.01 and 0.001, respectively, unless otherwise noted.  
 
Results 
PPM1A directly dephosphorylates RelA 
To better understand drivers of cancer progression and metastases, we sought to identify 
phosphatase inhibitors of NF-κB that work directly to dephosphorylate of RelA. Because the PPM 
family member Wip1 is one of the two described RelA phosphatases, we considered a PPM family 
member, PPM1A, as a candidate RelA phosphatase. To begin exploring this possibility, the effect of 
endogenous PPM1A on RelA phosphorylation was determined in U2OS and HeLa cells. Following 
PPM1A depletion using two independent siRNAs, RelA phosphorylation at S536 was increased in 
both cell lines while total RelA levels were not altered (Fig. 2.1A). Depletion of PPM1A further 
increased RelA phosphorylation following stimulation with TNFα (Fig. 2.2A). siRNA-mediated 
depletion of PPM1A did not alter total RelA levels (Fig. S1A) and did not affect PPM1B or Wip1 
protein expression (Fig. 2.2B). Expression of wild-type PPM1A decreased S536 phosphorylation of 
ectopically expressed RelA both with and without TNFα stimulation, whereas phosphatase-dead 
(R174G) PPM1A had no effect (Fig. 2.1B). Interestingly, RelA S276 phosphorylation was similarly 
decreased by expression of PPM1A (Fig. 1B) and siRNA-mediated depletion of PPM1A increased 
S276 phosphorylation after TNFα treatment (Fig. 2.2C). Phosphorylation of S468, a known 
transcriptional inhibition phosphorylation site of RelA
41, 111
 was unaffected by expression of PPM1A 
(Fig. 2.1B, 0.9 normalized to vector control as 1).   
We confirmed reports that PPM1A decreases IKKα and IKKβ phosphorylation49 (Fig. 2.2D); 
therefore, decreased RelA phosphorylation observed following expression of PPM1A could be a 
result of direct activity to dephosphorylate RelA or be mediated by IKKs. To begin exploring these 
possibilities, PPM1A was expressed in IKKalpha-/-, IKKbeta-/- double-null mouse embryonic 
fibroblasts. Notably, PPM1A expression resulted in decreased RelA S536 phosphorylation in the 
41 
absence of IKKα or IKKβ (Fig. 2.1C lanes 4, 5) indicating that PPM1A regulates RelA independent 
of IKKs. In these cells, decreased RelA phosphorylation was also dependent on PPM1A phosphatase 
activity and did not alter in RelA protein levels (Fig. 2.1C). 
Although PPM1A activity toward RelA was independent of IKKs, PPM1A regulation of RelA 
phosphorylation could be mediated through unknown indirect activities or through direct 
dephosphorylation of RelA. To begin distinguishing these possibilities, in vitro phosphatase assays 
using full-length RelA or RelA-specific phospho-peptides as substrates were performed. To 
determine PPM1A activity toward the full-length protein, expressed Flag-RelA was 
immunoprecipitated from 293T cells then incubated with bacterially synthesized GST-PPM1A 
proteins. Incubation with wild-type (Fig. 2.1D lanes 1-5) but not phosphatase-dead PPM1A (Fig. 
2.1D lane 6), decreased RelA phosphorylation at S536 in a dose-dependent fashion. As with all PPM 
family members, PPM1A phosphatase activity was magnesium dependent (Fig. 2.1D, compare lanes 
5 and 7). Because reliable phospho-specific antibodies are available only for S536 and to confirm 
findings of the full-length phosphatase assay, a peptide-based phosphatase assay was performed. 
Synthesized RelA phospho-peptides corresponding to phospho-serine 536 and 276 (pS536, pS276) 
(LifeTein, South Plainfield, NJ) were used as substrates and dephosphorylation was quantified using 
malachite green assay
47
. Wild-type, but not phosphatase-dead PPM1A dephosphorylated the pS536 
peptide with equivalent efficacy as the known RelA S536 phosphatase, Wip1 (Fig. 2.1E, compare 
lanes 4 and 7). As opposed to Wip1, PPM1A also dephosphorylated the pS276 peptide (Fig. 2.1F, 
compare lanes 4 and7). As expected, magnesium was required for activity of both PPM1A and Wip1 
(Figs. 2.1E and F, lane 6) and the phosphatase-dead mutant of PPM1A had no activity toward either 
pS536 or pS276 peptides (Figs. 2.1E and F lane 5). Together, these data suggest that PPM1A is a 
direct RelA phosphatase and the first phosphatase with potential activity toward pS276 of RelA.
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Fig. 2.1 PPM1A is a RelA phosphatase. (A) U2OS and HeLa cells were 
transfected with indicated siRNAs. PPM1A as well as endogenous phospho- and 
total RelA were visualized by immunoblotting. GAPDH served as loading 
control. (B) U2OS cells were transfected with indicated plasmids and proteins 
visualized by immunoblotting with GAPDH serving as loading control. PPM1A-
wt, wild type PPM1A; PPM1A-PD, phosphatase dead PPM1A (C) Wild-type 
mouse embryonic fibroblasts (MEFs) and IKKα-/-, IKKβ-/- double null MEFs 
were transfected with indicated plasmids. Endogenous Ikkα and Ikkβ and 
transfected phospho- and total RelA, as well as PPM1A were visualized by 
immunoblotting. (D) Immunoprecipitated full-length Flag-RelA was used as 
substrate for in vitro phosphatase assay. Phospho- and total RelA were visualized 
by immunoblotting. Exclusion of PPM1A or magnesium in the phosphatase 
buffer served as negative controls.  (E and F) S536 and S276 specific-
phosphorylated RelA peptides were incubated with equal amounts of GST-
PPM1A or His-Wip1 and free phosphate measured by malachite green assay. 
 
Figure 2.0.1 PPM1A is a RelA phosphatase 
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Fig. 2.2 (A) U2OS and HeLa cells were transfected with indicated siRNA 
and stimulated with 10ng/ml TNFα for 10 min. Endogenous RelA 
phosphorylation at S536 was visualized by immunoblotting cell lysates. 
Total RelA was immunoblotted after stripping the membrane. PPM1A and 
GAPDH were also immunoblotted. (B) U2OS cells were transfected with 
indicated siRNA. PPM1A, PPM1B and Wip1 were visualized by 
immunoblotting.  (C) U2OS cells were transfected with indicated siRNA and 
stimulated with 10ng/ml TNFα for 10 min. Endogenous RelA 
phosphorylation at S276 was visualized by immunoblotting cell lysates. (D) 
U2OS cells were transfected with plasmids encoding Myc3-tagged RelA 
with empty vector, Myc3-tagged wild type PPM1A or phosphatase-dead 
(PD) mutant of PPM1A. Endogenous proteins of NF-κB pathway including 
phospho-IKKα and IKKβ, total IKKα and IKKβ and IκBα were visualized 
by immunoblotting. 
 
Figure 2.0.2 PPM1A regulates RelA phosphorylation under TNFα stimulation 
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PPM1A inhibits RelA transcription activity, decreases NF-B-dependent cell invasion, 
sensitizes cell to TNFα, but does not alter RelA nuclear localization or DNA binding 
Phosphorylation at serine residues S536 and S276 is critical for RelA transactivation activity
14
. 
To determine if dephosphorylation by PPM1A inhibits RelA transcriptional activity, a dual-
luciferase reporter assay was performed
110
. In U2OS cells, endogenous NF-κB transcriptional 
activity was decreased following ectopic co-expression of wild-type PPM1A and NF-κB responsive 
reporter (Fig. 2.3A). Likewise, PPM1A also inhibited endogenous NF-κB transcriptional activity 
after stimulation by TNF or IL-1 and reversed luciferase transcription increased by ectopic 
expression of RelA (Fig. 2.3B) while PPM1A did not inhibit transcription of control reporter without 
NF-κB responsive element (Fig. 2.4A). Consistent with our observations that phosphatase activity 
was required for PPM1A to alter RelA phosphorylation, phosphatase-dead PPM1A had no effect on 
RelA transcriptional activity (Fig. 2.3A and B). S536 and S276 contribute to RelA transcriptional 
activity and both residues were dephosphorylated by PPM1A in vitro. To explore the relative 
contribution of these two residues to PPM1A-mediated RelA inhibition, RelA mutants mimicking 
phosphorylation at these sites (RelAS536D and RelAS276D) were expressed with or without 
PPM1A. S536D and S276D mutants displayed increased transcriptional activity compared to wild-
type RelA (Fig. 2.3C). Ectopically expressed PPM1A inhibited transcription by RelAS276D 
(p<0.001), but not by RelA S536D (p=0.86). Of note, PPM1A inhibited slightly less efficiently the 
transcription by the S276D mutant than wild-type RelA (inhibition rate 56% vs. 64%, p<0.01). 
Taken together, these data suggest that dephosphorylation of S276 by PPM1A may contribute to 
inhibit RelA transcriptional activity, but the majority of PPM1A activity to inhibit RelA transcription 
relies on dephosphorylation of S536 of RelA.  
Given that PPM1A robustly inhibited RelA transcription (Fig. 2.3A-C), we explored NF-κB 
target genes regulated by endogenous PPM1A by comparing expression between HeLa cells with 
and without lentivirus-driven PPM1A knockdown. Of tested genes (RT² Profiler™ PCR Array, 
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SABiosciences, Valencia, CA), expression of selective RelA responsive genes (Table. 2.1) including 
MCP-1and IL6 were increased at least 1.5-fold following PPM1A depletion. These data are 
consistent with earlier reports
49,88
 that PPM1A regulates IL-6 expression as we confirmed in PC3 
(human prostate cancer) cells (Fig. 2.4B). Ability of PPM1A manipulation to alter expression of 
MCP-1, a chemokine that is linked to tumor progression and metastases, was confirmed by real time 
PCR (Fig. 2.3D). To determine if PPM1A directly alters ability of NF-κB to bind the promoter 
region of the MCP-1 gene
86, 130
 RelA chromatin immunoprecipitation was performed following 
PPM1A depletion in HeLa cells. Following PPM1A depletion, endogenous RelA association with 
the MCP-1 promoter was observed (Fig. 2.4C). Compared to control cells, cells with PPM1A knock 
down showed a moderate but significant increase (48 % increase, 20.8 % vs. 30.8 %, p<0.05) of 
endogenous RelA binding to the MCP-1 proximal promoter region (Fig. 2.3E). These data suggest 
that PPM1A selectively regulates NF-κB transcription activity.  
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Fig. 2.3 PPM1A inhibits NF-κB transcription activity, NF-κB-dependent cell invasion and 
sensitizes cells to TNFα. (A) U2OS cells were co-transfected with indicated plasmids and 
renilla luciferase and the NF-κB responsive reporter 3κB-ConA-luc firefly luciferase. In this 
and subsequent luciferase assays, firefly luciferase activity was normalized to renilla 
luciferase and normalized firefly luciferase activity from cells transfected with control 
plasmids was assigned a value of 1. Error bars, SD derived from 3 analyses. ** p<0.01 (B) 
NF-κB-dependent luciferase activity was determined as described in (A) in cells expressing 
wild-type or phosphatase dead PPM1A and either ectopic expression of RelA or 4 hr treatment 
with TNFα or IL-1β. ** p<0.01 (C) Luciferase activity was determined following transfection 
of U2OS  with plasmids encoding wild-type or mutant Flag-RelA (S536D or S276D) with or 
without PPM1A as indicated. ** p<0.01 (D) q-RT-PCR analyses of MCP-1 expression in 
HeLa cells selected after infection with PPM1A shRNA encoding lentivirus. Error bars = SD. 
* p<0.05 PPM1A, pS536RelA, and RelA levels were confirmed by immunoblotting. (E) ChIP 
assays of the binding of RelA to MCP-1 proximal promoter. Samples from HeLa cells as 
described in (D) were prepared and analyzed using antibodies specific for RelA or IgG as 
control. Immunoprecipitated DNA fragments and input DNA were analyzed by real-time PCR. 
Values were normalized to input DNA in each group. Error bars = SD. * p<0.05 (F) HeLa 
cells infected with indicated viruses were plated on matrigel coated transwells and invasion 
measured by direct counting of trespassed cells. Representative photomicrographs are shown 
(scale bars, 100µm). Quantification of cell invasion in results represents cell counts from ten 
randomly selected low-power fields (200×) ** p<0.01. PPM1A and IκBα-SR expression levels 
were confirmed by immunoblotting (Fig. S2D). (G) HT1080 cells were infected as indicated 
and treated with indicated doses of TNFα for 24 hr. Cells were stained with trypan blue and 
live cells were counted. Error bars = SD. *p<0.05 
 
 
 
 
   
  
Figure 2.0.3 PPM1A inhibits NF-κB transcription activity, NF-
κB-dependent cell invasion and sensitizes cells to TNFα 
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Fig. 2.4 (A) U2OS cells were co-transfected with plasmids encoding wild type 
PPM1A and control vector or Myc-tagged RelA in addition to renilla luciferase 
and the control reporter conA-luc firefly luciferase as indicated. Luciferase 
activities were determined by the dual-luciferase assay system 2 days after 
transfection. In this and subsequent luciferase assays, firefly luciferase activity 
was normalized to renilla luciferase from the CMV promoter as the internal 
control, and normalized firefly luciferase activity from cells transfected with 
control plasmids was assigned a value of 1. Error bars, SD over 3 analyses. (B) 
PPM1A decreased IL-6 expression in mRNA level. PC3-LUC infected with 
PPM1A expression or control retrovirus and selected by 1ng/ml puromycin for 
10 days. mRNA was extracted for q-RT-PCR analyses of IL-6 mRNA level  
(primer sequences: forward 5’gcccagctatgaactccttct3’, reverse 
5’gaaggcagcaggcaacac3’). GAPDH was used as control. PPM1A expression was 
confirmed by immunoblotting. Error bars, SD over 3 analyses. ** p<0.001 (C) 
PPM1A and IκBα-SR expression levels from cells described in (Fig. 2F) were 
confirmed by immunoblotting.  
 
  
Figure 2.0.4 PPM1A inhibits RelA transcriptional activity 
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We previously reported that the tumor suppressor LZAP inhibits NF-B activity and diminishes 
HeLa cell invasion
110
. To determine if PPM1A inhibition of RelA similarly decreased HeLa invasion, 
matrigel invasion was measured after PPM1A depletion. Knockdown of PPM1A increased HeLa cell 
invasion by approximately 5-fold (Fig. 2.3F). IBdegradation leads to release and nuclear 
localization of NF-κB dimmers with the RelA/p50 heterodimer representing the most abundant and 
the primary target of IB131,132 To determine if increased invasion associated with PPM1A 
depletion was dependent on NF-κB and especially RelA, a non-degradable IB, termed IB-super 
repressor (IB-SR), was expressed in PPM1A depleted cells. Inhibition of NF-κB abrogated the 
increased invasion observed following PPM1A knockdown (Fig. 2.3E). These data suggest that 
depletion of PPM1A enhances NF-κB-dependent cell invasion. 
TNFα activates apoptotic pathways but rarely results in massive cell death due to simultaneous 
induction of NF-κB transcription133. To determine if PPM1A-mediated inhibition of NF-κB would 
sensitize cells to TNFα, PPM1A was expressed in HT1080 cells before treatment with increasing 
doses of TNF. Remarkably, PPM1A sensitized HT1080 cells to TNF-induced cell death, albeit to 
a lesser extent than IB-SR (Fig. 2.3F). In the absence of expressed PPM1A or IB-SR, HT1080 
cell survival was minimally impacted by TNF concentrations tested. 
Inhibition of RelA nuclear translocation is a well described mechanism for regulation of NF-κB. 
Our data suggest that PPM1A is a direct RelA phosphatase, and although phosphorylation of RelA is 
not required for nuclear translocation, it is possible that PPM1A could inhibit both RelA 
phosphorylation and nuclear localization. To explore this possibility, subcellular distribution of 
expressed RelA and phospho-RelA were determined following co-expression of RelA with wild-type 
or phosphatase-dead PPM1A. Immunoblotting of cell fractions revealed that neither wild-type nor 
phosphatase-dead PPM1A inhibited nuclear translocation of RelA (Fig. 2.5A, compare lane 4 to 
lanes 5 and 6). Consistent with our finding that PPM1A decreased RelA phosphorylation (Fig. 2.1A-
C), phospho-S536 RelA was markedly decreased in the nuclear fraction following expression of 
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wild-type, but not phosphatase-dead, PPM1A. PPM1A was primarily localized to the nucleus (data 
not shown and
82
), suggesting that PPM1A may act to dephosphorylate RelA after translocation to the 
nucleus. Next we determined if overall DNA-binding activity of RelA was altered by PPM1A. RelA 
DNA binding was stimulated by TNFα and DNA-bound RelA identified and quantitated (Active 
Motif, Carlsbad, CA). PPM1A expression did not alter TNF-stimulated DNA-binding activity of 
RelA compared to control cells at any time point tested (Fig. 2.5B). As a positive control, ectopic 
expression of IB-SR efficiently inhibited DNA binding by RelA at all the time points. 
Collectively, these data suggest that PPM1A inhibition of RelA does not depend on inhibition of 
RelA nuclear translocation and that PPM1A regulation of RelA transcription is gene or promoter 
specific.  
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     gene PPM1AshRNA TNFα 
PPM1A 0.57 0.97 
CCL2/MCP-1 1.67 2.93 
HMOX1 3.29 0.52 
ICAM1 1.51 4.14 
IL1R1 2.14 0.68 
IL6 1.87 4.14 
IL8 2.14 7.73 
TNFAIP3 38.80 106.01 
TNFRSF10A 36.76 35.51 
TNFSF10 12.13 43.71 
 
 
 
Table 2.1. Fold changes of NF-κB target 
genes measured by RT² Profiler™ PCR 
Array. mRNA extraction and RT-PCR were 
performed according to manufacturer’s 
instructions. Compared to HeLa cells 
infected with control lentivirus, genes listed 
had more than 1.5 fold increased expression 
in HeLa cells infected with lentivirus 
delivering PPM1A shRNA. mRNA 
extracted from TNFα (10ng/ml 4hrs) 
stimulated HeLa cells was used as positive 
control and the fold changes were 
normalized to the gene expression level in 
untreated cells. 
 
Fig. 2.5 PPM1A does not interfere 
with nuclear translocation or DNA 
binding of RelA. (A) U2OS cells 
transfected with indicated plasmids 
were lysed and total or phospho-
RelA visualized by immunoblotting 
from total lysate or subcellular 
fractions. Nucleolin and β-actin 
served as nuclear and cytosol 
markers, respectively.  Amount of 
protein loaded is indicated.  (B) 
Following TNFα stimulation, 
nuclear extracts were prepared from 
HeLa cells stably expressing 
PPM1A, IκBα-SR or control. RelA 
DNA-binding activity was measured 
using TransAM NF-κB 
p65transcription factor kit. Error 
bars = SD. 
 
Table 2.0.1 Fold changes of NF-κB target 
genes measured by RT² Profiler™ PCR 
Array  
Figure 2.0.5 PPM1A does not interfere 
with nuclear translocation or DNA 
binding of RelA 
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PPM1A inhibits NF-κB activation, MCP-1 expression and cell invasion in prostate cancer cell 
lines  
We were intrigued that PPM1A regulated expression of MCP-1 (Fig. 2.3D), a chemokine whose 
expression has been strongly linked to bony metastasis in prostate and advanced breast cancers
71, 134
. 
To begin exploring a potential role of PPM1A in regulating bony metastases in prostate cancer, we 
explored PPM1A expression and the effect of PPM1A manipulation in a pair of prostate cancer cell 
lines with well-described metastatic and invasive potential, PC3 and LNCaP. LNCaP cells are 
androgen-dependent with low metastatic potential, whereas, PC3 cells are androgen-independent and 
highly metastatic. Perhaps related to their aggressive metastatic potential, PC3 express higher levels 
of MCP-1
128
. We observed that PPM1A protein (Fig. 2.6A) and mRNA (data not shown) expression 
were approximately 2-fold lower in PC3 cells compared to LNCaP. Although total RelA expression 
was similar in the two cell lines, RelA S536 phosphorylation was markedly higher in PC3 cells 
compared to LNCaP (Fig. 2.6A). 
Since LNCaP cells expressed higher levels of PPM1A, effects of PPM1A on RelA 
phosphorylation, MCP-1 expression and cellular invasion were determined by depletion of PPM1A. 
Consistent with results from other cell lines, PPM1A depletion in LNCaP cells increased RelA S536 
phosphorylation (Fig.2.6B), MCP-1 mRNA expression (Fig. 2.6C) and cell invasion (Fig. 2.6D). To 
determine the effect of PPM1A in PC3-LUC cells with lower endogenous levels of PPM1A, PPM1A 
was expressed. Ectopic PPM1A expression did not alter total RelA expression, but markedly 
decreased RelA S536 phosphorylation (Fig. 2.6E) and resulted in a 50% reduction of MCP-1 mRNA 
expression and a similar reduction of secreted MCP-1 detected in conditioned media (Fig. 2.6F). 
Remarkably, expression of PPM1A reduced invasion of otherwise aggressive PC3 cells by more than 
50% (Fig. 2.6G).  
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Fig. 2.6 PPM1A inhibits NF-κB and prostate cancer cell invasion (A) Endogenous total 
and phospho-RelA (S536) and PPM1A were visualized in LNCaP and PC3 cells by 
immunoblotting. GAPDH serves as loading control. (B) LNCaP cells were transfected 
with indicated siRNA and indicated phospho- or total proteins visualized by 
immunoblotting. (C) MCP-1 expression was measured by q-RT-PCR in LNCaP cells 
transfected as indicated. Error bars = SD. * p<0.05 (D) Transwell invasion of LNCaP 
cells following transfection with indicated constructs were quantified as described in Fig. 
2 (F). **p<0.001 (E) PC3-LUC cells were infected with indicated retrovirus, selected 
using puromycin and expression of indicated phospho- or total proteins visualized by 
immunoblotting. (F), PC3-LUC cells were infected with indicated retroviruses and 
expression of MCP-1 mRNA or protein, determined by q-RT-PCR or ELISA, Error bars 
= SD. * p<0.05 (G) PC3-LUC cells were infected with indicated retroviruses and 
transwell invasion determined as in (D). **p<0.001 
 
Figure 2.0.6 PPM1A inhibits NF-κB and prostate cancer cell invasion 
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PPM1A expression is lower in metastatic human prostate cancer and PPM1A expression 
inhibits metastases in a mouse model  
Since PPM1A expression inversely correlated with MCP-1 expression and invasiveness of two 
prostate cancer cell lines (Fig. 2.6), we examined PPM1A expression in publically available 
expression data derived from human prostate cancers to determine if PPM1A expression differed in 
metastatic lesions compared to primary tumors. Indeed PPM1A expression was 2-fold lower in 
distant prostate cancer metastases compared to primary prostate tumors in patients without distant 
metastases (Fig. 5A, NCBI GEO, GDS2546
135, 136
). To begin exploring a potential role of PPM1A in 
metastasis, an intracardiac injection model was used to study critical behaviors for prostate cancer 
cell metastases: extravasation and growth in distant sites. Aggressive PC3 cells were chosen since 
LNCaP cells fail to develop metastasis after intracardiac injection
137
. PC3 cells expressing luciferase 
(PC3-LUC) with or without stable PPM1A expression (Fig. 2.6E) were injected intracardially into 
nude mice and bony metastases quantified. Bioluminescent imaging was performed on mice 1 hour 
after injection and weekly for 4 weeks (example shown Fig. 2.7). Expression of PPM1A in PC3-
LUC cells significantly reduced the incidence of metastases in injected mice (38% vs. 93%, Fig. 
2.8B), as well as the number of metastases per mouse (Fig. 2.8C). Metastases were confirmed by X-
ray imaging (Fig. 2.8D, white arrows indicate osteolytic lesions) and hematoxylin/eosin staining 
showing metastases of control PC3-LUC cells to the bone marrow cavity (Fig. 2.8E left) and normal 
bone tissues from mice injected with PPM1A-expressing PC3-LUC cells for comparison (Fig. 2.8E 
right). Immunostaining of cleaved-caspase-3 revealed that apoptosis (cleaved-caspase-3 
positive/total cells) in metastases of PPM1A expression cells increased by roughly 50% compared to 
control tumors (Fig. 2.8F, 56.7% vs. 77%, p<0.01). 
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Fig. 2.7 Bioluminescent imaging of mice after intracardiac injection of PC3-LUC 
cells. Serial Xenogen bioluminescent images from representative mice are shown at 
indicated time points after intracardiac injection of PC3-LUC with or without 
expression of PPM1A (Fig. 2.6 E). Color scale of photon radiance is shown on the 
right. 
Figure 2.0.7 Bioluminescent imaging of mice after intracardiac injection 
of PC3-LUC cells 
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Fig. 2.8. PPM1A expression is lower in metastatic human prostate cancer and inhibits prostate cancer cell metastasis in vivo. (A) A GEO 
search indicated that PPM1A expression is lower in metastatic deposits of prostate cancer compared to: primary prostate cancers without 
distant metastases (p=2.43E-9, fold change 1.82); normal prostate tissue adjacent to cancer (p=9.77E-14, fold change 2.00); or normal 
prostate (p=2.17E-7, fold change 2.06). (B) Percentage of mice that developed metastases after intracardiac injection of PC3-LUC cells 
with or without expression of PPM1A. The number of mice with metastases/injected mice is indicated on top of each bar *p<0.05. (C) 
The number of metastases per mouse at 4 weeks after intracardiac injection of PC3-LUC cells with or without PPM1A expression is 
indicated  *p<0.05 (D) Xenogen bioluminescent images of representative mice 4 weeks after intracardiac injection of PC3-LUC cells 
infected with control retrovirus or retrovirus driving expression of PPM1A. (E) X-ray images of representative mice in (B). Lytic bone 
lesions are indicated by white arrows. (F) Representative hematoxylin/eosin staining of bone and adjacent tissue samples obtained from 
mice in (B) are shown. Magnification: top 40×, bottom 200×. (G) Sections of bony metastases described in (B) were immunostained with 
using anti-cleaved-caspase 3. Percentage of positive staining cells in each group was measured from at least 3 representative tumors and 
in each tumor at least 5 randomly selected fields (200×). Error bars, SD. **p<0.001.   
 
 
Figure 2.0.8 
PPM1A 
expression is 
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PPM1A decreases xenograft tumor growth 
Given that NF-κB signaling can enhance tumor growth in addition to cellular invasion and 
metastasis, we further explored the role of PPM1A depletion in primary tumor growth. HeLa cells 
with and without shRNA-mediated PPM1A-depletion were injected subcutaneously into the flank of 
nude mice. Immunoblotting confirmed PPM1A loss before injection (Fig. 2.9A). Mice were 
sacrificed and tumors harvested after 9 weeks. PPM1A knockdown was variably maintained in 
tumors despite selection of cells before injection. At the endpoint, 7 of 12 tumors derived from 
PPM1A knockdown cells maintained PPM1A depletion, whereas 5 tumors had regained PPM1A 
expression to levels equivalent to those observed in control tumors. Tumors that maintained PPM1A 
knockdown grew faster and were larger compared to control tumors (Fig. 2.9A, p<0.0001). 
Remarkably, tumors that did not maintain PPM1A knockdown were of similar size compared to 
control tumors (Fig. 2.9A). Analyses of tumor growth maintained statistical significance even if 
including tumors that failed to maintain PPM1A knockdown in the PPM1A knockdown group 
comparing to control ones (P<0.01, data not shown).  Consistent with tumor growth data, the mean 
wet weight of tumors maintaining PPM1A knockdown was greater than both control tumors and 
tumors that did not maintain PPM1A knockdown (Fig. 2.9B, p<0.05). Before sacrifice, mice were 
injected with BrdU and harvested tumors were immunostained to determine proliferative index 
(BrdU-positive cells/total cells). The proliferative index in tumors maintaining PPM1A knockdown 
was almost twice as high as that of control tumors (Fig. 2.9C, 33% vs. 17%, p<0.001) while the 
proliferative index in tumors not maintaining PPM1A knockdown was similar to that of control 
tumors (Fig. 2.10 B, 19% vs. 17%, p=0.62) and significantly lower than that of the tumors 
maintaining PPM1A knockdown (Fig. 2.10 B, p<0.05). Immunostaining of cleaved-caspase 3 in 
xenograft tumor sections was used to calculate an apoptotic index (cleaved-caspase 3 positive 
cells/total cells) revealing that apoptosis in PPM1A knockdown tumors was less than half of that in 
control tumors (Fig. 2.9D, 5% vs. 12%, p<0.001). As observed for the proliferative index, the 
apoptotic index in tumors not maintaining PPM1A knockdown was similar to control cells (Fig. 2.10 
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C 15% vs. 12%, p=0.28) and significantly higher than that of the tumors maintaining PPM1A 
knockdown (Fig. 2.10 C, p<0.0001). Although tumor latency and tumor size were altered by loss of 
PPM1A expression, tumor incidence was similar in this xenograft model (data not shown). These 
data suggest that loss of PPM1A increases tumor growth and is associated with increased 
proliferation and decreased apoptosis. Analyses of tumors that did not maintain PPM1A knockdown 
further support PPM1A loss as a driver of tumor growth, increased proliferation and decreased 
apoptosis. 
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Fig. 2.9 PPM1A inhibits tumor growth in vivo. (A) HeLa cells were infected with either control 
retrovirus or retrovirus delivering PPM1A shRNA and selected with 1ng/ml puromycin for 10 
days. Five mice (20 injections) in each group were inoculated with 1× 10
6
 manipulated HeLa cells. 
Tumor growth was monitored weekly by measurement of length (L) and width (W) using calipers 
until the largest tumors approached 20 mm in length. Tumor volumes were calculated by using the 
formula: volume = ½×L×W
2
. Error bars, mean ± SD. **p<0.01.***p<0.0001 (B), tumors from the 
indicated groups were weighed immediately after removal.  Medium xenograft tumor weight is 
indicated. Error bars, SD. *p<0.05. C and D, five micrometer sections of xenograft tumor 
described in (A) were immunostained with cleaved Caspase 3 or BrdU-specific antibodies 
respectively. Mice received 1mg BrdU i.p. injection 2 hr before sacrificing. Percentage of positive 
staining cells in each group was measured from at least 3 representative tumors and in each tumor 
at least 5 randomly chose fields (200×). Error bars, SD. **p<0.001. 
 
 
 
Figure 1.0.9 PPM1A inhibits tumor growth in vivo 
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Fig. 2.10 (A) HeLa cells were infected with either control retrovirus or 
retrovirus delivering PPM1A shRNA and selected with 1ng/ml puromycin for 
10 days. Before injection, decreased PPM1A expression was confirmed by 
immunoblotting. B and C, five micrometer sections of xenograft tumor 
described in (A) were immunostained with cleaved caspase 3 or BrdU-specific 
antibodies, respectively. Mice received 1mg BrdU i.p. injection 2 hr before 
sacrifice. The percentage of cells with immunostaining in each group was 
measured from at least 3 representative tumors and in each tumor at least 5 
randomly selected fields (200×). Error bars = SD. 
Figure 1.0.10 Comparing apoptotic and proliferative 
index of tumor maintain or not maintain PPM1A 
depletion 
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Discussion 
RelA phosphorylation is necessary for transcriptional competence of nuclear NF-κB138, and 
dephosphorylation of RelA is an important mechanism for homeostatic down-regulation of NF-κB 
activity
42
. In many human tumors NF-κB activity enhances tumorigenic behavior with upstream 
kinases largely implicated in triggering or maintaining inappropriate NF-κB transcription139, 140. Data 
we present here identify a new RelA phosphatase and suggest that loss of RelA phosphatases may be 
equally important or an alternative mechanism of NF-κB activation in human cancer.  
We found that PPM1A, a PPM family member, is a direct RelA phosphatase at S536 as indicated 
by activity of bacterially synthesized PPM1A toward both RelA phospho-peptides and 
immunoprecipitated full-length RelA. Data presented here also support PPM1A as a phosphatase for 
the S276 site of RelA. S/TQ and TXY are known consensus target sequences for PPM 
phosphatases
141,142
. Since S536 and S276 of RelA are not consensus targets, additional studies with 
more endogenous PPM targets may reveal additional consensus sequences. Previous reports show 
that PPM1A targets NF-κB through dephosphorylation of IKKα and IKKβ49. Our data reveal that 
PPM1A inhibited RelA phosphorylation independent of IKKs (Fig. 2.1C). Inability of PPM1A to 
inhibit RelA nuclear translocation further suggests that IKKs are not the dominant mechanism of 
RelA inhibition by PPM1A. Taken together, PPM1A inhibits NF-κB through at least two 
mechanisms: 1) inhibition of upstream IKKs, and 2) direct dephosphorylation of RelA. Further 
studies are required to determine if other kinases responsible for RelA phosphorylation at S536 or 
S276 (Table 1.1) are regulated by PPM1A.We observed PPM1A-mediated inhibition of RelA with 
and without stimulation, whereas PPM1A activity to inhibit IKKs was observed only at later time 
points and after TNFα stimulation49, suggesting that PPM1A regulation of RelA directly or through 
IKKs may depend on timing, as well as cellular and signaling context.  
NF-κB regulation to selectively alter transcription has been widely reported and also varies from 
cell type to cell type
110, 143, 144
. For example, the known RelA phosphatase, Wip1, inhibits a subset of 
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NF-κB targets47. We found that among others, PPM1A decreased expression of NF-κB targets IL-6 
as previously reported
49,88
 and MCP-1. ChIP assay showed depletion of PPM1A increased RelA 
associated with the MCP-1 proximal promoter (Fig. 2.3E), but the phosphorylation status of 
promoter-associated RelA could not be determined due to absence of suitable antibodies. Increased 
mRNA levels of MCP-1 under similar circumstances suggests that promoter associated NF-κB was 
transcriptionally active and therefore phosphorylated. These data suggest that PPM1A regulates 
RelA phosphorylation resulting in altered expression of select NF-κB targets. 
IL-6 and MCP-1 are implicated in metastases, particularly in cancers of the prostate
67
, colon
68,145
, 
and breast
71, 69
. Distant metastases in breast and prostate cancer are tightly associated with poor 
patient outcomes. Targeting MCP-1 is an effective therapeutic approach to prevent metastases in 
animal models of prostate and breast cancer
146
, and a phase II clinical trial using a neutralizing 
monoclonal antibody against MCP-1 is being conducted in metastatic prostate cancer patients 
(NCT00992186). IL-6 and IL-6 receptor are also therapeutic targets for prevention of inflammation, 
tumor progression and metastasis, and their inhibition has shown promise in pre-clinical models
72
. A 
phase II trial was completed to determine efficacy of anti-IL-6 chimeric monoclonal antibody in 
patients with metastatic hormone-resistant prostate cancer (NCT00433446) while the results have not 
been published yet. Given that PPM1A inhibited expression of IL-6 and MCP-1, we explored the 
role of PPM1A in metastases. Expression data from human prostate cancers revealed that metastatic 
prostate deposits had significantly lower PPM1A expression when compared to primary tumors in 
patients without metastases. This exciting finding combined with increased invasion associated with 
PPM1A depletion (Fig. 2.3E) led us to examine the effect of PPM1A expression in an androgen-
independent highly metastatic prostate cancer cell line, PC3. Interestingly, PC3 cells express lower 
levels of PPM1A when compared to androgen-dependent and less aggressive LNCaP cells. PPM1A 
expression significantly inhibited PC3 cell invasion (Fig. 2.6G) and abrogated PC3 bony metastases 
in an intravascular metastases model (Fig. 2.8B-D). Notably, mean PPM1A expression is also 
decreased in breast cancer and colorectal cancers compared to normal tissue (Oncomine, PPM1A 
62 
gene, TCGA breast, TCGA colorectal and colorectal 2 data sets), and a xenograft model of breast 
cancer MCF7 cells revealed that PPM1A depletion increases tumorigenic potential and tumor 
growth
147
. These data suggest that loss or decreased PPM1A activity may increase aggressive 
behavior in different tumor types. Although survival data was not included in the prostate cancer 
dataset to correlate PPM1A expression with prognosis, it will be informative to explore when larger 
public datasets become available.  
Our data suggest that PPM1A is a direct RelA phosphatase with tumor suppressor-like activity 
that, at least partially, depends on PPM1A ability to inhibit NF-κB. The pathway involves in PPM1A 
inhibition of xenograft tumor growth is not clear. In addition to NF-κB, PPM1A targets tumor centric 
proteins including smad2/3, p38 and cdk2 implicating PPM1A in cell cycle regulation, as well as 
TGFβ and MAPK signaling pathways82, 1. Although data presented here suggest that invasion in 
HeLa cells was completely dependent on NF-κB, regulation of tumor invasion, progression, and 
metastasis by PPM1A, likely involves additional PPM1A activities. Decreased expression of PPM1A 
in distant metastases of human prostate cancer coupled with in vivo data suggest that increased 
PPM1A expression inhibits prostate cancer bony metastases. Neither deletions nor inactivating 
mutations of PPM1A have been described, suggesting that strategies to increase PPM1A expression 
or activity in cancer cells could be explored as a therapeutic strategy in human cancers.   
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CHAPTER III 
 
LZAP REGULATES TARGET PROTEIN PHOSPHORYLATION BY FACILITATING TARGET 
PROTEIN ASSOCIATION WITH PHOSPHATASES OF PPM FAMILY 
 
Part of the work presented in this chapter is published under the title of “LZAP Inhibits p38 MAPK 
(p38) Phosphorylation and Activity by Facilitating p38 Association with the Wild-Type p53 Induced 
Phosphatase 1 (WIP1)” in PLoS one, 2011117 
 
Abstract 
LZAP (Cdk5rap3, C53) is a putative tumor suppressor that inhibits RelA, Chk1 and Chk2, and 
activates p53. LZAP is lost in a portion of human head and neck squamous cell carcinoma and 
experimental loss of LZAP expression is associated with enhanced invasion, xenograft tumor growth 
and angiogenesis. p38/MAPK can increase or decrease proliferation and cell death depending on 
cellular context. LZAP has no known enzymatic activity, implying that its biological functions are 
likely mediated by its protein-protein interactions. To gain further insight into LZAP activities, we 
searched for LZAP-associated proteins (LAPs). Here we show that the LZAP binds p38, alters p38 
cellular localization, and inhibits basal and cytokine-stimulated p38 activity. Expression of LZAP 
inhibits p38 phosphorylation in a dose-dependent fashion while loss of LZAP enhances 
phosphorylation and activation with resultant phosphorylation of p38 downstream targets. 
Mechanistically, the ability of LZAP to alter p38 phosphorylation depends, at least partially, on the 
p38 phosphatase, Wip1, a PPM family member. LZAP also binds Wip1. Expression of LZAP 
increased both LZAP and Wip1 binding to p38. In vitro phosphatase assay using full-length p38 as 
substrate revealed that LZAP enhances p38 dephosphorylation by Wip1 in a dose dependent fashion. 
LC-MS/MS was used to identify LZAP-associated proteins and found that LZAP interaction with 
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other PPM family members including PPM1A and PPM1B. Our previous study showed both LZAP 
and PPM1A inhibit RelA phosphorylation and negatively regulates NF-κB signaling. Here, we show 
that the ability of LZAP to alter RelA phosphorylation depends, at least partially, on the RelA 
phosphatase, PPM1A. Taken together, these data suggest that the ability of LZAP to decrease target 
protein phosphorylation and activity (e.g. p38 and RelA) is at least partially mediated through 
altering interaction of target proteins and phosphatases.  
 
Introduction 
LZAP (Cdk5rap3, C53) was originally identified as a binding partner of the Cdk5 activator p35
107
, 
but insight into LZAP activity was gained when it was found to bind the alternate reading frame 
protein of the INK4a gene locus, ARF (p14ARF in human and p19ARF in mice). LZAP activates 
p53 both in the presence and absence of ARF resulting in a G1 cell cycle arrest and inhibition of 
clonogenic growth
112
. Further, LZAP inhibits cellular transformation, xenograft tumor growth, and 
xenograft tumor vascularity at least partially mediated by LZAP's ability to bind and inhibit RelA
110
. 
Evidence of a tumor suppressor-like role for LZAP was bolstered when LZAP protein levels were 
found to be markedly decreased in  a subset of head neck squamous cell carcinoma (HNSCC) where 
its loss inversely correlates with expression of NF-κB target genes110. LZAP also inhibits the 
checkpoint kinases (Chk1 and Chk2), promotes mitotic entry and, in the presence of DNA damaging 
agents, sensitizes to cell death
113, 116
. Collectively, these data are consistent with a role of LZAP in 
tumor suppression. Intriguingly, morpholino-directed loss of LZAP expression in zebrafish was 
lethal during very early embryogenesis resulting in cell death and developmental delay
111
. Combined, 
these data suggest that either increased or decreased LZAP levels may have detrimental effects on 
cell survival. LZAP has no known enzymatic activity, implying that its biological functions are 
likely mediated by its protein-protein interactions. To identify proteins that may contribute to 
biological activities of LZAP, we screened human LZAP amino acid sequence for motifs recognized 
by modular signaling domains using the Scansite algorithm
148
. Using high stringency criteria, 
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Scansite analyses suggested that LZAP contained motifs predicted to bind 14-3-3-zeta and the 
docking domain (D domain) of mitogen activated protein kinases (MAPKs) (Table. 3.1). 
  
        RelA Chk1/2 p38 p53 MDM2 
LZAP + ↓ + ↓ + ? – ↑ – ↓ 
Wip1*    ↓    ↓   ↓    ↓    ↑ 
PPM1A*    ↓       ↓      ↓ 
 
 
    
Table 3.1 LZAP predicted motifs from Scansite. LZAP protein coding sequence 
was analyzed using high stringency criteria to identify possible binding motifs. 
 
 Table 3.2 Summary of LZAP, Wip1 and PPM1A activity and binding for 
shared target proteins. + direct binding, - no direct binding; ↑/↓ indicates 
stimulation or inhibition of activity, * not all Wip1 or PPM1A targets are listed. 
Table 3.0.2 LZAP 
predicted motifs from 
Scansite 
Table 3.0.1 Summary of LZAP, Wip1 
and PPM1A activity and binding for 
shared target proteins 
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p38MAPK belongs to a family of stress-activated MAPKs that respond to cellular stress and 
cytokines. Expression patterns suggest that p38α is the primary p38 kinase in most cell types149. 
Activity of p38 reflects a balance between the upstream activating kinases (MKK3 and MKK6) and 
inactivating protein phosphatases, primarily the wild-type p53-induced phosphatase 1 
(Wip1/PPM1D/PP2Cδ)94, 150. p38 activity results in pleiotropic downstream cellular and tissue effects 
including: cytokine production, inflammation, cellular differentiation, cell-cycle arrest, apoptosis, 
and senescence
149, 151,152-155
. Given the roles of p38 as an inducer of apoptosis and inhibitor of cellular 
proliferation, it is ironic that elevated p38 expression has been found in many cancer types, including 
breast, lung, thyroid and HNSCC, and that p38 has been implicated in promoting cell survival
152, 156-
159
. Given the conflicting cellular effects that can result from p38 activation, the role of p38 in human 
cancer as a tumor promoter or a tumor suppressor likely depends on tumor and cell specific 
context
149
. 
Including p38 as a potential LZAP binding partner, we noticed that LZAP and PPM family 
members, especially Wip1, shared a pool of target proteins. As summarized in table 3.2, the roles of 
LZAP, Wip1 and PPM1A in the regulation of RelA, p38, Chk1/2, p53, and MDM2 are detailed.  The 
phosphorylation and activity of RelA is inhibited by LZAP, Wip1 and PPM1A, and similarly, LZAP 
and Wip1 regulate phosphorylation and activity of Chk1/2 in the same direction. Since p38 is a target 
of Wip1 and PPM1A and because p38 and LZAP have been shown to activate p53 and to interact 
physically or functionally with Chk1
112,152,160
, we explored LZAP activity to bind and regulate p38 
activity. In addition, we examined if LZAP altered p38 phosphorylation and explored if this activity 
may be dependent on   co-factors such as PPM phosphatases.  
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Materials and Methods 
Plasmid constructs 
The full coding sequence and truncation mutants of LZAP were subcloned into pcDNA3-Myc3 
and pET-His expression vectors 
112
, 
110
. Plasmids Flag-p38α and Gal-ATF2 were generous gifts from 
Dr. Jiahuai Han (The Scripps Research Institute, La Jolla, CA). LZAP that was not a target of 
siRNA-2(sense strand: 5′-CAAGGTATGTGGACCGAGT) 110 was constructed by introducing the 
silent mutations G294A and G297A in pCI-Neo-LZAP. 
Antibodies and Reagents 
LZAP polyclonal rabbit antibody has been previously described
112
, Mouse monoclonal antibody 
were purchased as follows: Flag (M2), and anti-Flag M2 affinity gel (Sigma); mouse monoclonal 
antibodies specific to Myc (9E10), p38 (A-12), rabbit GAPDH, normal mouse and Rabbit IgG, and 
secondary mouse and rabbit antibodies (Santa Cruz Biotechnology); rabbit monoclonal to phospho-
T180/Y182 p38 (Cell Signaling); Wip1 rabbit polyclonal antibody (Bethyl); flurophore-conjugated 
secondary antibodies (Jackson ImmunoResearch Laboratories); chicken anti-human Myc-tag 
polyclonal antibody (Thermo Scientific); and all other antibodies (Cell Signaling). TNFα, IL-1β, and 
LPS were purchased from PeproTech. 
Cell culture and transfection 
Cell lines were maintained at 37°C with 5% CO2, in growth media with 10% fetal bovine serum 
(FBS) (Invitrogen, Carlsbad, CA). Cell lines were obtained from ATCC or collaborators and have 
been passed in the Yarbrough lab with biannual authentication of identity based on microsatellite 
analyses of 3 markers (D7S1482A, Mycl1A and DXS981C). Plasmids were transfected using 
FuGene6 (Roche, Indianapolis, IN) or TransIT-2020 (Mirus, Madison, WI) for MEFs according to 
the manufacturer's instructions. The total amount of transfected DNA in any single experiment was 
kept constant by adding control vector (pcDNA3). Small interfering RNA (siRNA) was transfected 
at 20 nM using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA). Control siRNA duplex (non-
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targeting #1) was purchased from Dharmacon (Dharmacon, Chicago, IL). The LZAP siRNA-2 was 
previously described 
112
 with on-TARGETplus modification, 5′-CAAGGTATGTGGACCGAGT 
(sense strand); the sequence of Wip1 siRNA is: 5′- GGCUUUCUCGCUUGUCACC dTdT 161 
purchased from Dharmacon. 
Immunoprecipitation and immunoblotting 
Cells were lysed in 0.5%(v/v) Nonidet P40 lysis buffer
162
 supplemented with protease inhibitor 
cocktail (Roche). Total cell extracts were incubated with specific antibodies and precipitated with 
protein A or G sepharose beads (GE Healthcare) before washing and suspension in Laemmli and gel 
electrophoresis followed by immunoblotting as described 
163
. 
Immunofluorescence assay 
Briefly, cells were fixed with paraformaldehyde permeabilized with Triton X-100, and blocked 
with BSA. Target proteins were visualized following incubation with primary antibodies followed by 
fluorophore secondary antibodies and visualization as described
164
. 
Cell fractionation 
Cells were scraped in cytosolic lysis buffer (10 mM Tris-HCl [pH 7.5], 100 mM NaCl, 2.5 mM 
MgCl2, and 40 mg/ml digitonin). The lysate was incubated on ice for 5 min and centrifuged (2100 g, 
8 min, 4°C), and the supernatant was designated as soluble cytosolic fraction. The pellet was washed 
with the same buffer before adding RIPA lysis buffer (10 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1% 
NP-40, 1 mM EDTA, 0.1% SDS, and 1 mM DTT), incubated on ice for 5 min and centrifuged 
(14,000 rpm, 10 min, 4°C), to obtain the nuclear fraction. Whole cell lysates were prepared using 
RIPA buffer, as described
127
. 
Luciferase reporter assay 
ATF2 reporter gene assay was performed using the Dual-Luciferase Reporter Assay System 
(Promega) as described 
110
. Reporter constructs were co-transfected into U2OS cells maintaining 
equal plasmid amounts. Luciferase activity was measured 24 hours after transfection following the 
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manufacturer's instructions. Luciferase activity was normalized to renilla activity as a control of 
transfection efficiency. 
Mass spectrometry 
Flag-tagged LZAP was expressed in HEK293T cells and purified using Flag-conjugated resin as 
described in Chapter 2. The elution buffer containing LZAP and other potential LZAP-binding 
proteins were submitted to Vanderbilt Mass Spectrometry Research core lab for LC-MS/MS assay 
and data analyses. 
 
Results 
LZAP interacts with p38 MAPK in vivo 
To confirm the predicted interaction between LZAP and p38, Myc-tagged LZAP was transiently 
expressed singly or with Flag-tagged p38 in mammalian U2OS cells before immunoprecipitation. 
When co-expressed, bands corresponding to Myc-tagged LZAP and untagged LZAP were detected 
in p38 immunoprecipitates (Fig. 3.1A, lane 2, top panel). Likewise, p38 was readily detected in 
LZAP immunoprecipitates (Fig. 3.1A, lane 4, top panel). Expressed LZAP was also detected in 
immunoprecipitates of endogenous p38; however, endogenous p38 could not be detected in LZAP 
immunoprecipitates following LZAP expression (Fig. 3.1A, lanes 1 and 3, top panels). Expression of 
proteins was confirmed (bottom panels) and non-immune mouse IgG (middle panels) was used as a 
control for non-specific immunoprecipitation. To determine if endogenous p38 and LZAP associated 
in mammalian cells, co-immunoprecipitation of LZAP and p38 was performed using asynchronously 
growing MCF7 cells, in which LZAP and p38 expression levels are relatively higher compared to 
U2OS cells (data not shown). p38 was detected in LZAP immunoprecipitates both with and without 
UV irradiation, but not in precipitates using non-immune rabbit IgG (Fig. 3.1B, compare lanes 3 and 
4 to lanes 5 and 6, where the arrow indicates p38). Reciprocal immunoprecipitation using p38-
specific antibody did not allow detection of LZAP (data not shown). These data suggest that 
expressed and endogenous LZAP and p38 exist in a common complex. 
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Fig. 3.1 LZAP binds to p38. (A) Ectopically expressed LZAP and p38 mutually co-
immunoprecipitate. U20S cells were transfected with indicated plasmids directing expression of 
tagged LZAP or p38. Immunoprecipitates were prepared using mouse antibodies recognizing Myc 
(LZAP) or p38, resolved on SDS-PAGE, and immunoblotted using rabbit antibodies recognizing 
LZAP or p38. Expression of LZAP and p38 was confirmed by immunoblotting (1% of each input 
lysate was loaded as reference.) Pre-immune IgG was used as control for non-specific 
immunoprecipitation. (B) Endogenous LZAP binds endogenous p38. Lysates from untransfected 
MCF7 cells without or with UV irradiation (20 J/m2) were immunoprecipitated using LZAP-specific 
rabbit antiserum or non-immune rabbit IgG, then immunoblotted with antibodies specific to p38 or 
LZAP as indicated. (C) LZAP co-localizes with p38 and alters p38 subcellular localization. U2OS 
cells were transfected with plasmids directing expression of Flag-p38 with or without LZAP. Cells 
were fixed and p38 and LZAP expression and localization determined by indirect 
immunofluorescence using anti-Flag monoclonal antibody and affinity-purified rabbit anti-LZAP 
antibody. Cytoplasmic, nuclear and peri-nuclear localization of p38 was determined by direct 
visualization and quantified based on at least 100 cells from at least 3 independent experiments. The 
shift of p38 localization from perinuclear region to nucleus was statistically significant (p<0.0001, 
using unpaired 2 tailed t test). (D) Increased p38 abundance in the nuclear following LZAP co-
expression. U2OS cells were transfected with plasmids directing expression of Flag-p38 with or 
without LZAP. Whole cell, cytoplasmic and nuclear cell lysate were prepared, then 
immunoprecipitates from each lysate were prepared using anti-Flag M2 affinity gel, resolved on SDS-
PAGE, and immunoblotted by rabbit p38 antibody. The levels of C23 (nucleolar protein) and β-actin 
(cytoplasmic protein) were used to monitor the quality of the fractionation and the even loading of 
samples (1% of each input lysate was loaded as reference.). Expression of LZAP was confirmed by 
immunoblotting (1% of each input lysate was loaded as reference). Endogenous LZAP was detected 
after longer exposure (data not shown). 
 
Figure 3.0.1 
LZAP binds to 
p38 
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To determine if LZAP and p38 co-localized or altered one another's subcellular localization, 
immunofluorescent staining of LZAP and p38 were performed following single or combined 
transient expression (Fig. 3.1C). When expressed without p38, LZAP localizes to both the nucleus 
and cytoplasm, but is excluded from nucleoli as previously described (data not shown and 
112, 110
). In 
the absence of LZAP, expressed p38 localized to both the cytoplasm and nucleoplasm with more 
than 60% of cells showing stronger localization to the peri-nuclear region (Fig. 3.1C, top panel 
arrows). LZAP localization was not altered by co-expression of p38; however, co-expression of 
LZAP with p38 resulted in a shift of p38 staining from predominantly peri-nuclear to predominantly 
nuclear (Fig. 3.1C, p38 stained panels and graph, p<0.0001). 
To confirm the observation that LZAP altered p38 subcellular localization, cellular fractionation 
was performed on cells expressing p38 with and without LZAP. As expected, both p38 and LZAP 
localized to both the nuclear and cytoplasmic fractions; however, expression of LZAP increased the 
amount of p38 detected in the nuclear fraction (Fig. 3.1D). Fidelity of the nuclear and cytoplasmic 
fractions was confirmed by expression of nucleolin/C23 and β-actin. Combined, 
immunofluorescence and cellular fractionation data suggest that LZAP and p38 co-localize and that 
expression of LZAP increases p38 nuclear localization. 
To begin defining regions of LZAP required for p38 interaction, LZAP truncation mutants were 
co-expressed with full length p38 (Fig. 3.2). p38 or LZAP immunoprecipitations revealed that an 
extended LZAP amino terminus region (αα1-303) was sufficient for binding to p38. Within the 
amino terminal region of LZAP, αα 1-111 was unable to bind p38, suggesting that αα 112-303 were 
required for this binding. A separate and non-overlapping extended carboxyl terminal region of 
LZAP (αα 329-506) was also sufficient for p38 binding. Truncation of the extended carboxyl 
terminal region abrogated p38 binding suggesting that αα 329-359 of LZAP are required for p38 
binding; however, amino acids 329-359 of LZAP were not sufficient for binding to p38 because a 
central LZAP truncation containing this region (αα 201-358) failed to bind. Within the central region, 
an LZAP fragment containing residues 112-358 was capable of binding p38 suggesting that a critical 
72 
domain for p38 binding exists between amino acids 112 and 201 of LZAP (Fig. 3.2). Results of these 
p38 binding experiments using LZAP truncations are summarized (Fig. 3.2). 
 
 
    
  
Fig. 3.2 Independent and non-overlapping areas of LZAP are sufficient for association 
with p38. U2OS cells were transfected with plasmids directing expression of Myc3-
tagged truncation mutants of LZAP and full-length Flag-tagged p38. P38 was 
immunoprecipitated using anti-Flag and LZAP truncation mutants were 
immunoprecipitated using anti-Myc antibodies before immunoblotting with anti-Myc (to 
detect LZAP truncations) or anti-p38. Expression of LZAP truncation mutants was 
confirmed by immunoblotting and binding activity of LZAP truncation mutants is 
schematically summarized. 
 
Figure 3.0.2 Independent 
and non-overlapping 
areas of LZAP are 
sufficient for association 
with p38 
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LZAP inhibits phosphorylation of p38 
MAPK family members are activated by phosphorylation and upon activation are translocated 
from the cytoplasm to the nucleus
165-167
. The dramatic re-localization of p38 from predominantly 
peri-nuclear to predominantly nuclear in the presence of LZAP (Fig. 3.1C and D) suggests that 
LZAP may alter p38 activity. To begin exploring effects of LZAP on p38 activity, total and 
phosphorylated p38 (phospho-T180/Y182) were detected following transient expression of p38 with 
or without increasing amounts of Myc-LZAP (Fig. 3.3A). Expression of LZAP decreased the amount 
of phospho-p38 detected in a dose dependent fashion, but did not alter total p38 levels. As expected, 
the amount of LZAP found in p38 immune-complexes increased as LZAP expression increased (Fig. 
3.3A, bottom panel). 
Expression of LZAP was associated with increased nuclear p38 levels, but surprisingly, LZAP 
was also found to decrease total cellular phospho-p38 levels (Fig. 3.1C, D, and 3.3A). To determine 
if nuclear p38 was phosphorylated in the presence of LZAP, immunofluorescent staining of p38, 
phospho-p38, and LZAP was performed following transient expression of Flag-p38 with or without 
Myc-LZAP and activation of p38 using UV irradiation (20 J/m2). Consistent with our previous 
findings, LZAP expression increased nuclear localization of p38 as indicated by 
immunofluorescence (Fig. 3.3B, lower panel green). Despite its ability to increase levels of nuclear 
p38, LZAP strongly inhibited accumulation of nuclear phospho-p38 following UV irradiation (Fig. 
3.3B, compare upper and lower red panels). Quantification of phospho-p38 results revealed that 48% 
of p38 expressing cells were positive for nuclear phospho-p38 in the absence of expressed LZAP, 
compared to only 11% of p38 expressing cells positive for nuclear phospho-p38 in the presence of 
expressed LZAP (Fig. 3.3B, p<0.0001). Regardless of LZAP expression, cytoplasmic phospho-38 
was not detected. Data represent examination of more than 100 cells from 3 independent experiments. 
Combined, these data suggest that LZAP inhibits phosphorylation of nuclear p38. 
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Fig. 3.3 LZAP regulates p38 phosphorylation. 
(A) LZAP inhibits phosphorylation of p38 at Thr180/Tyr182. U2OS 
cells were transfected with plasmids encoding Flag-p38 and with or 
without increasing amounts of Myc3-LZAP plasmid as indicated. p38 
was immunoprecipitated using anti-Flag antibody and p38 
phosphorylation at Thr180/Tyr182 determined by immunoblotting. 
Levels of p38 and LZAP in p38 immunoprecipitates were determined 
by immunoblotting with antibodies recognizing p38 or LZAP as 
described [2]). (B) LZAP inhibits accumulation of phosphorylated 
p38 in the nucleus. U2OS cells were transfected with plasmids 
directing expression of Flag-p38 with or without Myc3-LZAP. After 
UV irradiation (20 J/m2), cells were triply immunostained with anti-
phopho-p38, anti-Flag, and anti-Myc. The fraction of p38 expressing 
cells with detectable phosphorylated p38 was determined by direct 
visualization. Expression of LZAP was associated with a significant 
decrease in detection of phosphorylated p38 in p38 expressing cells 
((p<0.0001, using unpaired 2 tailed t test). Data are derived from 
examination of at least 200 cells from at least three independent 
experiments. (C) Depletion of LZAP increases phosphorylation of 
p38 in U2OS cells. U2OS cells were transiently transfected with 
control siRNA or siRNA specific to LZAP. Activating 
phosphorylation of p38 at Thr180/Tyr182 was determined in 
untreated cells or in cell treated with TNFα or IL-1β by 
immunoblotting. Expression of LZAP and total p38 was confirmed 
and GAPDH was used as a loading control. (D) Depletion of the 
LZAP protein correlates with p38 activation. Twenty-four hours after 
transfection with control siRNA or siRNA targeting LZAP, U2OS 
cells were transfected with plasmid encoding RNAi-insensitive 
LZAP. Transfected cells were selected with G-418 stimulated using 
TNFα and p38 phosphorylation determined by immunoblotting. 
Immunoblotting confirmed expression of p38 and si-RNA insensitive 
LZAP as described [2]. Immunoblotting of GAPDH served as control. 
(E) Depletion of LZAP increases phosphorylation of p38 in other cell 
types. MCF7, UM-SCC47 and FaDu cells were transiently transfected 
with control siRNA or siRNA specific to LZAP. Activating 
phosphorylation of p38 at Thr180/Tyr182 was determined by 
immunoblotting in cells treated with IL-1β. Expression of LZAP and 
total p38 was confirmed and GAPDH was used as a loading control. 
 
 
Figure 3.0.3 LZAP 
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Depletion of endogenous LZAP activates p38 
To determine if endogenous LZAP regulates p38, LZAP was depleted by siRNA and p38 
phosphorylation determined. Knockdown of LZAP in U2OS cells did not alter p38 expression; 
however, loss of LZAP was associated with increased levels of phospho-p38 levels in either the 
presence or absence of activating cytokines, TNFα and IL-1β (Fig. 3.3C). LZAP loss following 
siRNA treatment was confirmed and GAPDH was used as a loading control (Fig. 3.3C). Off target 
effects of siRNA were explored by simultaneous siRNA mediated knockdown and expression of 
LZAP containing silent mutations within the targeting siRNA sequence (RNAi-insensitive LZAP). 
As described above, cells were treated with TNFα to activate p38 resulting in robust phospho-p38 
signal following LZAP knockdown (Fig. 3.3D, lane 1). Regardless of transfection with siRNA 
targeting LZAP, expression of RNAi-insensitive LZAP resulted in marked inhibition of phospho-p38 
levels (Fig. 3.3D, lanes 2 and 3). To determine if LZAP activity was cell type specific, p38 
phosphorylation after LZAP knockdown and IL-1β stimulation was determined in 1 breast cancer 
cell line (MCF-7) and in 2 head and neck squamous cell carcinoma lines (UM-SCC47, FaDu). As 
observed in U2OS cells, siRNA-mediated loss of LZAP was associated with increased p38 
phosphorylation (Fig. 3.3E). Taken together, these data suggest that endogenous LZAP alters p38 
phosphorylation both in the presence or absence of activating cytokines. 
Upstream MAPK kinases (MKK3 or MKK6) activate p38 through direct phosphorylation at 
Thr180 and Tyr182
168
. Once activated, p38 phosphorylates downstream target proteins including: 
MAPKAPK2 and the transcription factor ATF2. To determine if increased p38 phosphorylation 
observed upon loss of endogenous LZAP correlates with p38 kinase activity, phosphorylation of p38 
target proteins was measured in the presence or absence of siRNA targeting LZAP (Fig. 3.4A). After 
cytokine or LPS stimulation, knockdown of LZAP resulted in increased phosphorylation of p38 
targets ATF2 and MAPKAPK2. MAPKAPK2 is itself a kinase that directly phosphorylates HSP27. 
siRNA-mediated loss of LZAP was associated with increased HSP27 phosphorylation suggesting 
that a kinase cascade downstream of p38 was activated upon LZAP loss. To begin exploring 
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potential mechanisms of LZAP activity toward p38, the effect of LZAP loss on MKK3 and MKK6 
phosphorylation was determined. LZAP knockdown was not associated with increased 
phosphorylation of upstream p38 kinases, MKK3 or MKK6 (Fig. 3.4A). Decreased LZAP 
expression was confirmed by immunoblotting following siRNA treatment (data not shown). 
p38-mediated phosphorylation of ATF2 activates ATF2 transcriptional activity 
169
. In the 
presence of cytokines, loss of LZAP expression was associated with increased ATF2 
phosphorylation (Fig. 3.4A), suggesting that LZAP expression may inhibit ATF2 transcriptional 
activity. To explore this possibility, a luciferase reporter system relying on a chimeric transcription 
factor construct containing the GAL4 DNA binding domain fused to ATF2 transcriptional activating 
domain was used as a surrogate for measurement of ATF2 transcriptional activity
170
. In the presence 
of p38, expression of LZAP resulted in a dose-dependent decrease in ATF2 transcriptional activity 
(Fig. 3.4B). Data represent 3 independent experiments. Taken together, these data suggest that 
phosphorylation and activity of p38 and downstream p38 targets are inhibited by endogenous LZAP 
and  upstream MKKs are not mediating LZAP activity toward p38. 
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  Fig. 3.4 Loss of LZAP increases p38 kinase activity, but does not alter MKK activation. 
(A) Depletion of LZAP increases phosphorylation of p38 targets, but does not alter 
phosphorylation of MKK3/MKK6. U2OS cells were transfected with control siRNA or 
siRNA targeting LZAP before stimulation with TNFα, IL-1β, or LPS. Phosphorylation of 
direct or indirect p38 targets ATF2, MAPKAPK2, HSP27 and activators of p38, MKK3 and 
MKK6, was visualized by immunoblotting. LZAP knockdown was confirmed by 
immunoblotting and expression of GAPDH was used as a loading control. (B) LZAP inhibits 
transcriptional activity of the p38 target ATF2. U2OS cells were transfected with plasmids 
directing expression of GAL-ATF2 and p38, with or without increasing amounts of LZAP 
along with a luciferase reporter containing the GAL DNA binding sequence, as indicated. 
Firefly luciferase activity was normalized based on renilla luciferase activity and assigned a 
value of 1 in cells without transfected LZAP. All normalized luciferase assay data are 
expressed as the mean with the standard error and are the result of the least three independent 
experiments. 
 
Figure 1.0.4 Loss of LZAP increases 
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LZAP regulates p38 phosphorylation through altering Wip1 association with p38 
Loss of LZAP did not result in activation of upstream p38-activating kinases MKK3 or MKK6 
(Fig. 3.4A), suggesting that LZAP-mediated inhibition of p38 occurred through an alternate 
mechanisms. Activity and phosphorylation of p38 reflects a balance between upstream activating 
kinases and inactivating protein phosphatases. Wip1 is a nuclear protein phosphatase that is 
expressed in response to p53 completing a negative feedback loop through inhibition of p53
99
. In 
addition to its role in abrogating p53 activity, Wip1 was found to form a physical complex with p38 
in vivo and to directly dephosphorylate and inactivate p38 
94, 96, 99, 114, 171
. 
To determine if the Wip1 phosphatase was involved in LZAP's inhibition of p38, binding of 
Wip1 to p38 was determined following transient expression of p38 singly or with increasing 
expression of LZAP. Before p38 immunoprecipitation, cells were UV treated to increase p38 
phosphorylation and expression of endogenous Wip1
92, 94
. Wip1 was not detected in p38 co-
immunoprecipitation in the absence of LZAP (Fig. 3.5A, lane 2); however, with increasing LZAP 
expression, Wip1 association with p38 became detectable and increased concordant with LZAP 
expression (Fig. 3.5A, lanes 3–5). In agreement with our earlier findings (Fig. 3.1A), LZAP 
expression had no effect on total p38 level; however, increased expression of LZAP correlated with 
detection of Wip1 in p38 immunoprecipitates (Fig. 3.5A). 
Expression of LZAP resulted in increased association between p38 and its direct phosphatase, 
Wip1, suggesting that decreased phosphorylation and activity of p38 following LZAP expression 
may be mediated by Wip1. To explore this possibility, phosphorylation of p38 was compared 
following transient expression of LZAP with or without siRNA mediated inhibition of Wip1 
expression. As expected, expression of LZAP resulted in decreased p38 phosphorylation (Fig. 3.5B, 
top panel compare lanes 1 and 2). In the presence of LZAP, loss of Wip1 expression restored p38 
phosphorylation suggesting that LZAP-mediated inhibition of p38 phosphorylation was at least 
partially dependent on Wip1 (Fig. 3.5B). Increased p38 phosphorylation following Wip1 loss in the 
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absence of expressed LZAP has been previously demonstrated 
171,172
 and was confirmed in U2OS 
cells following transfection of siRNA targeting Wip1 (Fig. 3.5B, right panel). 
We showed that LZAP binds (Fig. 3.1A, B) and inhibits phosphorylation of p38 (Fig. 3.3) and 
increases p38 interaction with the Wip1 phosphatase (Fig. 3.5 A). To elucidate mechanisms 
connecting these observations, an in vitro phosphatase assay was performed using bacterially 
synthesized His-Wip1 and His-LZAP. Expressed full-length Flag-p38 was immunoprecipitated from 
293T cells to be used as substrate then incubated with His-Wip1 or LZAP only (Fig. 3.5C lane 1, 2 
and 7). p38 was dephosphorylated in vitro by Wip1 but not LZAP, which is consistent with the 
literature and confirms that under these conditions, LZAP has no phosphatase activity. Interestingly, 
increasing the amount of LZAP incubated with a fixed amount of p38 and Wip1 decreased p38 
phosphorylation at lower doses (Fig. 3.5C lane 3,4) which is consistent with our data in vivo (Fig. 
3.5A). Further increases of LZAP however, reversed this trend resulting in increased levels of 
phospho-p38 (Fig. 3.5C lane 5, 6).  Reactions lacking Mg
2+
 in the buffer served as negative control 
(Fig. 3.5 lane 8-10). These data suggest LZAP regulates p38 through directly mediating Wip1 
binding and/or activity toward p38 and probably in a stoichiometric way. Similarly, in vitro 
phosphatase assays using synthesized pT180 site-specific p38 peptide as substrate (Fig. 3.5D) were 
performed with bacterially synthesized Wip1 and LZAP
47
. LZAP did not increase p38 peptide 
dephosphorylation by Wip1 in the peptide assay suggesting that a correct protein structure of p38 is 
required for LZAP to enhance Wip1 activity.  These data suggest that LZAP does not increase Wip1 
intrinsic phosphatase activity, but that LZAP may enhance interaction between phosphatase and 
substrate.  
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Fig. 3.5 LZAP regulation of p38 phosphorylation involves Wip1. (A) LZAP increases Wip1 
association with p38 in vivo. U2OS cells were transfected with plasmids directing expression 
of Flag-p38 with or without increasing amounts of Myc3-LZAP as indicated. 
Immunoprecipitation of Flag-tagged p38 was followed by immunoblotting using antibodies 
specific to Wip1, or p38. (B) Wip1 is required for inhibition of p38 phosphorylation directed 
by LZAP. U2OS cells were transfected with control siRNA or siRNA targeting Wip1, and 
after 1 day co-transfected with Flag-p38 with and without Myc3-LZAP, as indicated. 
Phosphorylation of p38 was visualized by immunoblotting after Flag-p38 
immunoprecipitation. Immunoblotting was used to confirm expression of p38 and GAPDH as 
an indicator of loading. (C) Flag-p38 expression vector was transfected into HEK 293T cells, 
immunoprecipitated with the anti-Flag M2 affinity gel and eluted by 3× Flag peptide, then 
incubated with indicated amount of recombinant His-Wip1 or His-LZAP in PP2C phosphatase 
buffer for 30 min before analyzed by immunoblotting as in (A). Magnesium was removed in 
lane 8-10 as negative control.  (D) p38MAPK T180 specific-phosphorylated peptides were 
incubated with recombinant His-Wip1 with or without His-LZAP in PP2C phosphatase buffer 
for 30 min. Free phosphate was measured by malachite green assay and absorbance at 650nm. 
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LZAP interacts with Wip1 in vivo 
To continue explore the mechanism of LZAP-mediated Wip1 and p38 interaction, LZAP and 
Wip1 interaction was determined. Overexpression of Flag-LZAP and Myc-Wip1 in both U2OS and 
MCF-7 cells followed by immunoprecipitation with either Flag conjugated beads (Fig. 3.6 A left 
panel) or Myc antibody (Fig. 3.6 A right panel) showed co-immunoprecipitation of Wip1 or LZAP, 
respectively Non-specific IgG was unable to immunoprecipitate either protein. Also 
immunoprecipitation using LZAP specific antibody for endogenous protein showed co-
immunoprecipitation of endogenous Wip1 (Fig. 3.6 B). Following expression of LZAP and Wip1, 
immunofluorescent staining revealed that Wip1 co-localized with LZAP in the nucleus (Fig. 3.6 C). 
And interestingly, after co-expression, LZAP nuclear staining changed from a pattern that excluded 
the nucleolus (98%) to a more evenly distributed pattern including nucleolar staining (17% nucleolar 
excusive). Together, these experiments suggest a direct interaction between LZAP and Wip1 in vivo. 
In addition, these data suggest that LZAP regulates p38 phosphorylation and activity by enhancing or 
stabilizing a protein complex containing both Wip1 and p38. 
LZAP partially depends on PPM phosphatases to regulate RelA phosphorylation 
Immunoprecipitation and LC-MS/MS identified PPM1A (sequence coverage 33%) and PPM1B 
(sequence coverage 77%) as potential LZAP binding partners (chapter 4). Since both Wip1 and 
PPM1A are RelA phosphatases targeting Ser536, which is also a LZAP regulated phosphorylation 
site, we hypothesize that like p38, LZAP regulation of RelA phosphorylation and activity is may be 
mediated by phosphatase(s) in a manner similar to what we found for p38. To begin testing this 
hypothesis, the effect of LZAP on RelA Ser536 phosphorylation was determined in cells with or 
without siRNA-mediated depletion of PPM1A. As expected, expression of LZAP resulted in 
decreased RelA phosphorylation in control cells without PPM1A depletion (Fig. 3.7 A, compare 
lanes 1 and 2). On the other hand, loss of PPM1A expression partially abrogated the ability of LZAP 
to decrease RelA phosphorylation (Fig. 3.7 A, compare lanes 2 and 4); however, LZAP regulation of 
PPM1A was not completely dependent on PPM1A (compare lanes 3 and 4). These data suggest that: 
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1) LZAP-mediated inhibition of RelA phosphorylation was at least partially dependent on PPM1A, 2) 
there may be additional LZAP-mediated RelA phosphatase(s).  
 
 
  
Fig. 3.6 LZAP binds to Wip1. (A) Ectopically expressed LZAP and Wip1 mutually co-
immunoprecipitate. U20S and MCF-7 cells were transfected with indicated plasmids directing 
expression of tagged LZAP or Wip1. Immunoprecipitates were prepared using mouse 
antibodies recognizing Myc (LZAP) or Flag (Wip1), resolved on SDS-PAGE, and 
immunoblotted by rabbit antibodies recognizing LZAP or Wip1. Expression of LZAP and 
Wip1 was confirmed by immunoblotting (1% of each input lysate was loaded as reference.) 
Pre-immune IgG was used to control for non-specific immunoprecipitation. (B) Endogenous 
LZAP binds endogenous Wip1. Lysates from untransfected MCF7 cells were 
immunoprecipitated using LZAP-specific rabbit antiserum or non-immune rabbit IgG, then 
immunoblotted with antibodies specific to Wip1 or LZAP as indicated. (C) Wip1 co-localizes 
with LZAP and alters LZAP nuclear localization. U2OS cells were transfected with plasmids 
directing expression of Myc3-LZAP with or without Wip1. Cells were fixed and LZAP and 
Wip1 expression and localization visualized by indirect immunofluorescence using anti-Flag 
monoclonal antibody and affinity-purified rabbit anti-LZAP antibody. Nucleolar localization 
of LZAP was determined by direct visualization and quantified based on at least 100 cells 
from at least 3 independent experiments. The shift of LZAP localization from exclusion of the 
nucleolus to the whole nucleus (including nucleolus) was statistically significant (p<0.0001, 
using unpaired 2 tailed t test). 
Figure 3.0.6 LZAP 
binds to Wip1 
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 Then to determine if PPM1A dephosphorylation of RelA can be regulated by the presence of 
endogenous LZAP, phosphorylation of S536 RelA was compared in cells expressing PPM1A, but 
with or without LZAP depletion by siRNA. As expected, ectopic expression of PPM1A decreased 
RelA phosphorylation (Fig. 3.7 B, compare lanes 1 and 3) and depletion of LZAP alone increased 
RelA phosphorylation (Fig. 3.7 B compare lines 1 and 2). Interestingly in the absence of LZAP, 
expressed PPM1A was not associated with the level of  RelA dephosphorylation seen in cells 
expressing endogenous levels of LZAP (Fig. 3.7 B, compare lanes 3 and 4) though there was still a 
moderate decrease of RelA phosphorylation compared to LZAP knockdown only (Fig. 3.7 B, 
compare lanes 2 and 4). In vitro PPM1A phosphatase assay using full-length RelA as substrate also 
revealed that addition of LZAP increases RelA dephosphorylation in a dose dependent manner(Fig. 
3.7 C).LZAP alone, even at the highest dose, did not alter RelA phosphorylation (Fig. 3.7 C lane 7). 
These results indicate that LZAP regulates RelA at least partially through mediating PPM1A 
dephosphorylation of RelA. Since Wip1 is also reported as a RelA phosphatase 
47
 and we showed 
here that Wip1 binds LZAP (Fig. 3.6), Wip1-/-, p53-/- double null mouse embryonic fibroblasts 
(MEFs) were used to determine the dependency of LZAP on Wip1 to regulate RelA. As expected, 
Wip1 knockout was associated with higher basal RelA phosphorylation levels compared to wild-type 
MEFs (1.64 fold) (Fig. 3.7 D, compare lanes 1 and 3). LZAP decreased RelA phosphorylation in the 
absence of Wip1, but the amount of decreased phosphorylation was less than in MEFs with 
endogenous Wip1 (35% vs. 18%, normalized to pS536RelA level in vector control of each group as 
100%). These data suggest that part of LZAP’s activity toward RelA depends on Wip1. Taking 
together, these results suggest that the ability of LZAP to regulate RelA phosphorylation largely 
depends on PPM phosphatases, PPM1A and Wip1. 
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Fig. 3.7 LZAP PP2C phosphatases require one another for efficient regulation of RelA 
phosphorylation. (A) PPM1A is required for inhibition of RelA phosphorylation directed by 
LZAP. U2OS cells were transfected with control siRNA or siRNA targeting PPM1A, and 
after 1 day co-transfected with or without Myc3-LZAP, as indicated. Phosphorylation of 
endogenous RelA at S536 was visualized by immunoblotting. Immunoblotting was used to 
confirm expression of RelA and GAPDH as an indicator of loading.  (B) LZAP is required for 
PPM1A to efficiently dephosphorylate RelA. U2OS cells were transfected with control siRNA 
or siRNA targeting LZAP, and after 1 day co-transfected with Myc3-RelA with and without 
Myc3-PPM1A, as indicated. Phosphorylation of RelA, total RelA, LZAP and GAPDH was 
detected as described in (A). (C) Flag-RelA expression vector was transfected into HEK 293T 
cells, immunoprecipitated with the anti-Flag M2 affinity gel and eluted by 3× Flag peptide, 
then incubated with indicated amount of recombinant GST-PPM1A with or without His-
LZAP in PP2C phosphatase buffer for 30 min before analysis by immunoblotting as described 
in (A). (D) Wild-type or Wip1-/-, p53-/- double null MEFs were co-transfected with Myc3-
RelA and control or Flag-LZAP plasmids, as indicated. RelA phosphorylation and LZAP 
expression level were determined as described in (A). 
Figure 3.0.7 LZAP PP2C phosphatases require one another 
for efficient regulation of RelA phosphorylation 
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Discussion 
Based on loss of LZAP expression observed in human HNSCC, as well as cellular effects 
associated with LZAP loss such as enhanced invasion, anchorage independent growth, angiogenesis, 
and growth of xenograft tumors, LZAP has been identified as a putative tumor suppressor 
110
. LZAP 
contains no enzymatic motifs suggesting that its activities may be derived through protein-protein 
interactions. A remarkable number of molecules that are implicated in tumorigenesis (e.g. ARF, 
RelA, Chk1, Chk2, and p38) bind to LZAP suggesting that LZAP activity may be protean
110, 112, 113, 
116
. Although identification of binding partners has provided insight into LZAP functions, satisfying 
mechanisms of pleiotropic LZAP activities have been lacking. 
Here we report that LZAP bound to the stress activated protein kinase p38, altered p38 
subcellular localization and inhibited p38 phosphorylation and activity. Mechanistically, our data 
suggest that LZAP inhibition of p38 phosphorylation depends on the Wip1 phosphatase, and that in 
the presence of LZAP, more Wip1 is associated with p38. Conceivably, LZAP may sequester p38 in 
the nucleus in a complex with Wip1 as a means of p38 inactivation. Alternatively, unphosphorylated 
nuclear p38 may have unknown activities or may be sequestered in the nucleus so that upon loss of 
LZAP, rapid activation of p38 could occur through phosphorylation by nuclear kinases. 
Depending on cellular context, p38 can mediate opposing cellular responses as an inducer or 
inhibitor of proliferation and apoptosis
149
. To date, most data highlights LZAP as a tumor suppressor, 
but its role as a p38 regulator implies that LZAP could also have opposing cellular effects or that 
LZAP inhibition of p38 could be restricted to circumstances where inhibition of p38 suppresses 
tumor promoting activity. 
The mechanism of LZAP activity toward the growing list of LZAP-associated proteins (LAPs) is 
not well understood. The finding that a portion of LZAP exists in large molecular weight complexes 
combined with a potential for LZAP to oligomerize (chapter 4) lends credence to this argument and 
further suggests that LZAP may serve to bring together effector proteins. A large portion of LZAP 
interacting proteins are phosphorylated, and LZAP expression has been associated with decreased 
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phosphorylation of these proteins. These observations led us to explore if LZAP had activity to 
inhibit p38 upstream kinases or to activate p38 phosphatases. We found that LZAP did not alter 
kinase activity, as measured by phosphorylation, of MKK3 or MKK6; however, LZAP was found to 
increase association of p38 with its direct phosphatase Wip1in vivo (Fig. 3.5A) and increase Wip1-
mediated dephosphorylation of p38 in vitro (Fig. 3.5.B). Also depletion of Wip1 reversed the 
decrease of p38 phosphorylation by LZAP, suggesting at least part of the LZAP activity toward p38 
depends on Wip1. To explore if this is a mechanism for LZAP regulated RelA phosphorylation, 
similar experiments were performed with RelA and suggest that LZAP and RelA phosphatases, 
PPM1A and Wip1, depend on each other to dephosphorylate RelA (Fig. 3.7). Identification of the 
interaction between LZAP and Wip1 or other PPM phosphatases (Fig. 3.6 and data not shown), 
which are phosphatases for several LZAP target proteins, further add to the possibility that LZAP 
form a multi-protein complex with key proteins and  their cognate phosphatases to regulate signaling 
pathways.  However, it is still unclear if regulation of phosphatases is a general mechanism of LZAP 
activity, but it is clear that it is not a universal mechanism since phosphorylation has not been 
described to play a role in LZAP-mediated ARF activity. It is intriguing that additional described 
LAPs including Chk1 and Chk2 are also targets of phosphatases, including Wip1
96,102
. We have 
previously shown that LZAP activates p53 in the absence of ARF
112
 raising the possibility that this 
ARF-independent activity of LZAP may also depend on Wip1, PPM1A or PPM1B. 
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CHAPTER IV 
 
REGULATION OF LZAP 
 
Abstract 
Our studies and those from other groups suggest that LZAP is a putative tumor suppressor with 
critical activities to regulate key proteins in cancer signaling pathways including: p53, RelA, Chk1 
and Chk2 and p38. However little is known about through which LZAP activity is regulated. The 
activity of many proteins is regulated by post-translational modification (PTM), protein stability, and 
association with binding partners. Here, we began to explore these mechanisms as well as LZAP 
self-association as potential means of LZAP regulation. Inorganic 
32
P isotope labeling revealed that 
LZAP is phosphorylated in vivo, and in vitro phosphatase assays using synthesized LZAP phospho-
peptides as substrate suggested that Wip1, PPM1A and PPM1B may directly dephosphorylate LZAP. 
We also observed that manipulation of Wip1 levels resulted in symmetric changes in LZAP protein 
levels while the ubiquitination of LZAP was decreased upon Wip1 expression. Together with data 
that PPM phosphatases bind LZAP, these data suggest PPM family phosphatases likely regulate 
LZAP phosphorylation and stability in vivo. The embryonic lethal phenotype of LZAP homozygous 
knockout mouse model, as well as the impaired zebrafish embryonic development after LZAP knock 
down indicate that LZAP is an essential protein during vertebrate embryonic development; however 
functions of LZAP responsible for its requirement for normal development are not clear.  To identify 
potential LZAP regulators or effectors proteins in a complex with LZAP were immunoprecipitated 
and subjected to LC-MS/MS. Members of the PPM family, PPM1B and PPM1A, were identify and 
the PPM1B-LZAP interaction was confirmed in vivo. Additional proteins, KIAA0776, DDRGK1 
and UFM1, have since been described as LZAP binding proteins involved in regulation of LZAP 
protein level were also identified in the LC-MS/MS analysis. We noted that several proteins involved 
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in ufmylation were identified as LZAP associated proteins. KIAA0776 has recently been described 
as an E3-ligase in the ufmylation pathway. UFM1 is the small ubiquitin-like protein that is 
conjugated to proteins, and DDRGK1 is substrate of KIAA0776. Together these data suggest that 
LZAP may be regulated by this ubiquitin-like conjugation system or perhaps regulate the ufmylation 
pathway. To identify the domains of LZAP responsible for interaction with associated proteins, 
truncation mutants of LZAP were created. Both N-terminal and C-terminal non-overlapping regions 
of LZAP associate with RelA, p38 and PPM1B suggesting to us that LZAP may be forming homo-
dimers or homo-oligomers. Co-immunoprecipitation using differentially tagged LZAP confirmed the 
existence of at least LZAP dimers.  These preliminary data suggest that LZAP activity and protein 
level are regulated by phosphorylation through interaction with PPM family phosphatase and 
ubiquitination, and that in addition, LZAP may be modified or regulate the ufmylation pathway.  
 
Introduction 
The function, activity, and/or stability of many proteins are controlled by post-translational 
modification (PTM), by interaction with other proteins or by self-association of proteins to form 
dimers and higher-order oligomers. 
Protein post-translational modification (PTM) increases the functional diversity of the proteome 
by the covalent addition of functional groups or proteins, proteolytic cleavage of regulatory subunits 
or degradation of entire proteins. These modifications include, amongst others, phosphorylation, 
glycosylation, ubiquitination, nitrosylation, methylation, acetylation, lipidation and proteolysis and 
influence almost all aspects of normal cell biology and pathogenesis. Post-translational modification 
can occur at any step in the "life cycle" of a protein and can dramatically alter a protein’s activity, 
localization and stability (Thermo Scientific website/Overview of post translational modification). 
Many proteins are modified shortly after completion of translation to mediate proper protein folding 
or stability or to direct the nascent protein to distinct cellular compartments (e.g. nucleus, membrane). 
Other modifications occur after folding and localization are completed to activate or inactivate 
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catalytic activity or to otherwise influence biological activity. Phosphorylation of proteins by kinases 
at specific amino acid side chains, principally on serine, threonine or tyrosine residues, is a common 
method of catalytic activation or inactivation and the most important and well-studied PTM. 
Conversely, phosphatases hydrolyze the phosphate group to remove it from the protein acting as a 
counterbalance to kinases. Proteolytic cleavage of peptide bonds is a thermodynamically favorable 
reaction and therefore permanently removes peptide sequences or regulatory domains. Proteases 
comprise a family of enzymes that cleave peptide bonds and are critical for many normal cellular 
processes including: antigen processing, apoptosis, surface protein shedding and cell signaling. 
Proteins are also covalently linked to tags that target a protein for degradation or can direct 
subcellular localization. Ubiquitination is a common modification of this type. Ubiquitin is an 8-kDa 
polypeptide consisting of 76 amino acids that is appended to the NH2 of lysine in target proteins via 
the C-terminal glycine of ubiquitin. Following an initial mono-ubiquitination event, a ubiquitin 
polymer can be created by linking ubiquitin to ubiquitin and creating poly-ubiquitinated proteins that 
are the targeted for degradation by the 26S proteasome Proteins can also be sequentially modified by 
processes such as post-translational cleavage and the addition of functional groups for production of 
mature and active proteins. For some proteins, phosphorylation and  ubiquitination are tightly linked 
as illustrated by examples like IκBα173, RelA174 and GSK175 in which phosphorylation within target 
proteins (phosphodegrons) is required to trigger ubiquitination and degradation. Consequently, 
characterization of PTMs, although challenging, provides invaluable insight into the cellular 
functions of proteins. 
Protein-protein interactions are intrinsic to virtually every cellular process. Any listing of major 
research topics in biology—for example, DNA replication, DNA repair, transcription, translation, 
splicing, secretion, cell cycle control, signal transduction, and intermediary metabolism—is also a 
listing of processes in which protein complexes have been implicated as essential components
176
. In 
addition to well-known examples of multi-subunit proteins, there are also a large number of transient 
protein-protein interactions, which in turn control a large number of cellular processes. All 
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modifications of proteins mentioned above necessarily involve such transient interactions. Transient 
protein-protein interactions are also involved in the recruitment and assembly of the transcription 
complex on specific promoters, the transport of proteins across membranes, the folding of native 
proteins catalyzed by chaperones, individual steps of the translation cycle, and the breakdown and 
re-formation of subcellular structures during the cell cycle (such as the cytoplasmic microtubules, the 
spindle apparatus, nuclear lamina, and the nuclear pore complex)
176
. Thus, identification of binding 
partners can help advance understanding of protein activity and regulation. Co-immunoprecipitation 
coupled with liquid chromatography–mass spectrometry (LC-MS/MS) and provides a powerful tool 
for identification of large number of potential binding proteins.  
The self-association of proteins to form dimers and higher-order oligomers is a common 
phenomenon contributing to numerous cellular processes. Dimerization and oligomerization confers 
structural and functional advantages to proteins, including improved stability, control of accessibility 
and specificity of active sites, and increased complexity. Oligomerization or dimerization expands 
the opportunities for regulation by providing combinatorial specificity, allostery, activation and 
inhibition. Recent structural and biophysical studies show that protein dimerization or 
oligomerization is a key factor in the regulation of proteins such as enzymes, ion channels, receptors 
and transcription factors contributing to increased enzyme activity by concentrating the active site, 
facilitation of local concentration of molecules, transmission of signals, and channeling of reagents 
(small molecules and ions) across membranes. In addition, self-association can help to minimize 
genome size, while maintaining the advantages of modular complex formation. However, 
inappropriate formation of oligomers can be associated with pathogenic states. Specific protein 
dimerization is integral to biological function, structure and control, and must be under substantial 
selection pressure to be maintained with such frequency throughout biology
177
.  
Upon initiation of this project, information related to regulation of LZAP including modification, 
enzymes responsible for potential modification (except for Cdk5
107
), LZAP-associated proteins, and 
self-association status were not well described. With the emerging results indicating that LZAP has 
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tumor suppressor-like activity, regulates major cancer signaling pathways, is essential for early 
vertebrate development exploration of LZAP regulation under both physiological and pathological 
conditions is warranted. Here we present preliminary and hypothesis generating data exploring 
aspects of LZAP regulation. 
 
Materials and Methods 
Plasmid constructs and mutagenesis 
His-LZAP was PCR from pCDNA3-LZAP and subcloned in to pCDNA3 vector. Truncation 
mutants of LZAP were as described in chapter 3. Single deletion mutations of LZAP were PCR from 
pCDNA3-Flag-LZAP wild type construct and mutations of LZAP containing multiple deletions were 
PCR from the single and double mutations. Primers use for deletion mutagenesis: LZAPD1 forward 
GTC AAC TAT GAG ATC CCC TCA GGG GCT GCC GAG ATG CGG GAG, LZAPD1 reverse 
CTC CCG CAT CTC GGC AGC CCC TGA GGG GAT CTC ATA GTT GAC, LZAPD2 forward 
CCA GAT GCC CTG ACA CTG CTT GAA ATC TTC TTA GCC CAG AGA GCA GTG, 
LZAPD2 reverse CAC TGC TCT CTG GGC TAA GAA GAT TTC AAG CAG TGT CAG GGC 
ATC TGG, LZAPD3 forward TCC CAG CTG CTG GCT TTG AAG AAA GAC ATC TCC AAG 
AGG TAC AGC GG, LZAPD3 reverse CC GCT GTA CCT CTT GGA GAT GTC TTT CTT CAA 
AGC CAG CAG CTG GGA. 
Antibodies and reagents 
Anti-His antibody was from Qiagen (#34698). Anti-HA antibody was from Santa Cruz (sc-
7392).EZ view anti-Flag M2 affinity gel (F2426-5X1ML) and anti-c-Myc Agarose Affinity Gel 
(A7470) were purchased from Sigma-Aldrich.  
in vivo 
32
P orthophosphate labeling  
24 hrs after transfection of His-LZAP or control vector, U2OS cells were washed and maintained 
in phosphate-free DMEM (Life Technologies #11971) supplied with 10% dialyzed FBS (Life 
Technologies #26400) for 24 hrs. After metabolically labeled with 100 µCi/ml [
32
P] orthophosphate 
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(Perkin Elmer) for 6 hrs, supernatant from cell lysate in 0.5%NP-40 lysis buffer were incubated with 
anti-His or LZAP antibody. Immunoprecipitates were analyzed by SDS-PAGE and subsequent 
autoradiography using auto-radiography film. 
 
Results 
LZAP is phosphorylated and ubiquitinated 
LZAP can be phosphorylated in vitro by Cdk5
107
; however, Cdk5 expression is limited to cells of 
neural derivation and LZAP phosphorylation had not been observed in vivo. 
32
[P] orthophosphate 
labeling of cells ectopically expressing His-tagged or un-tagged LZAP followed by 
immunoprecipitation with anti-His or anti-LZAP antibodies revealed that both His-tagged and un-
tagged LZAP were phosphorylated in vivo (Fig. 4.1 A). Our findings that LZAP is a phosphoprotein 
that binds to PPM phosphatases coupled with the observation that alteration of Wip1 levels changes 
LZAP levels (Fig. 4.1C) led us do examine PPM phosphatase activity toward potential 
phosphorylation sites of LZAP. We also suspected that residues dephosphorylated by PPM 
phosphatases may indicate residues of LZAP that are phosphorylated in vivo. In vitro phosphatase 
assays using LZAP phospho-peptides (S91, T237 and S426) as substrate were performed. S426 was 
reported to be phosphorylated by cdk5 in the in vitro kinase assay
107
 whileS91 (S91Q92) and T237 
(T237V238Y239) are consensus motifs, S/TQ or TXY, for Wip1 and PPM phosphatases
141, 142
. 
Bacterially synthesized His-Wip1, GST-PPM1A and GST-PPM1B were incubated with LZAP-
specific peptides All three phosphatases dephosphorylated pS91 and pT237 sites robustly while 
dephosphorylation of pS426, the in vitro cdk5 site, was not observed except by the control lambda 
phosphatase (Fig. 4.1 B).  
Interestingly, we found that endogenous LZAP protein levels were decreased after siRNA 
knockdown of Wip1 (Fig. 4.1 C) suggesting that expression or stability of LZAP might be regulated 
by phosphorylation. Since phosphorylation is sometimes required as marker triggering ubiquitin 
93 
conjugation, LZAP ubiquitination status was measured by co-expression of Myc3-LZAP with HA-
ubiquitin. After immunoprecipitation with anti-Myc antibody, ladder of ubiquitin conjugated LZAP 
was detected by anti-HA antibody (Fig. 4.1 C compare lanes 1 and 2). Consistent with decreased 
LZAP after depletion of Wip1 LZAP levels were increased with co-expression of Wip1 (Fig. 4.1 D 
compare lanes 5 and 6). It is possible that LZAP stability is increased upon Wip1 expression as 
indicated by decreased ubiquitination of LZAP when co-expressed with Wip1 (Fig. 4.1D compare 
lanes 2 and 3). 
 
  
Fig. 4.1 LZAP phosphorylation and ubiquitination. (A) U2OS cells overexpressing His-
tagged or untagged LZAP was phosphate starved overnight before incubation with 
32
[P] 
orthophosphate for 6 hr. After immunoprecipitation with His or LZAP antibody, samples 
were separated by SDS-PAGE and autoradiography performed. (B) LZAP-specific 
peptides with phosphorylation at residues corresponding to S91, T237 and S426 
specific-phosphorylated LZAP peptides were incubated with recombinant His-Wip1, 
GST-PPM1A, or PPM1B in PP2C phosphatase buffer for 30 min. Free phosphate 
released into the buffer was measured by addition of malachite green and absorbance at 
650nm. λ-phage phosphatase (λ-PPase) was used as positive control. (C) Cell lysate 
from U2OS cells with transient transfection of control or Wip1 siRNA was subjected to 
SDS-PAGE and Wip1, LZAP and GAPDH detected by immunoblotting. (D) Myc3-
LZAP was co-expressed with or without HA-ubiquitin (HA-Ub) and Flag-Wip1 in 
U2OS cells treated with the proteasome inhibitor, MG132. LZAP immunoprecipitates 
were separated by SDS-PAGE and ubiquitin or LZAP  detected by immunoblotting. 
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Identification of LZAP binding partners and LZAP binding domain mapping 
To date, understanding of LZAP tumor suppressor pathways has been expanded by identification 
and understanding of the pathways and proteins LZAP regulates, but we still understand very little 
about pathways and proteins that LZAP regulates that are important in causing embryonic lethality 
associated with LZAP loss during early vertebrate development. To identify LZAP activities, we 
used an unbiased approach to identify additional LZAP binding proteins which might function as 
LZAP regulators or effector in cancer and/or normal development. Initially yeast two hybrid 
screening was performed on a human placenta library using full-length LZAP as bait (HybriGenics). 
However the pilot experiment showed that LZAP has a self-activation activity which prevented 
further screening. Therefore we turned to co-immunoprecipitation coupled with LC-MS/MS 
(Vanderbilt mass spectrometry research core lab). Flag-LZAP was ectopically expressed in 
HEK293T cells followed by immunoprecipitation using Flag-antibody conjugated beads. 
Immunoprecipitated proteins were eluted using 3x Flag peptide enzymatically digested then peptides 
analyzed by LC-MS/MS. More than 500 proteins and 1000 of their isoforms were identified by two 
or more peptides (Table 4.1) Putative LZAP binding proteins included:  PPM1A and PPM1B, the 
two PPM family members and several enzymes related to PTM. A high portion of PPM1B protein 
sequence was covered (75%) and subsequent co-immunoprecipitation using Flag-PPM1B and Myc3-
LZAP confirmed interaction between these proteins (Fig. 4.2 A lane 2). The interaction between 
nucleolin/C23 and LZAP was also recently confirmed using co-immunoprecipitation (data not 
shown). After our findings, other groups have reported that KIAA0776, DDRGK1 and UFM1 are 
LZAP-associated proteins
118-121
. Interestingly, these reports suggest that KIAA0776, DDRGK1 and 
UFM1 are involved in regulation of LZAP ubiquitination, stability and localization.  
To identify domains of LZAP mediating its binding to LZAP-associated proteins, binding 
between LZAP truncation mutants and known binding partners (p38, RelA and PPM1B) was 
determined. As described in chapter 3 (Fig. 3.2), both N-terminal (αα 112-358, M3) and C-terminal 
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(αα 329-506, M7) of LZAP bound to p38. Similar results were observed from co-
immunoprecipitation of selective LZAP mutants and PPM1B (Fig. 4.2 A) or RelA (Fig. 4.2 B and 
data not shown). PPM1B binds to LZAP N-terminal mutants M2 (αα 1-303) and M3 (αα 112-358) 
and C-terminal mutant M7 (αα 329-506). RelA binds to the majority of LZAP truncations excluding 
a domain of LZAP occupying the mid portion of the protein (M4, αα 201-358). The results of 
binding domains from our lab and the literature suggest that binding of LZAP to effectors or 
regulators is not straight forward (diagrammatically displayed, Fig. 4.3).  
 
 
 
  
Fig. 4.2 Mapping of LZAP domains involved in binding to LZAP-associated 
proteins. (A) Flag-PPM1B was co-expressed with indicated Myc3-tagged full 
length or truncated LZAP in U2OS cells. Cell lysates were immunoprecipitated 
using anti-Flag M2 affinity gel and samples analyzed by SDS-PAGE and 
immunoblotting with Myc antibody. Arrows on the right panel indicate the bound 
LZAP truncations. (B)  Flag-RelA was co-expressed with indicated Myc3-tagged 
full length or truncated LZAP or in U2OS cells. Cell lysate were 
immunoprecipitated using Myc antibody conjugated agarose beads. Samples were 
analyzed by SDS-PAGE and immunoblotting with anti-Flag and anti-Myc antibody. 
Figure 4.0.2 Mapping of LZAP domains 
involved in binding to LZAP-associated 
proteins 
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   Gene Name Coverage % Description 
CDK5RAP3 93 LZAP 
UBC 87 Ubiquitin 
KIAA0776 81 UPF0555 protein  
WDR77 79 Methylosome protein 50, Androgen receptor cofactor p44 
PPM1B 75 Protein phosphatase 2C isoform beta. 
MYCBP 72 C-Myc-binding protein 
PRMT5 71 Protein arginine N-methyltransferase 5 
UFM1 68 Ubiquitin-fold modifier 1 
DDRGK1 61 DDRGK domain-containing protein 1  
HSPA8 52 Heat shock cognate 71 kDa protein 
SPIN1 52 Spindlin-1, Ovarian cancer-related protein 
STK8 50 Serine/threonine-protein kinase 38, NDR1 protein kinase 
NMP1 44 Nucleophosmin, Nucleolar phosphoprotein B23 
UFC1 44 Ufm1-conjugating enzyme 1, Ubiquitin-fold modifier-conjugating enzyme 1 
EIF5A 43 Eukaryotic translation initiation factor 5A-1 
HUWE1 36 E3 ubiquitin-protein ligase HUWE1, ARF-binding protein 1 
PPM1A 33 Protein phosphatase 1A, Protein phosphatase 2C isoform alpha 
NCL 30 Nucleolin, Protein C23 
PPP1CA 21 Serine/threonine-protein phosphatase PP1-alpha catalytic subunit 
MAP3K7 11 Mitogen-activated protein kinase kinase kinase 7 
HDAC2 11 Histone deacetylase 2 
  
 
 
Table 4.2 Summary of LZAP truncations interaction with RelA or LZAP. The number of  “+” 
indicates the signaling strength based on immunoblotting following co-immunoprecipitation, (-) 
indicates no detectable binding. 
 
Myc-LZAP wt M1 M2 M3 M4 M5 M6 M7 M8 
aa residues 
Full 
length 
1-
111 
1-
303 
112-
358 
201-
358 
428-
506 
359-
506 
329-
506 
226-
506 
RelA ++ - ++++ +++ – NA ++ +++ ++++ 
LZAP  ++  NA  +++  ++   +   NA   +++   ++++  +++  
 
 
 
  
Table 4.1 selective results from LZAP binding partner analysis. Proteins identified by others are yellow 
highlighted 
Table 4.0.1 Selective results from LZAP 
binding partner analysis 
Table 4.2 Summary of LZAP 
truncations interaction with RelA or 
LZAP 
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Fig. 4.3 LZAP motifs and binding of LZAP truncations to known LZAP associated proteins and diagram for LZAP protein motifs.  
The number of “+” indicates the signaling strength based on immunoblotting following co-immunoprecipitation, (-) indicates no detectable binding. 
Protein name in black indicates results of our studies, protein names in blue indicate results from the literature. 
 
 
Figure 4.0.3 LZAP 
motifs and binding of 
LZAP truncations to 
known LZAP 
associated proteins 
and diagram for 
LZAP protein motifs 
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Binding domain mapping was complex with non-overlapping fragments of LZAP binding to 
multiple proteins suggesting two binding scenarios 1) both N-terminal and C-terminal LZAP contain 
motifs that directly bind p38, RelA and PPM1B, and/or 2) full length endogenous LZAP dimerizes 
with LZAP truncation mutants and bridges interaction between truncations and LZAP-associated 
proteins.  LC/MALDI mass spectrometry suggested that some higher molecular weight bands 
following PAGE and silver staining of Flag-LZAP immunoprecipitation represent LZAP dimers 
119
. 
To determine if LZAP self-associates, full-length Flag-LZAP was co-expressed with either full-
length Myc3-LZAP or Myc3-LZAP truncation mutants in U2OS cells followed by 
immunoprecipitation using anti-Flag affinity gel. Full-length LZAP and the mutants M2 and M8 co-
immunoprecipitated with LZAP respectively (Fig. 4.4 A, co-IP results of LZAP truncation mutants 
are summarized in Table 4.2). These results suggest that LZAP indeed can self-associate forming at 
least dimers. To determine the domain of LZAP mediating self-association, Flag-tagged C-terminal 
LZAP truncation M6 was co-expressed with Myc-M6 or Myc-tagged N-terminal LZAP truncation, 
M2. Immunoprecipitation of Flag-M6 revealed binding to M6 itself and N-terminal truncation 
mutant M2 (Fig. 4.4 B lanes 5 and 7). These experiments highlight the requirement for further 
experiments to distinguish if the interaction of truncation mutant association is direct or mediated by 
full-length LZAP that is expressed in all cells. In addition to testing truncation mutants of LZAP, a 
coiled coil domain predicted to be involved in protein-protein interaction was also deleted in LZAP 
and tested for binding activity. Coiled-coil motifs are characterized by two or more helices wound 
around one another. In some proteins (e.g. c-Jun), a two-stranded coiled coil is responsible for 
dimerization
178
. Amino acids 129-152, and 452-488 in LZAP are regions likely to form coiled-coil 
motif (COILS
131
, score 95 of 100) and amino acids 346-361 is also predicted to form a coiled coil 
motif (score 50 of  100) (Fig. 4.4 C). These predicted regions are part of the N- and C- terminal 
truncation mutants which bind full length LZAP suggesting that they may be involved in 
dimerization. Flag-tagged deletion mutant 123, lacking all three coiled-coil domains, was co-
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expressed with Myc3-LZAP. Interestingly, the deletion mutation still co-immunoprecipitated with 
LZAP with affinity based on band intensity similar to wild-type LZAP suggesting that either these 
domains are not necessary or that more residues and larger domain(s) are involved in LZAP self-
association. 
 
 
  
Fig. 4.4 Mapping of LZAP self-association domains (A) Flag-LZAP was co-expressed with 
indicated Myc3-tagged LZAP species, full length or truncations, in U2OS cells. Cell lysate were 
immunoprecipitated using anti-Flag M2 affinity gel and samples analyzed by SDS-PAGE and 
immunoblotting with Myc antibody. Arrows on the right panel indicate bound LZAP species. 
(B) Flag-LZAP M6 mutant was co-expressed with indicated Myc3-tagged LZAP species, full 
length or truncations, in U2OS cells. Binding was determined as described in (A). (C) Upper 
panel: diagram of analyses predicting the coiled-coil domains in LZAP. Lower panel: Myc3-
LZAP was co-expressed with Flag-tagged LZAP species, full length or deletions, in U2OS cells. 
Binding was determined as described in (A).  
Figure 4.0.4 Mapping of LZAP self-association domains 
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Discussion 
Since we reported that LZAP binds and activates the alternate reading frame protein p14
ARF 
in 
humans and activates p53
82, LZAP’s role in tumorigenesis has continued to emerge. We and others 
have described LZAP functions to regulate activities of ARF, p53, p38 MAPK
117
, NF-κB110, Wip1, 
Chk1 and Chk2
113, 116
. Tumor suppressor qualities of LZAP were highlighted by our findings that 
LZAP is lost in 30% of head and neck squamous cell carcinomas (HNSCC)
110
. However, the 
mechanism(s) loss of LZAP expression in cancer remains unknown as does regulation of LZAP 
activity, stability or subcellular localization. The importance of LZAP biological functions calls for 
the studies to elucidate the mechanisms of LZAP regulation.  
Here, we showed LZAP is phosphorylated and that LZAP binds PPM phosphatase Wip1, PPM1A 
and PPM1B and may itself be a substrate through PPM family members targeting amino acids S91 
and T237. Peptide phosphatase assays suggest that PPM members cannot dephosphorylate the S426 
residue of LZAP; however, S426 may still be a phosphorylated site of LZAP. Since LZAP may be 
targeted for dephosphorylation by Wip1 and phosphorylation can be associated with protein stability 
(e.g. IκBα173, RelA174 and GSK175), we examined effects of Wip1 on LZAP expression levels. 
Interestingly, depletion of Wip1 was accompanied by a decrease of LZAP protein. In the absence of 
phospho-specific LZAP antibodies, we could not directly correlate LZAP phosphorylation status 
with stability, but we did explore if LZAP was ubiquitinated and if ubiquitination of LZAP was 
altered in the presence of Wip1 (Fig. 4.1 D). Remarkably, expression of Wip1 with LZAP was 
associated with increased LZAP protein levels, but decreased LZAP ubiquitination (Fig. 4.1 D). 
Interestingly, liquid chromatography and tandem mass spectrometry (LC-MS/MS) used for detection 
of LZAP-associated proteins identified several proteins involved in ubiquitination including 
ubiquitin and an E3 ubiquitin ligase. Perhaps just as interesting, several proteins including UFM1, 
UFC1 and KIAA0776 were also identified as LZAP associated proteins.  These three proteins belong 
to a novel ubiquitin-like protein conjugating system, of which UFM1 is ubiquitin-like protein, UFC1 
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functions as the E2 enzyme
122
 and KIAA0776/UFL1 is recently identified as the E3 ufmylation 
ligase
123
. While there is no data to suggest LZAP is modified by UFM1, it is interesting that another 
LZAP associated proteinDDRGK1, is a substrate of this small protein conjugating system
123
. Studies 
have confirmed that KIAA0776 binds LZAP and these two proteins form a complex with UFM1
118
 
suggesting that LZAP may be a substrate for ufmylation or potentially regulate the E3 ligase 
KIAA0776. LZAP is reported as a stable protein that is not rapidly degraded in control cells (
119
 and 
our data not shown). Both Wip1 and KIAA0776 decrease LZAP ubiquitination
120, 119
 and KIAA0776 
is an E3 ligase for the novel UFM1 conjugating system, it is possible that UFM1 and ubiquitin 
compete for the modification on LZAP and dephosphorylation of LZAP by Wip1 at specific residues 
favors ufmylation over ubiquitination.  
Protein-protein interactions are essential, especially in the regulation of biochemical pathways 
and signaling cascades in the cells. With the increase in numbers of LZAP-associated proteins we 
sought to map critical binding domains to see if distinct functions for LZAP could be separated. 
Using truncations of LZAP, we found that both N- and C-terminal portions bind to p38 suggesting 
that independent regions in LZAP may bind p38; however, similar results found with two additional 
LZAP binding partners, RelA and PPM1B, suggested that LZAP self-association could also explain 
the propensity of non-overlapping regions of LZAP to bind a wide variety of proteins. This 
hypothesis was supported by findings that Myc3-LZAP co-immunoprecipitated with Flag-LAZP and 
that N- and C-terminal truncation mutants bound not only to full length LZAP but also other 
truncations. In an attempt to identify LZAP residues critical or required for self-association, 3 of 3 
predicted coiled-coil domains were interrupted by deletion (129-152, 346-361 and 452-488, a total of 
76 amino acid deletion). Unfortunately, co-immunoprecipitation experiments continued to display 
the binding of this triple-deletion mutant to full length LZAP suggesting additional or distinct 
residues in LZAP are required for self-association. Further, it is not clear if LZAP forms dimers or 
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higher-order oligomers or whether the activity of LZAP and the binding to other proteins depends on 
self-association. 
In summary, we identified that LZAP is phosphorylated and ubiquitinated in vivo and that LZAP 
binds to PPM phosphatases Wip1 and PPM1B, as well as, to components of ubiquitin and UFM1 
conjugation systems. Binding domain mapping revealed that LZAP is a self-association protein. All 
these primary findings raise questions and will lead to further study of the regulation of LZAP.       
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CHAPTER V 
 
SUMMARY AND FUTURE DIRECTIONS 
 
1. Summary 
The objective of this work was to: 1) improve mechanistic understanding of LZAP activity 
through identification of binding partners and co-effectors of LZAP activity; 2) determine 
mechanism(s) through which LZAP is regulated. Known LZAP associated proteins, RelA and p38, 
were used as model LZAP target proteins for many studies dissecting LZAP activity. Findings 
presented in this dissertation demonstrate that: 1) PPM1A, a PPM family member, is a novel RelA 
phosphatase with tumor suppressor-like activity; 2) LZAP’s ability to decrease target protein (e.g. 
RelA and p38) phosphorylation is at least partially dependent on PPM phosphatases (PPM1A and 
Wip1 respectively); 3) LZAP alters PPM activity, at least in some cases (e.g. p38) by enhancing the 
association of phosphatase and substrate; 4) LZAP is phosphorylated and ubiquitinated, 5) LZAP 
protein levels are altered by Wip1, suggesting that phosphorylation of LZAP may regulate its 
stability, 6) LZAP self-associates to form dimer or high-order oligomer with both N- and C-terminal 
regions of LZAP capable of self-association, and 7) LZAP has many potential binding partners some 
of which are unexplored, such as ubiquitination and ufmylation pathway components .  
Dysregulation of the NF-κB pathway contributes to tumorigenesis in varied cancer types and is a 
driving force of prostate cancer metastasis. Previous studies in the Yarbrough lab revealed that 
LZAP is lost in 30% of head and neck squamous cell carcinomas (HNSCC) and those tumors with 
LZAP loss overexpress select RelA targets. The work here identified a new regulator of NF-κB, 
PPM1A, and provided evidence that PPM1A expression is decreased in human prostate cancer 
metastases. Excitingly, restoration of PPM1A expression inhibited NF-κB activity and growth of 
bony metastases after intravascular injection of prostate cancer cells. Thus, expression status of 
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LZAP and PPM1A may be used to identify tumors for therapies targeting   NF-κB. In addition, since 
neither deletions of the PPM1A gene nor inactivating mutations of PPM1A have been described in 
cancer, enhancing expression or activity of PPM1A is potential therapeutic strategy that may inhibit 
bony metastasis or tumor growth. 
 
2. Future directions 
Our findings have provided insight into mechanisms of LZAP activity and LZAP regulation. In 
particular, regulation of PPM phosphatase activity toward substrates appears to be a central theme in 
LZAP activity; however, our findings have also raised exciting questions and generated a number of 
ideas yet to be explored. 
 
2.1. Additional NF-κB target genes and NF-κB related proteins regulated by PPM1A 
In this study, we used a NF-κB signaling pathway real time PCR array as the initial tool to 
identify genes regulated by PPM1A. This array profiles the expression of 84 genes related to NF-κB-
mediated signaling transduction, of which about 30 genes are NF-κB responsive genes including 
cytokines and receptors. A large number of NF-κB regulated genes are not tested in this array 
indicating that PPM1A may regulate additional NF-κB target genes. An explorative study using 
RNAseq or microarray comparing gene expression between cells with or without PPM1A depletion 
will provide more candidate genes whose expression are regulated by PPM1A and may identify 
additional pathways impacted by PPM1A. Our data indicate that PPM1A decreases tumor cell 
invasion and prostate cancer cell bony metastasis, which at least partially depends on the inhibition 
of NF-κB pathway; therefore, a more extensive study identifying additional NF-κB genes regulated 
by PPM1A may find additional effectors of cancer cell invasion and metastasis.  
The RANK/RANKL/OPG triad is one potential group of such genes. Osteoclastic bone resorption 
contributes to the establishment of tumors in the skeleton. It is now widely understood that the 
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molecular triad--receptor activator of NF-κB ligand (RANKL), its receptor RANK, and the 
endogenous soluble RANKL inhibitor, osteoprotegerin (OPG)--play direct and essential roles in the 
formation, function, and survival of osteoclasts
179
. Recently Jin et al. showed that the activation of 
NF-κB signaling in prostate cancer cells increased the expression of the osteoclast inducing genes 
RANKL and PTHrP
130
. It is unclear if NF-κB is a direct transcriptional activator that increases 
expression of RANKL
180
, but indirect effects of NF-κB activation, namely TNFα and IL-1, stimulate 
RANKL expression in cells through activation of gp130 signal transducer following IL-1 stimulated 
expression of IL-6-type cytokines 
181, 182. Although our data do not suggest that PPM1A alters TNFα 
or IL-1 expression, effects of PPM1A on RANKL, RANK or OPG expression should still be tested. 
PPM1A activity to inhibit metastases also suggest that its effects on parathyroid hormone-related 
protein (PTHrP), which induces both mRNA and protein expression of MCP-1 in human bone 
marrow endothelial cells and osteoblasts
183
, should be explored.  
Pathways and key proteins controlling epithelial-mesenchymal transition (EMT) are additional 
and interesting potential target of PPM1A. EMT is a complex stepwise phenomenon that occurs 
during embryonic development and tumor progression. EMT is characterized by the disruption of 
intercellular junctions, replacement of apical-basolateral polarity with front-to-back polarity and 
acquisition of migratory and invasive phenotypes
184
. The loss of E-cadherin, a cell-cell adhesion 
molecule is the hallmark of EMT and E-cadherin is regulated by the transcriptional repressor, Snail. 
Absence of Snail results in embryonic lethality because of severe defects of gastrulation
185
. 
Overexpression of Snail and its function in promoting tumor metastasis has been reported in breast 
cancer
186,187
 and, more recently in prostate cancer
188
. NF-κB is one of the major regulators of Snail at 
both the translational and post-translational levels. NF-κB has been shown to associate with the 
Snail1a promoter in zebrafish and directly activate Snail1a expression resulting in altered cell cycle 
during gastrulation
189
. NF-κB also binds the human snail promoter between −194 and −78 bp, 
leading to increased Snail transcription
190
. Raf kinase inhibitor protein (RKIP), a metastatic 
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suppressor, was shown to inhibit NF-κB activity, and conversely, Snail can repress the expression of 
RKIP. Therefore, there is a positive feedback circuitry between RKIP, NF-κB and Snail, in which 
overexpression of Snail in tumors inhibits RKIP and induce EMT
191,192
. Dysregulated NF-
κB/Snail/RKIP circuitry promotes tumor persistence and metastasis through activation of the 
epithelial to mesenchymal transition program
193
. Since PPM1A inhibits NF-κB transcription activity 
and decreases prostate cancer cell metastasis, it will be interesting to determine PPM1A activities 
can inhibit the NF- κB /Snail pathway and EMT. 
In this study, we showed PPM1A inhibited RelA phosphorylation in vivo independent of IKKα 
and IKKβ,and PPM1A dephosphorylated RelA in vitro which suggest PPM1A is a RelA phosphatase 
in vivo. However, these data do not exclude the possibility that PPM1A might also regulate other 
upstream kinases (e.g. IKKε) or proteins in NF-κB activation to indirectly inhibit RelA 
phosphorylation. Recently, Hildebrand et al. reported that IκBζ, the atypical IκB family member, is a 
key transcription regulator of MCP-1/CCL2
132
. IκBζ-deficient macrophages exhibited impaired 
secretion of MCP-1 when challenged with diverse inflammatory stimuli, such as LPS or 
peptidoglycan. Chromatin immunoprecipitation demonstrate that IκBζ is directly recruited to the 
proximal promoter region of the Ccl2 gene and is required for transcription-enhancing histone H3 
trimethylation at lysine-4. We showed that MCP-1 expression in cancer cells is inhibited by PPM1A, 
at least partially, through decreasing RelA binding to the CCL2 promoter. Given the recent finding 
that IκBζ is critical for transcription of Ccl2, effects of PPM1A to regulate IκBζ, phosphorylation 
and downstream effects on MCP-1 expression should be explored. Moreover, it is not clear whether 
PPM1A regulates phosphorylation of other NF-κB family members such as p50 and RelB. These 
possibilities could be explored using phospho-specific antibodies, kinase inhibitors and MEFs with 
knockout of gene(s) coding kinases. 
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2.2 Mechanisms of decreased PPM1A expression in prostate cancer and the role of PPM1A in other 
cancer types 
Available public cancer datasets revealed that PPM1A mRNA expression was decreased 
approximately 2-fold in distant metastases of prostate tumors compared to primary prostate tumors 
without distant metastases (Fig. 2.8A). However, since the distant metastases and primary tumors 
were from different patients, it is not clear 1) whether the patients with distant metastasis had pre-
existing lower PPM1A expression in their primary tumors vs. PPM1A expression decreasing during 
metastases, or 2) if there is heterogeneity of PPM1A expression in primary tumors and the 
metastases were derived from this subpopulation. Additionally, metastases usually in patients after 
primary cancer treatment; therefore, it is possible that the treatment selects for cells with decreased 
PPM1A expression. To efficiently answer these questions, a PPM1A antibody useful for IHC and 
tissue microarray is needed. A cohort study comparing PPM1A expression in samples from the same 
patient at different time points and disease stages (e.g. initial diagnostic biopsy, primary tumor 
without distant metastasis, primary tumor with lymph node metastasis and tumor from metastatic 
sites) will help to understand how and when PPM1A expression is altered in prostate cancer cells.  
Microarray/next generation sequencing can be used to determine PPM1A mRNA levels and tissue 
microarray using an anti-PPM1A antibody would determine PPM1A protein levels and expression 
patterns in tumor and adjacent tissues.  
Interestingly, PPM1A expression is also decreased in breast cancer and colorectal cancers 
compared to normal tissue, suggesting that PPM1A loss may also be important in progression of 
these tumors (Oncomine, PPM1A gene, TCGA breast, TCGA colorectal and colorectal 2 data sets). 
To determine if PPM1A expression level is different based on the aggressiveness or subtypes of 
breast cancer or colorectal cancers, further analyses of the TCGA data could be helpful. The role of 
PPM1A in colorectal cancer has not been studied, but a single study, using xenograft of breast cancer 
MCF7 cells, revealed that PPM1A depletion increases MCF7 tumorigenic potential and tumor 
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growth
147
 suggesting that loss or decreased PPM1A activity may increase aggressive behavior in 
breast cancer. While the molecular mechanisms of PPM1A’s activity are not elucidated, 
dephosphorylation of RelA and inhibition of NF-κB activation could play a major role. IL-6 and 
MCP-1, two of the NF-κB targets inhibited by PPM1A, are also implicated in metastases in cancers 
of colon
68,145
, and breast
69, 71
. Experiments using cancer cells, as well as, metastatic mouse models are 
proposed to determine PPM1A’s activity in breast or colorectal cancer progression and metastasis. 
Little is known about the mechanism(s) regulating expression of PPM1A in cancer. Both genetic 
and epigenetic mechanisms may play a role and should be investigated. To date, neither loss of 
function mutations nor deletions mutation have been reported for PPM1A. Congruent with the lack 
of reported mutations and deletions, we have not found point mutations in the catalytic domain of 
PPM1A using TCGA data for head and neck squamous cell carcinoma, lung adenocarcinoma, breast 
cancer, and colorectal cancer. PPM1A promoter methylation and histone acetylation status could 
contribute to expression defects. Given the effect of PPM1A to decrease metastases in a prostate 
cancer intracardiac injection model, exploration into mechanisms that could restore PPM1A 
expression or activity in tumor may provide ideas for development of therapy.  
 
2.3 LZAP as a potential regulator of PPM phosphatase activity toward LZAP-associated proteins  
In chapter 3, we described that in cells with decreased PPM phosphatase expression (Wip1 or 
PPM1A) LZAP has diminished ability to inhibit target protein phosphorylation (p38 and RelA 
respectively).  Conversely, PPM phosphatases have diminished activity to dephosphorylate targets in 
cells with depleted LZAP (Fig. 3.5 B and Fig.3.7 A and B). Together, these data suggest that LZAP 
and PPM phosphatases are, at least partially, dependent on each other to regulate target protein 
phosphorylation. Mechanistically, at least for p38, LZAP increases association of Wip1 with p38 
potentially by directly bridging these proteins since LZAP binds both Wip1 and p38. Based on these 
data, the current working model is that LZAP facilitates protein dephosphorylation through 
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increasing the binding of phosphatase to substrate. This model is supported by the results of Wip1 
and PPM1A in vitro phosphatase assays revealing that while LZAP increased PPM mediated 
dephosphorylation of full-length substrate, LZAP had no effect on dephosphorylation of peptide 
substrates which, due to the short sequence, probably lack the structure for LZAP to bind. 
Experiments with finer tuned concentration of each component in the reaction will be performed to 
test this working model.  
Because we do not have LZAP mutants that lack binding ability toward PPM phosphatases or 
substrates, we have not been able to directly test the requirement of LZAP binding to increase 
dephosphorylation. LZAP self-association combined with the absence of cells lacking LZAP 
expression has increased the difficulty of binding domain mapping.  Generation of a new conditional 
LZAP knockout mouse and experiments where mutant LZAP and binding proteins are created by 
IVT or in bacteria should help with these inquiries.   
The interplay and role of LZAP in regulating RelA in the presence of PPM1A is slightly different 
compared to p38 in the presence of Wip1. Although we showed that: PPM1A is a RelA phosphatase, 
LZAP binds RelA and decreases RelA phosphorylation, and  LZAP and PPM1A partially depend on 
one another to inhibit RelA phosphorylation, we did not observe RelA-PPM1A binding or LZAP-
PPM1A binding in co-immunoprecipitation experiments; however, PPM1A was detected as an 
LZAP-associated protein by LC-MS/MS. LC-MS/MS may be more sensitive compared to antibody-
based immunoblotting, which could explain why we saw PPM1A in the LZAP co-IP experiment by 
LC-MS/MS but not by SDS-PAGE and immunoblotting. To determine if the working model is a 
unifying mechanism for LZAP, we need to show more evidence of LZAP-PPM1A interaction and 
LZAP regulated PPM1A-RelA interaction, which may be transient interactions.  A typical binding 
constant for a tight interaction (for example, antibody–antigen or protease–protease inhibitor) is 10-12 
to 10
-9
M, yielding a half-life of 12 min–19 h and facile isolation by co-purification. A typical binding 
constant for a transient interaction is 10
-5–10-6M, which yields a half-life of 0.1–1 s, which is a 
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typical half-life of an enzymatic reaction
194
. These transit times hamper co-purification and co-
crystallization and require other methods to detect protein-protein interaction. Cross-linking was 
used to identify RelA interaction with PP2A, another RelA phosphatase, since PP2A could not be 
detected by RelA immunoprecipitation in the absence of cross-linker
43
. To better define the 
interaction of PPM1A with RelA, we will treat cells with cleavable or non-cleavable cross-linker 
then perform co-immunoprecipitation of RelA complexes and examine to determine if PPM1A and 
and/or LZAP can be detected. Recently, a PPM1A knockout mouse was created and reported by 
Yang et al.
195
. PPM1A-/- null mouse embryonic fibroblast cells will be a useful tool to test the 
molecular mechanism of the dependency of LZAP on PPM1A. Without endogenous wild-type 
PPM1A, it is easier to determine the interaction between LZAP and PPM1A by ectopic expression of 
mutants of PPM1A. Soft agar assays will be used to determine transformation of wild-type and 
PPM1A-/- MEFs with or without siRNA knockdown or ectopic expression of LZAP and with 
oncogenic stimulation.. Human cancer cell lines with LZAP and PPM1A stable double knockdown 
by shRNA could also be used to test for xenograft tumor formation and growth as well as tumor cell 
metastasis following intravascular injection. 
 
2.4 Regulation of LZAP expression, post-translational modification and stability 
2.4.1 LZAP promoter regulation 
Yarbrough lab found that LZAP is lost in 30% of head and neck squamous cell carcinomas 
(HNSCC) 
110
, but the mechanism(s) for the LZAP loss remains unknown. No genomic alteration (e.g. 
deletion mutation or point mutation) of LZAP has been identified including TCGA database searches, 
suggesting that epigenetic mechanism(s) are likely responsible for diminished  expression of LZAP. 
Studies to determine LZAP promoter regulation including identification of transcription factors and 
co-factors responsible for LZAP gene transcription and promoter methylation may shed light on 
regulation of LZAP expression.  
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Interestingly, NF-κB and p53 binding sites were predicted in the LZAP gene promoter region (-20 
kb to +10 kb relative to the transcription start site, SABioscience, Champion ChIP Transcription 
Factor Search Portal) (Fig. 5.1). We reported that LZAP regulates NF-κB110 and p53112 activity. It is 
possible that both transcription factors have feedback regulation of LZAP expression so the 
dysregulation of NF-κB or p53 in cancer cells might not only be the results of LZAP loss but also 
function to further suppress LZAP expression. Chromatin immunoprecipitation (ChIP) assay will be 
the first step to determine if NF-κB or p53 binds to LZAP promoter region followed by cloning the 
predicted binding region(s) in the LZAP promoter to luciferase reporter construct to measure the 
effect of NF-κB or p53 on transcription. Histone acetylation status in this region will be evaluated by 
ChIP and HDAC inhibitors will be used to treat cancer cells to determine if it will increase LZAP 
expression.  
  
Fig. 5.1 Relevant transcription factor binding sites in LZAP gene promoter (predicted by 
SABiosciences' Text Mining Application and the UCSC Genome Browser) 
Figure 5.0.1 Relevant transcription 
factor binding sites in LZAP gene 
promoter 
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DNA methylation, occurring at cytosines in CpG dinucleotides, is a potent mechanism of 
transcriptional repression. CpG islands are defined as DNA sequences that contain CpG 
dinucleotides at a frequency that is significantly higher than expected for a random distribution based 
on the base composition of the mammalian genome
196
. Many tumor suppressor genes (TSGs) 
including p14
ARF
 and p16
INK4A
 have their promoter situated in a CpG island and are silenced by 
aberrant methylation in cancer, which appears to be a significant pathway for TSG inactivation in 
neoplasia
197
. There are two predicted CpG islands located in -1.5kb to 0.5kb region of LZAP gene 
(predicted using MethPrimer). FaDu cells express the lowest level of LZAP protein among the 13 
HNSCC cell lines tested. To determine if the CpG island in LZAP is methylated, bisulphite 
sequencing will be determined.  
 
2.4.2 Phosphorylation sites in LZAP 
Here, we showed that LZAP is a phosphoprotein and our data suggest that PPM phosphatase 
Wip1, PPM1A and PPM1B may dephosphorylate LZAP at amino acid residues S91 and T237. To 
explore the phosphorylation sites of LZAP in vivo, liquid chromatography and tandem mass 
spectrometry (LC-MS/MS) will be performed on immunoprecipitated Flag-tagged LZAP affinity 
purified after expression in 293T cells using Flag M2 gel (Sigma). We used this system to detect 
LZAP-associated proteins and have determined that more than 90% of LZAP is covered by MS data, 
including all conserved potential phosphorylated residues. Phosphorylation will be maximized by 
inhibition of phosphatases during the last 1 hour of cell growth using peroxovanadate 
(vanadate/H2O2 mixture) and calyculin A and/or through use of Wip1-/- MEFs. Some 
phosphorylation sites (especially clusters of sites) can be very challenging to the LC-MS/MS method 
due to limitations in enzyme specificity and because of the potential for some phospho-groups to be 
especially labile in the gas phase (most often through beta elimination of T-phos and S-phos). As an 
alternative method, phosphorylation of 13 S, T or Y sites (Fig. 5.2), conservative or within SP/Q, 
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TXY motif, as well as sites identified in LC-MS/MS above will be assessed through site-directed 
mutagenesis (Tyr to Phe, Ser to Ala, and Thr to Ala) and 2D gel electrophoretic mapping of LZAP 
tryptic phospho-peptides. In case a single mutant does not inhibit phosphorylation, multiple 
simultaneous mutants will be made to identify critical sites of Ser, Thr, and Tyr phosphorylation. 
Phosphorylated residues will be identified by comparing wild-type and mutant LZAP tryptic 
phospho-peptide maps. Digestion of LZAP by trypsin should yield 26 peptides containing 
Ser/Thr/Tyr residues 8 of which contain the 9 highly conserved sites mentioned above. In vivo 
32
[P]-
phospho-labeling followed by immunoprecipitation, SDS-PAGE and autoradiography will be 
performed on an LZAP mutant containing all identified phosphorylation sites to verify results from 
LC-MS/MS and phospho-peptide mapping and to determine if all phospho-acceptor sites of LZAP 
have been identified.  Data from mass spectrometry may identify phosphorylated sites that are not as 
evolutionarily conserved as those that are chosen for initial analyses. Likewise, mutational analyses 
using phospho-peptide mapping can determine which Ser, Thr, or Tyr residues in tryptic fragments 
are phospho-acceptor sites.   
 
 
  
Fig. 5.2. Potential phosphorylation sites on LZAP.  Human LZAP protein sequence was 
analyzed using NetPhos 2.0 and GPS 2.1 to identify potential phosphorylation sites. 
Evolutionarily conserved potential phospho-Thr (circle), Ser (square), and Tyr (triangle) are 
indicated above the line representation of LZAP. Potential kinases are listed above and 
potential Wip1 targets below target residues. 
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Sequence analyses of identified phosphorylation sites of LZAP will provide insight into kinases 
and phosphatases that may regulate LZAP phosphorylation. Once phosphorylation sites of LZAP are 
identified, phospho-specific LZAP antibodies can be created to those phospho-acceptor residues that 
alter LZAP activity. These antibodies will be critical for correlation of LZAP phosphorylation and 
activity.  
Once phosphorylation sites of LZAP are identified and confirmed by mutagenesis, LZAP mutants 
targeting identified phosphorylated sites will be examined to determine consequences on LZAP half-
life, subcellular localization, and association/activity toward RelA, Chk1/2, and p38 using techniques 
as described in chapter II-IV above. Mutants that alter LZAP stability or activity will provide insight 
into phosphorylation-dependent regulation of LZAP. 
 
2.4.3 LZAP post-translational modification by ubiquitin or ubiquitin-like conjugating systems 
LZAP is ubiquitinated and binds to components of an ubiquitin-like conjugating (ufmylation) 
system (UFM1, UFC1 and KIAA0776). Consistent with  our data, Wu et al. showed LZAP was a 
stable protein that was protected from  proteasome-mediated degradation unless KIAA0776 was 
depleted
119
. Since both ubiquitin and UFM1 are conjugated to lysine residues, it is possible that the 
two compete for the conjugating sites on LZAP. In this scenario, UFM1 conjugation would protect 
LZAP from ubiquitination-mediated proteasomal degradation. Experiments to measure the level of 
UFM1 conjugation on LZAP and the role of ufmylation in regulation of LZAP protein stability 
would be interesting, but to date studies examining physiological target(s) and biological functions 
of ufmylation remain largely undefined. Recently, components of the ufmylation system were shown 
to be transcriptionally up-regulated in HCT116 (colon cancer cell line), HepG2 (hepatocellular 
carcinoma cells) and MEFs by disturbance of the ER homeostasis and inhibition of vesicle 
trafficking
198
 and similar results were reported in pancreatic cells
118
. Interestingly, LZAP was shown 
to be anchored to ER by KIAA0776, the E3 ligase of UFM1
121
 and another LZAP binding protein 
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C20orf116 /DDRGK1 was reported to be a target of ufmylation and to reside in the ER
123,118
. 
KIAA0776 and LZAP have been implicated in ufmylation of endogenous Ufm1 targets and 
depletion of either KIAA0776 or LZAP resulted in unfolded protein response, an ER stress response 
activated in response to an accumulation of unfolded or misfolded proteins in the lumen of the 
endoplasmic reticulum suggesting that LZAP and KIAA0776 might be involved in normal ER 
function through regulation of ufmylation
198
. Our data suggest that endogenous LZAP localizes 
preferentially in the nucleus and para-nuclear regions. It will be interesting to determine 1) if LZAP 
exerts different functions based on its subcellular localization, 2) if LZAP plays a similar role in 
ufmylation as it does in target protein phosphorylation by binding and introducing the substrate to 
the enzyme responsible for the specific post-translational modification, and 3) if the role of LZAP in 
normal ER functions makes LZAP indispensable in the early vertebrate embryonic development. 
 
2.4.4 Additional post-translational modifications of LZAP 
In addition to phosphorylation and ubiquitination, there are many types of PTM that can also 
regulate protein activity, stability and cellular localization . Specific antibodies are available for 
many known PTMs and sites; however, it is not practical or possible to localize unknown PTM sites 
by immunoblotting. Recent advances in mass spectrometry have increased the power of these 
techniques to identify protein post-translational modifications including: phosphorylation, 
acetylation, methylation and nitration.  Recently, tyrosine nitration has been explored using 
electrospray ionization-tandem mass spectrometry using electron capture dissociation
199, 200
. Non-
biased identification of lysine acetylation
201
, protein oxidation
202
 and sumoylation
203
 can be 
efficiently performed using high performance liquid chromatography tandem MS analysis. An 
unbiased approach to determine modifications of LZAP following alterations in subcellular 
localization (as was seen with expression of Wip1, Fig. 3.6) or following cellular stress or following 
inhibition of the proteasome will provide further insight into mechanisms of LZAP regulation.  
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